Fused tricyclic substituted isoxazolidinyl urea derivatives, pharmaceutical composition thereof and use thereof
By developing the isoxazolidinyl urea derivatives with fused tricyclic substituted, the problems of low inhibitory activity and great cardiotoxicity of existing TrkA inhibitors are solved, and effective inhibition of TrkA enzyme and better pharmacokinetics are achieved. Parameters are suitable for the treatment of diseases related to abnormal TrkA expression.
Patent Information
- Application Number
- PCT/CN2024/094894
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-23
- Filing Date
- 2024-05-23
- Publication Date
- 2024-11-28
AI Technical Summary
The existing TrkA inhibitors have low inhibitory activity, poor pharmacokinetic parameters and strong inhibitory effect on the current of hERG potassium channel, resulting in cardiotoxicity and it is difficult to effectively treat hyperactivation of TrkA pathway.
Developed fused tricyclic substituted isoxazolidinylurea derivatives, as TrkA selective inhibitors, have significant enzyme inhibitory activity and selective inhibitory activity, optimized pharmacokinetic parameters and lower cardiotoxicity.
The fused tricyclic substituted isoxazolidinylurea derivative has significant inhibitory effect on TrkAase and cells. The IC50 value is between 50nM and 100nM, which has better pharmacopoeia parameters and lower cardiotoxicity, and is suitable for use in Treatment of diseases related to abnormal TrkA expression.
Smart Images

Figure CN2024094894_28112024_PF_FP_ABST
Abstract
Description
Fused tricyclic substituted isoxazolidinyl urea derivatives, pharmaceutical compositions and applications thereof
[0001] This application claims priority to the Chinese patent application filed with the China Patent Office on May 23, 2023, with application number 202310585973.5 and invention name “Fused tricyclic substituted isoxazolidinyl urea derivatives, pharmaceutical compositions and applications thereof”, the entire contents of which are incorporated by reference into this application. Technical Field
[0002] The present application relates to the field of medical technology, and in particular to fused tricyclic substituted isoxazolidinyl urea derivatives, pharmaceutically acceptable salts, stereoisomers, pharmaceutical compositions and applications thereof. Background Art
[0003] Trks are high-affinity receptor tyrosine kinases activated by a group of soluble growth factors called neurotrophins (NTs). The Trk receptor family has three members: TrkA, TrkB, and TrkC. Among the neurotrophins are (i) nerve growth factor (NGF), which activates TrkA; (ii) brain-derived neurotrophic factor (BDNF) and NT-4 / 5, which activate TrkB; and (iii) NT3, which activates TrkC. Trks are widely expressed in neuronal tissue and are involved in the maintenance, signaling, and survival of neuronal cells.
[0004] Recent literature also suggests that activation of TrkA with NGF leads to pain-inducing downstream upregulation of certain ion channels that are important in increasing electrical signaling from nerve endings experiencing inflammation.
[0005] The binding of nerve growth factor (NGF) to TrkA triggers TrkA dimerization and activates downstream signaling pathways related to neuronal development and nociception. Each Trk receptor consists of an extracellular domain (ligand binding), a transmembrane region, and an intracellular domain (including the kinase domain). Upon ligand binding, the kinase domain catalyzes autophosphorylation and triggers downstream signaling pathways. In addition, overexpression, activation, amplification, or mutation of TrkA kinase is associated with many tumors and cancers.
[0006] Pharmacological inhibition of the TrkA pathway offers a promising approach for treating various diseases that rely on TrkA pathway hyperactivation. Numerous TrkA inhibitors have been reported, but studies have shown that these inhibitors exhibit limited inhibitory activity, poor pharmacokinetic parameters, and potent inhibition of hERG potassium channel currents. Therefore, the development of TrkA inhibitors with enhanced inhibitory activity, improved pharmacokinetic parameters, and reduced cardiotoxicity is of great importance.
[0007] Summary of the Invention
[0008] In a first aspect, the present application provides a compound represented by formula (I), or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof:
[0009] in,
[0010] Ring A is a benzene ring or a 5- or 6-membered heteroaryl ring;
[0011] Ring B is a 5- or 6-membered heteroaryl ring or a 5- to 8-membered heterocycloalkenyl ring;
[0012] Ring C is a benzene ring or a 5- or 6-membered heteroaryl ring;
[0013] (R1) n Indicates that the hydrogen on ring A is replaced by n R1, n is 0, 1, 2, 3, 4 or 5; each R1 is the same or different and is independently cyano, hydroxyl, carboxyl, halogen (in some embodiments, fluorine or chlorine), -NR a0 R b0 、C 3-6 Cycloalkyl, C 1-8 Alkyl (in some embodiments, C 1-6 Alkyl, in other embodiments C 1-3 Alkyl), C 1-8 Alkoxy (in some embodiments, C 1-6 Alkoxy, in other embodiments, is C 1-3 Alkoxy), -C(O)C 1-8 Alkyl (in some embodiments -C(O)C 1-6 Alkyl, in other embodiments -C(O)C 1-3 alkyl), -C(O)OC 1-8 Alkyl (in some embodiments -C(O)OC 1-6 Alkyl, in other embodiments -C(O)OC 1-3 alkyl), -OC(O)C 1-8 Alkyl (in some embodiments -OC(O)C 1-6 Alkyl, in other embodiments -OC(O)C 1-3 alkyl) or -C(O)NR a0 R b0 ; or any two R1 connected to the same ring atom or different ring atoms are connected to form a 3-7 membered saturated or partially unsaturated monocyclic heterocycle or a 3-7 membered saturated or partially unsaturated monocyclic ring; wherein said C 1-8 Alkyl, C 1-8The alkoxy, 3- to 7-membered saturated or partially unsaturated monocyclic ring and 3- to 7-membered saturated or partially unsaturated monocyclic ring are unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from the group consisting of deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -NR a1 R b1 、-SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl; wherein the phenyl and 5- to 6-membered heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from Substituent Group S;
[0014] (R2) m Indicates that the hydrogen on ring B is replaced by m R2, m is 0, 1, 2 or 3; each R2 is the same or different and is independently cyano, hydroxyl, carboxyl, halogen (in some embodiments, fluorine or chlorine), -NR a0 R b0 、C 3-6 Cycloalkyl, C 1-8 Alkyl (in some embodiments, C 1-6 Alkyl, in other embodiments C 1-3 Alkyl), C 1-8 Alkoxy (in some embodiments, C 1-6 Alkoxy, in other embodiments, is C 1-3 Alkoxy), -C(O)C 1-8 Alkyl (in some embodiments -C(O)C 1-6 Alkyl, in other embodiments -C(O)C 1-3 alkyl), -C(O)OC 1-8 Alkyl (in some embodiments -C(O)OC 1-6 Alkyl, in other embodiments -C(O)OC 1-3 Alkyl), -SO2C 1-8 Alkyl (in some embodiments -SO2C 1-6 Alkyl, in other embodiments -SO2C 1-3 Alkyl), -SO2C3-6 Cycloalkyl, -SO2NR a0 R b0 or -C(O)NR a0 R b0 ; Or any two R2 connected to the same ring atom or different ring atoms are connected to form a 3-7 membered saturated or partially unsaturated monocyclic ring or a 3-7 membered saturated or partially unsaturated monocyclic ring; wherein said C 1-8 Alkyl, C 1-8 The alkoxy, 3- to 7-membered saturated or partially unsaturated monocyclic ring and 3- to 7-membered saturated or partially unsaturated monocyclic ring are unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from the group consisting of deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -NR a1 R b1 、-SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl; wherein the phenyl and 5- to 6-membered heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from Substituent Group S;
[0015] (R3) t Indicates that the hydrogen on the ring C is replaced by t R3, t is 0, 1, 2 or 3; each R3 is the same or different and is independently hydrogen, cyano, hydroxyl, carboxyl, halogen (in some embodiments, fluorine or chlorine), C 3-6 Cycloalkyl, C 1-8 Alkyl (in some embodiments, C 1-6 Alkyl, in other embodiments C 1-3 Alkyl), C 1-8 Alkoxy (in some embodiments, C 1-6 Alkoxy, in other embodiments, is C 1-3 Alkoxy), -NR a0 R b0 、-C(O)C 1-8 Alkyl (in some embodiments -C(O)C 1-6 Alkyl, in other embodiments -C(O)C1-3 alkyl), -C(O)OC 1-8 Alkyl (in some embodiments -C(O)OC 1-6 Alkyl, in other embodiments -C(O)OC 1-3 alkyl), -OC(O)C 1-8 Alkyl (in some embodiments -OC(O)C 1-6 Alkyl, in other embodiments -OC(O)C 1-3 alkyl) or -C(O)NR a0 R b0 ; Or any two R3 connected to the same ring atom or different ring atoms are connected to form a 3-7 membered saturated or partially unsaturated monocyclic ring or a 3-7 membered saturated or partially unsaturated monocyclic ring; wherein said C 1-8 Alkyl, C 1-8 The alkoxy, 3- to 7-membered saturated or partially unsaturated monocyclic ring and 3- to 7-membered saturated or partially unsaturated monocyclic ring are unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from the group consisting of deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -NR a1 R b1 、-SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl; wherein the phenyl and 5- to 6-membered heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from Substituent Group S;
[0016] R0 is C 1-8 alkyl or 3 to 6 membered heterocycloalkyl, the C 1-8 The alkyl group is substituted by 1, 2 or 3 substituents each independently selected from the group consisting of hydroxy, halogen, C 1-8 Alkoxy and C 3-6 Cycloalkyloxy; the 3 to 6 membered heterocycloalkyl is unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from the group consisting of: C 1-8 Alkyl and C 3-6 Cycloalkyl;
[0017] R a 、R b are the same or different and are each independently hydrogen or C 1-8 Alkyl (in some embodiments, C 1-6 Alkyl, in other embodiments C 1-3 alkyl);
[0018] p is 1, 2, or 3;
[0019] The substituent group S is selected from the following groups: halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -NR a1 R b1 、-SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl;
[0020] R a0 、R b0 are independently hydrogen, C 1-3 Alkyl or acetyl; or R a0 、R b0 Together with the nitrogen atom to which it is connected, it forms a 4- to 6-membered saturated monocyclic heterocycle; the 4- to 6-membered saturated monocyclic heterocycle is unsubstituted or substituted by 1, 2 or 3 substituents independently selected from the group consisting of deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NH2, -C(O)NH(C 1-3 alkyl), -C(O)N(C 1-3 Alkyl)2, -C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6cycloalkyloxy and 3- to 6-membered heterocycloalkyl;
[0021] R a1 、R b1 are independently hydrogen, C 1-3 Alkyl or acetyl; or R a1 、R b1 Together with the nitrogen atom to which it is connected, it forms a 4- to 6-membered saturated monocyclic heterocycle; the 4- to 6-membered saturated monocyclic heterocycle is unsubstituted or substituted by 1, 2 or 3 substituents independently selected from the group consisting of deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NH2, -C(O)NH(C 1-3 alkyl), -C(O)N(C 1-3 Alkyl)2, -C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 cycloalkyloxy and 3- to 6-membered heterocycloalkyl.
[0022] In some embodiments, the compound represented by formula (I) is a trans racemic form or a trans single isomer.
[0023] In some embodiments, the compound represented by formula (I) is a trans racemic structure represented by formula (IA) or a trans single isomer thereof:
[0024] In some embodiments, R a 、R b All are hydrogen.
[0025] In some embodiments, p is 3.
[0026] In some embodiments, R a0 、R b0 All are hydrogen.
[0027] In some embodiments, R0 is C 1-8 Straight chain alkyl or 3 to 6 membered heterocyclic alkyl, the C 1-8 The linear alkyl group is substituted by 1, 2 or 3 substituents each independently selected from the group consisting of hydroxy, halogen, C 1-8 Alkoxy (in some embodiments, C 1-6Alkoxy, in other embodiments, is C 1-3 Alkoxy) and C 3-6 Cycloalkyloxy.
[0028] In some embodiments, R0 is -(CR 01 R 02 ) q OH, -(CR 03 R 04 ) q OC 1-8 Alkyl (in some embodiments -(CR 03 R 04 ) q OC 1-6 Alkyl, in other embodiments -(CR 03 R 04 ) q OC 1-3 Alkyl), -(CR 05 R 06 ) q OC 3-6 Cycloalkyl, halogenated C 1-8 Alkyl (in some embodiments, halogenated C 1-6 Alkyl, in other embodiments, is halogenated C 1-3 alkyl) or a 3- to 6-membered heterocycloalkyl;
[0029] q is 1, 2, 3, or 4;
[0030] R 01 、R 02 、R 03 、R 04 、R 05 、R 06 are the same or different and are each independently hydrogen or C 1-8 Alkyl (in some embodiments, C 1-6 Alkyl, in other embodiments C 1-3 alkyl).
[0031] In some embodiments, R0 is monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl or difluoroethyl, or is selected from one of the following structures:
[0032] Furthermore, R0 is
[0033] In some embodiments, the compound represented by formula (I) is a single isomer represented by formula (I-1) or a single isomer structure represented by formula (I-2):
[0034] In some embodiments, the compound represented by formula (I) is represented by formula (IIA) or formula (IIB):
[0035] in
[0036] Z1 is N or CR Z1 ; Z2 is CR Z2 or N; Z3 is -N=, -N(R Z31 )-or-C(R Z32 )=;
[0037] L1 is -N=C(R L1a )-、-N(R L1b )-C(O)-、-C(R L1c )=C(R L1d )-, -OC(O)-, -C(O)-O-, -O- or -N(R L1e )-;
[0038] L2 is -C(R L2a )=NC(R L2b )=、-N(R L2c )-C(O)-C(R L2d )=、-N(R L2e )-C(O)-N=or -N=C(R L2f )-C(R L2g )=;
[0039] is a single bond or a double bond;
[0040] R Z1 、R Z2 、R Z31 、R Z32 are each independently hydrogen, halogen (in some embodiments, fluorine or chlorine), cyano, hydroxyl, carboxyl, C 1-8 Alkyl (in some embodiments, C 1-6 Alkyl, in other embodiments C 1-3 Alkyl), C 1-8 Alkoxy (in some embodiments, C 1-6 Alkoxy, in other embodiments, is C 1-3 Alkoxy), -C(O)C 1-8 Alkyl (in some embodiments -C(O)C 1-6 Alkyl, in other embodiments -C(O)C 1-3 alkyl), -C(O)OC 1-8 Alkyl (in some embodiments -C(O)OC 1-6 Alkyl, in other embodiments -C(O)OC1-3 Alkyl), -C(O)NR a0 R b0 or -NR a0 R b0 ;
[0041] R L1a 、R L1c 、R L1d 、R L2a 、R L2b 、R L2d 、R L2f 、R L2g are independently hydrogen, halogen, C 1-8 Alkyl (in some embodiments, C 1-6 Alkyl, in other embodiments C 1-3 Alkyl), C 1-8 Alkoxy (in some embodiments, C 1-6 Alkoxy, in other embodiments, is C 1-3 Alkoxy) or -NR a0 R b0 ; the C 1-8 The alkyl group is unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from the group consisting of deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -NR a1 R b1 、-SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl; wherein the phenyl and 5- to 6-membered heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from Substituent Group S;
[0042] R L1b 、R L1e 、R L2c 、R L2e are independently hydrogen, C 1-8 Alkyl (in some embodiments, C 1-6 Alkyl, in other embodiments C 1-3Alkyl), -SO2C 1-3 Alkyl, -SO2C 3-6 Cycloalkyl or -SO2NR a0 R b0 ; the C 1-8 The alkyl group is unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from the group consisting of deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -NR a1 R b1 、-SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl; wherein the phenyl and 5- to 6-membered heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from Substituent Group S.
[0043] In some embodiments, the structure represented by Formula (IIA) or Formula (IIB) is a trans racemic form or a trans single isomer.
[0044] In some embodiments, the compound of formula (IIA) is a trans racemic structure represented by formula (IIAa) or a trans single isomer thereof:
[0045] In some embodiments, the compound of formula (IIB) is a trans racemic structure represented by formula (IIBa) or a trans single isomer thereof:
[0046] In some embodiments, the compound represented by formula (I) is a single isomer represented by formula (IIA-1), a single isomer represented by formula (IIA-2), a single isomer represented by formula (IIB-1), or a single isomer represented by formula (IIB-2):
[0047] In some embodiments, the structure Select one of the following structures:
[0048] In some embodiments, RL 1a 、R L1c 、R L 1d Each is independently hydrogen, methyl, ethyl, n-propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl, difluoroethyl, trifluoroethyl, -NH2, -NHC 1-3 Alkyl or -N(C 1-3 Alkyl)2.
[0049] In some embodiments, R L1b 、R L1e Each is independently hydrogen, methyl, ethyl, n-propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl, difluoroethyl, trifluoroethyl, -SO2C 1-3 Alkyl or -SO2C 3-6 Cycloalkyl.
[0050] In some embodiments, the structure Select one of the following structures:
[0051] In some embodiments, the structure Select one of the following structures:
[0052] In some embodiments, R L2a 、R L2b 、R L2d 、R L2f 、R L2g Each is independently hydrogen, methyl, ethyl, n-propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl, difluoroethyl, trifluoroethyl, -NH2, -NHC 1-3 Alkyl or -N(C 1-3 Alkyl)2.
[0053] In some embodiments, the structure Select one of the following structures:
[0054] In some embodiments, ring A is a benzene ring, a thiophene ring, a furan ring, a thiazole ring, an isothiazole ring, an imidazole ring, an oxazole ring, a pyrrole ring, a pyrazole ring, a triazole ring (including a 1,2,3-triazole ring, a 1,2,4-triazole ring, a 1,2,5-triazole ring, and a 1,3,4-triazole ring), a tetrazole ring, an isoxazole ring, an oxadiazole ring (including a 1,2,3-oxadiazole ring, a 1,2,4-oxadiazole ring, a 1,2,5-oxadiazole ring, and a 1,3,4-oxadiazole ring), a thiadiazole ring, a pyridine ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, a triazine ring, or a tetrazine ring.
[0055] In some embodiments, Ring A is a benzene ring.
[0056] In some embodiments, Ring C is a benzene ring or a pyridine ring.
[0057] Furthermore, ring C is selected from the following structures:
[0058] In some embodiments, (R1) n represents that the hydrogen on ring A is replaced by n R1, where n is 0, 1, 2, 3, 4 or 5; each R1 is the same or different and is independently halogen (in some embodiments, fluorine or chlorine), methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl or n-pentyl.
[0059] In some embodiments, (R2) m Indicates that the hydrogen on ring B is replaced by m R2, m is 0, 1, 2 or 3; each R2 is the same or different and is independently cyano, hydroxyl, carboxyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, methoxy, ethoxy, n-propoxy, isopropoxy, butoxy, -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, -SO2C 1-3 Alkyl, -SO2C 3-6 cycloalkyl, monochloromethyl, dichloromethyl, trichloromethyl, monochloroethyl, 1,2-dichloroethyl, trichloroethyl, monobromoethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl, difluoroethyl or trifluoroethyl.
[0060] In some embodiments, (R3) t represents that the hydrogen on the ring C is replaced by t R3, t is 0, 1, 2 or 3; each R3 is the same or different and is independently cyano, hydroxyl, carboxyl, halogen (in some embodiments, fluorine or chlorine), methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-methylcyclopropyl, 1-methylcyclobutyl, 1-methylcyclopentyl, 1-methylcyclohexyl, monochloromethyl, dichloromethyl, trichloromethyl, monochloroethyl, 1,2-dichloroethyl, trichloroethyl, monobromoethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl, difluoroethyl, trifluoroethyl, monodeuteromethyl, monodeuteroethyl, dideuteromethyl, dideuteroethyl, trideuteromethyl, trideuteroethyl, methoxy, ethoxy, n-propoxy, isopropoxy, butoxy, -NH2, -NH(C 1-3 alkyl), N(C 1-3 alkyl)2 or -C(O)NH2.
[0061] In some embodiments, any two substituents (e.g., R1, R2, R3) attached to the same ring atom or different ring atoms are connected to form a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring selected from the group consisting of: azetidine ring, oxetane ring, tetrahydrofuran ring, tetrahydrothiophene ring, tetrahydropyrrole ring, piperidine ring, pyrroline ring, oxazolidine ring, piperazine ring, dioxolane ring, dioxane, morpholine ring, thiomorpholine ring, thiomorpholine-1,1-dioxide, tetrahydropyran ring, azetidine-2-one ring, oxetane-2-one ring, pyrrolidine-2-one ring, pyrrolidine-2,5-dione ring, piperidine-2-one ring, dihydrofuran-2(3H)-one ring, dihydrofuran-2,5-dione ring, tetrahydro-2H-pyran-2-one ring, piperazine-2-one ring, Ketone ring, morpholin-3-one ring, 1,2-dihydroazetidine ring, 1,2-dihydrooxetadiene ring, 2,5-dihydro-1H-pyrrole ring, 2,5-dihydrofuran ring, 2,3-dihydrofuran ring, 2,3-dihydro-1H-pyrrole ring, 3,4-dihydro-2H-pyran ring, 1,2,3,4-tetrahydropyridine ring, 3,6-dihydro-2H-pyran ring, 1,2,3,6-tetrahydropyridine ring, 4,5-dihydro-1H-imidazole ring, 1,4,5,6-tetrahydropyrimidine ring, 3,4,7,8-tetrahydro-2H-1,4,6-oxadiazolidine ring, 1,6-dihydropyrimidine ring, 4,5,6,7-tetrahydro-1H-1,3-diazepine ring or 2,5,6,7-tetrahydro-1,3,5-oxadiazepine ring.
[0062] In some embodiments, the 3- to 7-membered saturated or partially unsaturated monocyclic heterocycle formed by any two substituents (e.g., R1, R2, R3) attached to the same ring atom or different ring atoms is a 4- to 6-membered saturated monocyclic heterocycle, and the 4- to 6-membered saturated monocyclic heterocycle is selected from: an azetidine ring, an oxetane ring, a tetrahydrofuran ring, a tetrahydrothiophene ring, a tetrahydropyrrole ring, a piperidine ring, a piperazine ring, a morpholine ring, a thiomorpholine ring, thiomorpholine-1,1-dioxide or a tetrahydropyran ring.
[0063] In some embodiments, any two substituents (e.g., R1, R2, R3) attached to the same ring atom or different ring atoms are connected to form a 3- to 7-membered saturated or partially unsaturated monocyclic ring selected from: a cyclopropyl ring, a cyclobutyl ring, a cyclopentyl ring, a cyclopentenyl ring, a cyclohexyl ring, a cyclohexenyl ring, a cyclohexadienyl ring, a cycloheptyl ring, a cycloheptatrienyl ring, a cyclopentanone ring or a cyclopentane-1,3-dione ring.
[0064] In some embodiments, the 3- to 7-membered saturated or partially unsaturated monocyclic ring formed by any two substituents (e.g., R1, R2, R3) attached to the same ring atom or different ring atoms is a 3- to 6-membered saturated monocyclic ring, and the 3- to 6-membered saturated monocyclic ring is selected from: a cyclopropyl ring, a cyclobutyl ring, a cyclopentyl ring or a cyclohexyl ring.
[0065] In some embodiments, in the above structural formulas, the 5- or 6-membered heteroaryl ring in each group is independently selected from: thienyl, furyl, thiazolyl, isothiazolyl, imidazolyl, oxazolyl, pyrrolyl, pyrazolyl, triazolyl (including 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, tetrazolyl), isoxazolyl, oxadiazolyl (including 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl), thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl or tetrazinyl.
[0066] In some embodiments, when Ring A, Ring B or Ring C is a 5- or 6-membered heteroaryl ring, the 5- or 6-membered heteroaryl ring is independently selected from: thienyl, furanyl, thiazolyl, isothiazolyl, imidazolyl, oxazolyl, pyrrolyl, pyrazolyl, triazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl or tetrazinyl.
[0067] In some embodiments, the 5- or 6-membered heteroaryl ring is independently selected from one of the following structures:
[0068] In some embodiments, in the above structural formulae, the 3- to 6-membered heterocycloalkyl group in each group is a 4- to 6-membered heterocycloalkyl group, each independently selected from: azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyrrolyl, oxazolidinyl, dioxolanyl, piperidinyl, piperazinyl, morpholinyl, dioxane, thiomorpholinyl, thiomorpholine-1,1-dioxide, tetrahydropyranyl, pyrrolidin-2-one, dihydrofuran-2(3H)-one, morpholin-3-one, piperazin-2-one or piperidin-2-one.
[0069] In some embodiments, R a0 、R b0 The 4- to 6-membered saturated monocyclic heterocyclic ring formed together with the nitrogen atom to which it is attached is selected from azetidinyl, tetrahydropyrrolyl, piperidinyl, piperazinyl or morpholinyl.
[0070] In some embodiments, R a1 、R b1 The 4- to 6-membered saturated monocyclic heterocyclic ring formed together with the attached nitrogen atom is selected from the group consisting of azetidinyl, tetrahydropyrrolyl, piperidinyl, piperazinyl and morpholinyl.
[0071] In some embodiments, the compound of formula (I) is any one of the following compounds, or its trans racemic form, or its pharmaceutically acceptable salt, or its stereoisomer:
[0072] In some embodiments, the compound of formula (I) is any of the following compounds, or a pharmaceutically acceptable salt or stereoisomer thereof:
[0073] The second aspect of the present application provides a pharmaceutical composition comprising the compound described in the first aspect of the present application, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and a pharmaceutically acceptable carrier.
[0074] The third aspect of the present application provides use of the compound described in the first aspect of the present application, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and the pharmaceutical composition described in the second aspect of the present application in the preparation of a drug for inhibiting TrkA.
[0075] The fourth aspect of the present application provides the use of the compound described in the first aspect of the present application, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and the pharmaceutical composition described in the second aspect of the present application in the preparation of a drug for treating or preventing pain, cancer, inflammation or neurodegenerative diseases.
[0076] The fifth aspect of the present application provides the compound described in the first aspect of the present application, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof for use as a medicine.
[0077] In one embodiment, the drug is used to treat or prevent a disease associated with abnormal expression of TrkA.
[0078] In one embodiment, the disease associated with abnormal expression of TrkA includes pain, cancer, inflammation or neurodegenerative disease.
[0079] The sixth aspect of the present application provides the compound described in the first aspect of the present application, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or the pharmaceutical composition described in the second aspect of the present application for treating or preventing pain, cancer, inflammation or neurodegenerative diseases.
[0080] The seventh aspect of the present application provides a method for treating or preventing pain, cancer, inflammation or neurodegenerative diseases, comprising administering to a subject a therapeutically effective amount of the compound described in the first aspect of the present application, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or the pharmaceutical composition described in the second aspect of the present application.
[0081] The eighth aspect of the present application provides a compound represented by formula (III-A):
[0082] wherein LG is a leaving group, such as -O-phenyl, wherein phenyl is unsubstituted or substituted with 1, 2 or 3 substituents each independently selected from the group consisting of deuterium, halogen, nitro, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)OC 1-3 Alkyl and -OC(O)C 1-3 alkyl;
[0083] R2' is as defined for R2, and when R2' is a hydroxyl group or an amino group, the hydroxyl group or the amino group is optionally protected by a corresponding hydroxyl protecting group or an amino protecting group;
[0084] Other groups are as defined in the above description.
[0085] In some embodiments, the compound of formula (III-A) is represented by formula (III-A-1):
[0086] where R p For deuterium, halogen, cyano, nitro, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)OC 1-3 Alkyl or -OC(O)C 1-3 alkyl; s is 0, 1, 2 or 3; other groups are as defined in the above description.
[0087] In some embodiments, in the compound of formula (III-A), ring B is a pyridine ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, an imidazole ring, a pyrrole ring, or a pyrazole ring.
[0088] In some embodiments, the compound of formula (III-A-1) is represented by formula (III-A-1a), formula (III-A-1b), or formula (III-A-1c):
[0089] where R L1a 'As R L1a Defined, and when R L1a 'When it is an amino group, the amino group is optionally protected by a corresponding amino protecting group;
[0090] R L1c 'As R L1c Defined, and when R L1c 'When it is an amino group, the amino group is optionally protected by a corresponding amino protecting group;
[0091] R L1d 'As R L1d Defined, and when R L1d 'When it is an amino group, the amino group is optionally protected by a corresponding amino protecting group;
[0092] R Z1 'As R Z1 Defined, and when R Z1 'When it is a hydroxyl group or an amino group, the hydroxyl group or the amino group is optionally protected by a corresponding hydroxyl protecting group or an amino protecting group;
[0093] R Z2 'As R Z2 Defined, and when R Z2 When ' is a hydroxyl group or an amino group, the hydroxyl group or the amino group is optionally protected by a corresponding hydroxyl protecting group or an amino protecting group.
[0094] In some embodiments, the compound of formula (III-A) is a structure selected from the group consisting of:
[0095] In the ninth aspect of the present application, there is provided a method for preparing the compound of formula (I), or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, comprising the following steps:
[0096] i) reacting a compound of formula (III-A) with a compound of formula (III-B) to obtain a compound of formula (I) or a compound of formula (I) protected by a hydroxyl protecting group or an amino protecting group,
[0097] Among them, ring A, ring B, ring C, (R1) n ,m,(R3) t , R0, R a 、R b , p is as defined in the compound represented by formula (I) of the first aspect of the present application, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof;
[0098] LG is a leaving group, such as -O-phenyl, wherein the phenyl group is unsubstituted or substituted with 1, 2 or 3 substituents each independently selected from the group consisting of deuterium, halogen, nitro, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)OC 1-3 Alkyl, -OC(O)C 1-3 alkyl;
[0099] R2' is as defined for R2 in the compound represented by formula (I) of the first aspect of the present application, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and when R2' is a hydroxyl group or an amino group, the hydroxyl group or the amino group is optionally protected by a corresponding hydroxyl protecting group or an amino protecting group;
[0100] The hydroxyl protecting group or amino protecting group can be a conventional protecting group well known to those skilled in the art, and a suitable protecting group can be used according to the structure of the compound. Examples of hydroxyl protecting groups include, but are not limited to, p-methoxybenzyl, benzyl, acetyl, benzyloxycarbonyl, methoxymethylene, methyl, triisopropylsilyl, triethylsilyl, tert-butyldiphenylsilyl, etc.; Examples of amino protecting groups include, but are not limited to, tert-butyloxycarbonyl (t-Boc), benzyloxycarbonyl (Cbz), methyloxycarbonyl (Fmoc), allyloxycarbonyl (Alloc), trimethylsilylethoxycarbonyl (Teoc), phthaloyl (Pht), p-toluenesulfonyl (Tos), trifluoroacetyl (Tfa), trityl (Trt), 2,4-dimethoxybenzyl (Dmb), p-methoxybenzyl (Pmb), benzyl (Bn), 2-biphenyl-2-propyloxycarbonyl (BPoc), p-toluenesulfonyl (Tosyl), trityl (Trityl), etc.
[0101] Optionally, when R2' is a hydroxyl group protected by a hydroxyl protecting group or an amino group protected by an amino protecting group, the compound of formula (I) protected by the hydroxyl protecting group or the amino protecting group is deprotected to obtain the compound of formula (I).
[0102] In some embodiments, the preparation method is carried out in the presence of an alkaline agent. The alkaline agent includes an inorganic base or an organic base, such as triethylamine, diisopropylethylamine, tributylamine, sodium methoxide, sodium ethoxide, potassium ethoxide, sodium tert-butoxide, potassium tert-butoxide, lithium tert-butoxide, 1,8-diazabicyclo[5,4,0]-7-undecene (DBU), lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, N-methylmorpholine, pyridine, or a combination of the above alkaline agents.
[0103] In some embodiments, the compound of formula (III-B) is a trans racemate or a trans single isomer.
[0104] In some embodiments, when the compound of formula (III-B) is a trans racemate, the preparation method further comprises subjecting the compound of formula (I) to chiral resolution to obtain a trans single isomer.
[0105] It should be understood that within the scope of this application, the above-mentioned technical features of this application and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. DETAILED DESCRIPTION
[0106] To make the purpose, technical solutions, and advantages of this application more clearly understood, the following examples are given to further describe this application in detail. Obviously, the described examples are only some examples of this application, rather than all examples. All other examples obtained by those skilled in the art based on this application are within the scope of protection of this application.
[0107] After extensive and in-depth research, the inventors of this application unexpectedly discovered that the fused tricyclic substituted isoxazolidinyl urea derivatives provided herein exhibit significant TrkA kinase and cell inhibitory and selective inhibitory activity, improved in vivo pharmacokinetic parameters, and reduced cardiotoxicity. Therefore, the fused tricyclic substituted isoxazolidinyl urea derivatives provided herein are expected to be developed as TrkA selective inhibitors and, therefore, can be used to treat or prevent diseases associated with abnormal TrkA expression (e.g., overexpression, activation, amplification, or mutation). Based on this, the inventors completed this application.
[0108] The present application provides a series of fused tricyclic substituted isoxazolidinyl urea derivatives. The fused tricyclic substituted isoxazolidinyl urea derivatives of the present application have high inhibitory activity against TrkA enzyme and TrkA-expressing cells, good selective inhibitory activity, better pharmacokinetic parameters and lower cardiotoxicity. The inhibitory IC values of the fused tricyclic substituted isoxazolidinyl urea derivatives of the present application against TrkA enzyme and TrkA-expressing cells are as follows: 50The values can range from 50 nM to 100 nM, and the IC 50 The values can also reach 10nM to 50nM, and the IC 50 The value can even reach 0.1nM to 10nM. Therefore, the fused tricyclic substituted isoxazolidinyl urea derivatives provided by the present application, including pharmaceutically acceptable salts or stereoisomers thereof, can be used as drugs for treating or preventing diseases related to abnormal expression (such as overexpression, activation, amplification or mutation) of TrkA, and can be used to effectively treat or prevent diseases related to abnormal expression of TrkA.
[0109] Definition of terms
[0110] In order to more clearly understand the technical content of this application, the terms of this application are further explained below.
[0111] "Alkyl" refers to straight-chain and branched saturated aliphatic hydrocarbon groups. 1-8 "Alkyl" refers to an alkyl group having 1 to 8 carbon atoms, in some embodiments C 1-6 Alkyl, in other embodiments C 1-3 Alkyl; Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl pentyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched-chain isomers thereof.
[0112] "Alkenyl" refers to a straight or branched unsaturated aliphatic hydrocarbon group having one or more carbon-carbon double bonds (C=C). 2-8"Alkenyl" refers to an alkenyl group having 2 to 8 carbon atoms, in some embodiments C 2-6 Alkenyl, in other embodiments C 2-4 Alkenyl is similarly defined; non-limiting examples of alkenyl include ethenyl, propenyl, isopropenyl, n-butenyl, isobutenyl, pentenyl, hexenyl, and the like.
[0113] "Alkynyl" refers to a straight-chain or branched unsaturated aliphatic hydrocarbon group having one or more carbon-carbon triple bonds. 2-8 "Alkynyl" refers to an alkynyl group having 2 to 8 carbon atoms, in some embodiments C 2-6 Alkynyl, in other embodiments C 2-4 Alkynyl is similarly defined; non-limiting examples of alkynyl include ethynyl, propynyl, n-butynyl, isobutynyl, pentynyl, hexynyl, and the like.
[0114] "Cycloalkyl" and "cycloalkyl ring" are used interchangeably and refer to a saturated monocyclic, bicyclic or polycyclic hydrocarbon group, which may be fused to an aryl or heteroaryl group. The cycloalkyl ring may be optionally substituted. In certain embodiments, the cycloalkyl ring contains one or more carbonyl groups, such as an oxo group. "C 3-8 "Cycloalkyl" refers to a monocyclic cycloalkyl group having 3 to 8 carbon atoms. Non-limiting examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclobutanone, cyclopentanone, cyclopentane-1,3-dione, and the like. In some embodiments, C 3-6 Cycloalkyl, including cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. 8-10 "Cycloalkyl" refers to a fused bicyclic hydrocarbon radical having 8 to 10 ring atoms, C 8-10 Non-limiting examples of cycloalkyl groups include
[0115] "Spirocyclyl" and "spirocycle" are used interchangeably and refer to polycyclic hydrocarbon groups in which the monocyclic rings share a single carbon atom (called a spiro atom). "7- to 11-membered spirocyclyl" refers to a spirocycle having 7 to 11 ring atoms. Spirocycles are classified as bispirocycles or polyspirocycles based on the number of rings, and in some embodiments, are bispirocycles. In other embodiments, they are 4-membered / 5-membered, 5-membered / 5-membered, or 5-membered / 6-membered bispirocycles. For example:
[0116] "Cycloalkenyl" and "cycloalkenyl ring" are used interchangeably and refer to a monocyclic, bicyclic, or polycyclic hydrocarbon group containing one or more carbon-carbon double bonds within the ring, which may be fused to an aryl or heteroaryl group. The cycloalkenyl ring may be optionally substituted. In certain embodiments, the cycloalkenyl ring contains one or more carbonyl groups, such as an oxo group. "C 3-8 "Cycloalkenyl" refers to a cycloalkenyl group having a monocyclic structure of 3 to 8 carbon atoms. In some embodiments, C3-6 Cycloalkenyl. Non-limiting examples of cycloalkenyl groups include cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, cyclopentyl-2-en-1-one, cyclohexyl-2,5-dien-1-one, cyclohexyl-2-en-1-one, cyclohex-2-ene-1,4-dione, and the like.
[0117] "Heterocycloalkyl" and "heterocycloalkyl ring" are used interchangeably and both refer to a cycloalkyl group comprising at least one heteroatom selected from nitrogen, oxygen and sulfur, which group may be fused to an aryl or heteroaryl group. The heterocycloalkyl ring may be optionally substituted. In certain embodiments, the heterocycloalkyl ring contains one or more carbonyl or thiocarbonyl groups, such as groups comprising oxo and thio. "3 to 8 membered heterocycloalkyl" refers to a monocyclic cyclic hydrocarbon group having 3 to 8 ring atoms, wherein 1, 2 or 3 ring atoms are heteroatoms selected from nitrogen, oxygen and sulfur, and in some embodiments, is a 4 to 8 membered heterocycloalkyl group. In other embodiments, it is a 3 to 6 membered heterocycloalkyl group having 3 to 6 ring atoms, wherein 1 or 2 ring atoms are heteroatoms selected from nitrogen, oxygen and sulfur. In other embodiments, it is a 4 to 6 membered heterocycloalkyl group having 4 to 6 ring atoms, wherein 1 or 2 ring atoms are heteroatoms selected from nitrogen, oxygen and sulfur. Non-limiting examples include aziridine, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyrrolyl, oxazolidinyl, dioxolanyl, piperidinyl, piperazinyl, morpholinyl, dioxane, thiomorpholinyl, thiomorpholine-1,1-dioxide, tetrahydropyranyl, azetidin-2-onyl, oxetan-2-onyl, dihydrofuran-2(3H)-onyl, pyrrolidin-2-onyl, pyrrolidin-2,5-dionyl, dihydrofuran-2,5-dionyl, piperidin-2-onyl, tetrahydro-2H-pyran-2-onyl, piperazin-2-onyl, morpholin-3-onyl, and the like. "6- to 12-membered heterocycloalkyl" and "6- to 12-membered fused heterocycloalkyl" are used interchangeably and refer to fused bicyclic cyclic hydrocarbon groups having 6 to 12 ring atoms, of which 1, 2, or 3 ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur. "8- to 10-membered heterocycloalkyl" and "8- to 10-membered fused heterocycloalkyl" are used interchangeably and refer to fused bicyclic cyclic hydrocarbon groups having 8 to 10 ring atoms, of which 1, 2, or 3 ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur. Non-limiting examples include hexahydro-1H-furo[3,4-c]pyrrole, octahydro-1H-cyclopenta[c]pyridine, hexahydro-1H-pyrrolo[2,1-c][1,4]oxazine, octahydropyrrolo[1,2-a]pyrazine, hexahydropyrrolo[1,2-a]pyrazin-4(1H)-one, octahydrocyclopenta[c]pyrrole, and the like. In fused bicyclic heterocycloalkyl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom as valence permits.Bicyclic heterocycloalkyl systems may include one or more heteroatoms in one or both rings.
[0118] "Heterospirocyclyl" and "heterospirocycle" are used interchangeably and refer to a monovalent non-aromatic ring system having two monocyclic rings sharing one carbon atom, which consists of carbon atoms and heteroatoms selected from nitrogen, oxygen, sulfur and phosphorus, does not contain unsaturation, and is connected to the parent nucleus by a single bond. The heterospirocycle can be optionally substituted. In certain embodiments, the heterospirocycle contains one or more carbonyl or thiocarbonyl groups, such as groups comprising oxo and thio. "7 to 11 membered heterospirocyclyl" refers to a heterospirocyclyl having 7 to 11 ring atoms, of which 1, 2 or 3 ring atoms are heteroatoms. Non-limiting examples of heterospirocyclyl include 2,6-diazaspiro[3.4]octan-5-onyl, 2-oxo-6-azaspiro[3.3]heptan-2-yl, 6-oxaspiro[3.3]heptan-2-yl, 7-methyl-7-azaspiro[3.5]nonan-2-yl, 7-methyl-2,7-diazaspiro[3.5]nonan-2-yl, 9-methyl-9-phosphaspiro[5.5]undec-3-yl, and the like.
[0119] "Heterocycloalkenyl" and "heterocycloalkenyl ring" are used interchangeably and refer to a heterocycloalkyl group containing one or more carbon-carbon double bonds or carbon-nitrogen double bonds in the ring, but are not intended to include heteroaryl moieties as defined herein. The group may be fused to an aryl or heteroaryl group. The heterocycloalkenyl ring may be optionally substituted. In certain embodiments, the heterocycloalkenyl ring contains one or more carbonyl or thiocarbonyl groups, such as groups comprising oxo and thio. "5- to 8-membered heterocycloalkenyl ring" refers to a heterocycloalkenyl ring having 5 to 8 ring atoms, wherein 1, 2, or 3 ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, it is a 5- to 6-membered heterocycloalkenyl ring. Non-limiting examples of heterocycloalkenyl rings include 4,5-dihydro-1H-imidazole ring, 1,4,5,6-tetrahydropyrimidine ring, 3,4,7,8-tetrahydro-2H-1,4,6-oxadiazolidine ring, 1,6-dihydropyrimidine ring, 4,5,6,7-tetrahydro-1H-1,3-diazepine ring, 2,5,6,7-tetrahydro-1,3,5-oxadiazepine ring, pyrimidin-2(1H)-one, pyrazin-2(1H)-one, pyridin-2(1H)-one, pyridazin-3(2H)-one.
[0120] "Aryl" and "aryl ring" are used interchangeably to refer to an all-carbon monocyclic or fused polycyclic (i.e., rings that share adjacent pairs of carbon atoms) group with a conjugated π electron system, which may be fused to a cycloalkyl ring, a heterocycloalkyl ring, a cycloalkenyl ring, a heterocycloalkenyl ring, or a heteroaryl ring. 6-10 The term "aryl" refers to a monocyclic or bicyclic aromatic group having 6 to 10 carbon atoms. Non-limiting examples of aryl include phenyl, naphthyl, and the like.
[0121] "Heteroaryl" and "heteroaryl ring" and "heteroaromatic ring" are used interchangeably and refer to a group of a monocyclic, bicyclic or polycyclic 4n+2 aromatic ring system (for example, having 6 or 10 π electrons shared in a cyclic arrangement) having ring carbon atoms and ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur. In the present application, heteroaryl also includes a ring system in which the above-mentioned heteroaryl ring is fused to one or more cycloalkyl rings, heterocycloalkyl rings, cycloalkenyl rings, heterocycloalkenyl rings or aromatic rings. The heteroaryl ring may be optionally substituted. "5- to 10-membered heteroaryl" refers to a monocyclic or bicyclic heteroaryl group having 5 to 10 ring atoms, of which 1, 2, 3 or 4 ring atoms are heteroatoms. "5- to 6-membered heteroaryl" refers to a monocyclic heteroaryl group having 5 to 6 ring atoms, wherein 1, 2, 3 or 4 of the ring atoms are heteroatoms, non-limiting examples of which include thienyl, furanyl, thiazolyl, isothiazolyl, imidazolyl, oxazolyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, tetrazolyl, isoxazolyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and tetrazinyl. "8- to 10-membered heteroaryl" refers to a bicyclic heteroaryl group having 8 to 10 ring atoms, wherein 1, 2, 3 or 4 of the ring atoms are heteroatoms, non-limiting examples of which include indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzo The term "heteroatom" refers to nitrogen, oxygen, or sulfur. In heteroaryl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom, as valence permits. Heteroaryl bicyclic ring systems may include one or more heteroatoms in one or both rings.
[0122] "Fused" refers to structures in which two or more rings share one or more bonds.
[0123] "Benzoheterocycloalkyl" refers to a group in which a benzene ring is fused to a heterocycloalkyl ring to form a bicyclic, tricyclic, or polycyclic ring system, wherein the heterocycloalkyl ring is as defined above. "7- to 11-membered phenylheterocycloalkyl" refers to a bicyclic cyclic group having 7 to 11 ring atoms, of which 1, 2, 3, or 4 ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, it is an 8- to 10-membered phenylheterocycloalkyl group having 8 to 10 ring atoms, of which 1, 2, or 3 ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur. Non-limiting examples include indoline, benzo[d][1,3]dioxazole, 1,2,3,4-tetrahydroisoquinoline, 3,4-dihydro-2H-benzo[b][1,4]oxazine, and the like.
[0124] "Heteroarylheterocycloalkyl" refers to a group in which a heteroaryl ring is fused to a heterocycloalkyl ring to form a bicyclic, tricyclic, or polycyclic ring system, wherein the heterocycloalkyl ring is as defined above. "7- to 11-membered heteroarylheterocycloalkyl" refers to a bicyclic cyclic group having 7 to 11 ring atoms, of which 1, 2, 3, or 4 are heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, it is an 8- to 10-membered heteroarylheterocycloalkyl group having 8 to 10 ring atoms, of which 1, 2, 3, or 4 are heteroatoms selected from nitrogen, oxygen, and sulfur. Non-limiting examples include 2,3-dihydro-1H-pyrrolo[2,3-b]pyridine, [1,3]dioxolane[4,5-b]pyridine, 2,3-dihydro-1H-pyrido[3,4-b][1,4]oxazine, 2,3,4,6-tetrahydropyrrolo[3,4-b][1,4]oxazine, 2,4,5,6-tetrahydropyrano[2,3-c]pyrazole, 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine, and the like.
[0125] "Alkoxy" refers to an -O-alkyl group, wherein alkyl is as defined above. In some embodiments, C 1-8 Alkoxy, in other embodiments, is C 1-6 Alkoxy, in other embodiments, is C 1-3 Alkoxy. Non-limiting examples of alkoxy include methoxy, ethoxy, n-propoxy, isopropoxy, butoxy, tert-butoxy, isobutoxy, pentoxy, and the like.
[0126] "Cycloalkyloxy" refers to an -O-cycloalkyl group, wherein cycloalkyl is as defined above. In some embodiments, C 3-8 Cycloalkyloxy, in other embodiments, is C 3-6 Cycloalkyloxy. Non-limiting examples of cycloalkyloxy include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
[0127] "A bond" means that the two groups connected thereto are connected by one covalent bond.
[0128] "Halogen" refers to fluorine, chlorine, bromine or iodine.
[0129] "Halo" refers to a group in which one or more (eg, 1, 2, 3, 4, or 5) hydrogen atoms are replaced by a halogen.
[0130] For example, "haloalkyl" refers to an alkyl group substituted with one or more (e.g., 1, 2, 3, 4, or 5) halogens, wherein alkyl is as defined above. 1-8 Alkyl, more preferably halogenated C 1-6 Alkyl, in other embodiments, is halogenated C 1-3 Examples of haloalkyl groups include, but are not limited to, monochloromethyl, dichloromethyl, trichloromethyl, monochloroethyl, 1,2-dichloroethyl, trichloroethyl, monobromoethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl, difluoroethyl, trifluoroethyl, and the like.
[0131] For another example, "haloalkoxy" refers to an alkoxy group substituted by one or more (such as 1, 2, 3, 4 or 5) halogens, wherein the definition of alkoxy is as described above. 1-8 Alkoxy, in other embodiments, is halogenated C 1-6 Alkoxy, in other embodiments, is halogenated C 1-3 Alkoxy. Haloalkoxy includes, but is not limited to, trifluoromethoxy, trifluoroethoxy, monofluoromethoxy, monofluoroethoxy, difluoromethoxy, difluoroethoxy, and the like.
[0132] For another example, "halocycloalkyl" refers to a cycloalkyl group substituted with one or more (e.g., 1, 2, 3, 4, or 5) halogens, wherein the definition of cycloalkyl is as described above. 3-8 Cycloalkyl, in other embodiments, is halogenated C 3-6 Cycloalkyl. Halocycloalkyl includes, but is not limited to, trifluorocyclopropyl, monofluorocyclopropyl, monofluorocyclohexyl, difluorocyclopropyl, difluorocyclohexyl, and the like.
[0133] "Deuterated alkyl" refers to an alkyl group substituted with one or more (e.g., 1, 2, 3, 4, or 5) deuterium atoms, wherein alkyl is as defined above. In some embodiments, deuterated C 1-8 Alkyl, in other embodiments deuterated C 1-6 Alkyl, in other embodiments deuterated C 1-3 Examples of deuterated alkyl groups include, but are not limited to, monodeuterated methyl, monodeuterated ethyl, dideuterated methyl, dideuterated ethyl, trideuterated methyl, trideuterated ethyl, and the like.
[0134] "Amino" refers to -NH2, "cyano" refers to -CN, "nitro" refers to -NO2, "benzyl" refers to -CH2-phenyl, "oxo" refers to =O, "carboxyl" refers to -C(O)OH, "acetyl" refers to -C(O)CH3, "hydroxymethyl" refers to -CH2OH, "hydroxyethyl" refers to -CH2CH2OH or -CHOHCH3, "hydroxy" refers to -OH, "mercapto" refers to -SH, and the structure of "cyclopropylene" is:
[0135] "Ms" refers to methylsulfonyl.
[0136] "Saturated or partially unsaturated monocyclic ring" refers to a saturated or partially unsaturated all-carbon monocyclic ring system, wherein "partially unsaturated" refers to a ring portion that includes at least one double bond or triple bond. "Partially unsaturated" is intended to cover rings with multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties as defined herein. In certain embodiments, the saturated or partially unsaturated monocyclic ring contains one or more carbonyl groups, such as an oxo group. "3- to 7-membered saturated or partially unsaturated monocyclic ring" has 3 to 7 ring carbon atoms, in some embodiments, a saturated or partially unsaturated monocyclic ring with 3 to 6 ring carbon atoms, and in other embodiments, a saturated monocyclic ring with 3 to 6 ring carbon atoms. Non-limiting examples of saturated or partially unsaturated monocyclic rings include cyclopropyl ring, cyclobutyl ring, cyclopentyl ring, cyclopentenyl ring, cyclohexyl ring, cyclohexenyl ring, cyclohexadienyl ring, cycloheptyl ring, cycloheptatrienyl ring, cyclopentanone ring, cyclopentane-1,3-dione ring, etc.
[0137] "Saturated or partially unsaturated monocyclic heterocycle" means a saturated or partially unsaturated monocyclic ring in which one, two or three carbon atoms are selected from nitrogen, oxygen or S(O) t(wherein t is an integer of 0, 1, or 2) is substituted with a heteroatom, excluding the ring portion of -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon. A "3- to 7-membered saturated or partially unsaturated monocyclic heterocycle" has 3 to 7 ring atoms, of which 1, 2, or 3 ring atoms are heteroatoms as described above. In some embodiments, it is a 3- to 6-membered saturated or partially unsaturated monocyclic heterocycle having 3 to 6 ring atoms, of which 1 or 2 ring atoms are heteroatoms as described above. In other embodiments, it is a 5- to 6-membered saturated or partially unsaturated monocyclic heterocycle having 5 to 6 ring atoms, of which 1 or 2 ring atoms are heteroatoms as described above. In other embodiments, it is a 5- or 6-membered saturated or partially unsaturated monocyclic heterocycle having 5 to 6 ring atoms, of which 1 or 2 ring atoms are heteroatoms as described above. In other embodiments, it is a 5- or 6-membered saturated monocyclic heterocycle. Non-limiting examples of saturated monocyclic heterocycles include an oxetane ring, an azetidine ring, an oxetane ring, a tetrahydrofuran ring, a tetrahydrothiophene ring, a tetrahydropyrrole ring, a piperidine ring, a pyrroline ring, an oxazolidine ring, a piperazine ring, a dioxolane ring, a dioxane ring, a morpholine ring, a thiomorpholine ring, a thiomorpholine-1,1-dioxide, a tetrahydropyran ring, an azetidine-2-one ring, an oxetane-2-one ring, a pyrrolidine-2-one ring, a pyrrolidine-2,5-dione ring, a piperidin-2-one ring, a dihydrofuran-2(3H)-one ring, a dihydrofuran-2,5-dione ring, a tetrahydro-2H-pyran-2-one ring, a piperazin-2-one ring, and a morpholine-3-one ring. Non-limiting examples of partially unsaturated monocyclic heterocycles include 1,2-dihydroazetidine, 1,2-dihydrooxetadiene, 2,5-dihydro-1H-pyrrole, 2,5-dihydrofuran, 2,3-dihydrofuran, 2,3-dihydro-1H-pyrrole, 3,4-dihydro-2H-pyran, 1,2,3,4-tetrahydropyridine, 3,6-dihydro-2H -pyran ring, 1,2,3,6-tetrahydropyridine ring, 4,5-dihydro-1H-imidazole ring, 1,4,5,6-tetrahydropyrimidine ring, 3,4,7,8-tetrahydro-2H-1,4,6-oxadiazolidine ring, 1,6-dihydropyrimidine ring, 4,5,6,7-tetrahydro-1H-1,3-diazepine ring, 2,5,6,7-tetrahydro-1,3,5-oxadiazepine ring, etc.
[0138] "Substituted" refers to one or more hydrogen atoms, in some embodiments, 1 to 5 hydrogen atoms, in other embodiments, 1 to 3 hydrogen atoms, independently replaced by a corresponding number of substituents in a group. It is understood that substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, amino or hydroxy groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (e.g., olefinic) bonds.
[0139] Unless otherwise defined, the "substituents independently selected from..." mentioned herein means that when more than one hydrogen on a group is replaced by a substituent, the substituents may be of the same or different types, and the substituents selected are of independent types.
[0140] Unless otherwise defined, the phrase "...same or different, and each independently is..." in this application means that when there are more than one identical substituent group in the general formula, the groups may be the same or different and are each independent species. For example, L is (CR L1 R L2 ) s , when s is 2, that is, L is (CR L1 R L2 )-(CR L1 R L2 ), where two R L1 Can be the same or different, two R L2 They can be the same or different and are independent species. For example, L can be C(CH3)(CN)-C(CH2CH3)(OH), C(CH3)(CN)-C(CH3)(OH) or C(CN)(CH2CH3)-C(OH)(CH2CH3).
[0141] Unless otherwise defined, any group herein may be substituted or unsubstituted. When the above groups are substituted, in some embodiments, the substituents are 1 to 5 groups independently selected from cyano, halogen (in some embodiments, fluorine or chlorine), C 1-8 Alkyl (in some embodiments, C 1-6 Alkyl, in other embodiments C 1-3 Alkyl), C 1-8 Alkoxy (in some embodiments, C 1-6 Alkoxy, in other embodiments, is C 1-3 Alkoxy), halogenated C 1-8 Alkyl (in some embodiments, halogenated C 1-6 Alkyl, in other embodiments, is halogenated C 1-3 Alkyl), C 3-8 Cycloalkyl (in some embodiments, C 3-6 Cycloalkyl), halogenated C 1-8 Alkoxy (in some embodiments, halogenated C 1-6 Alkoxy, in other embodiments, is halogenated C 1-3 Alkoxy), C 1-8 Alkyl-substituted amino, halogenated C 1-8 Alkyl-substituted amino, acetyl, hydroxy, hydroxymethyl, hydroxyethyl, carboxyl, nitro, C 6-10 Aryl (phenyl in some embodiments), C 3-8Cycloalkyloxy (in some embodiments, C 3-6 Cycloalkyloxy), C 2-8 Alkenyl (in some embodiments, C 2-6 Alkenyl, in other embodiments C 2-4 alkenyl), C 2-8 Alkynyl (in some embodiments, C 2-6 Alkynyl, in other embodiments C 2-4 Alkynyl), -CONR a0 `R b0 `、-C(O)OC 1-10 Alkyl (in some embodiments -C(O)OC 1-6 Alkyl, in other embodiments -C(O)OC 1-3 alkyl), -CHO, -OC(O)C 1-10 Alkyl (in some embodiments -OC(O)C 1-6 Alkyl, in other embodiments -OC(O)C 1-3 Alkyl), -SO2C 1-10 Alkyl (in some embodiments -SO2C 1-6 Alkyl, in other embodiments -SO2C 1-3 Alkyl), -SO2C 6-10 Aryl (in some embodiments, -SO2C6 aryl, such as -SO2-phenyl), -COC 6-10 Aryl (in some embodiments, -COC6 aryl, such as -CO-phenyl), 4- to 6-membered saturated or unsaturated monocyclic heterocyclic ring, 4- to 6-membered saturated or unsaturated monocyclic ring, 5- to 6-membered monocyclic heteroaryl ring, 8- to 10-membered bicyclic heteroaryl ring, spirocyclic ring, spiroheterocyclic ring, bridged ring, or bridged heterocyclic ring, wherein R a0 `、R b0 `Each independently is hydrogen or C 1-3 alkyl.
[0142] In the present application, when the number of substituents is greater than 1, any two substituents may be the same or different. For example, the substituents may be two halogens that are the same or different, or one halogen and one hydroxyl group.
[0143] Each type of substituent group described herein above can itself be substituted with the groups described herein.
[0144] When the 4- to 6-membered saturated monocyclic heterocycle described herein is substituted, the substituents may be positioned at their possible chemical positions. Representative substitutions of exemplary monocyclic heterocycles are shown below: Wherein "Sub" represents various substituents described herein; Indicates the connection position with other atoms.
[0145] This article involves numerical ranges, unless otherwise specified, including every integer between the minimum value (inclusive) and the maximum value (inclusive) of the range. 1-8 The "1-8" in the alkyl group may refer to 1, 2, 3, 4, 5, 6, 7 or 8.
[0146] In the present invention, the term "about" is defined as close to as understood by those of ordinary skill in the art. In a non-limiting embodiment, the term is defined as within 10%, preferably within 5%, more preferably within 1%, and further preferably within 0.5%.
[0147] Pharmaceutical composition
[0148] Generally, the compounds of the present application or their pharmaceutically acceptable salts, or their stereoisomers can be administered in a suitable dosage form with one or more pharmaceutical carriers. These dosage forms are suitable for oral, rectal, topical, oral, and other parenteral administrations (e.g., subcutaneous, intramuscular, intravenous, etc.). For example, dosage forms suitable for oral administration include capsules, tablets, granules, and syrups. The compounds of the present application contained in these preparations can be solid powders or particles; solutions or suspensions in aqueous or non-aqueous liquids; water-in-oil or oil-in-water emulsions, etc. The above dosage forms can be prepared from the active compound and one or more carriers or excipients via common pharmaceutical methods. The above carriers need to be compatible with the active compound or other excipients. For solid preparations, commonly used non-toxic carriers include but are not limited to mannitol, lactose, starch, magnesium stearate, cellulose, glucose, sucrose, etc. Carriers for liquid preparations include water, physiological saline, aqueous glucose solution, ethylene glycol, and polyethylene glycol, etc. The active compound can form a solution or suspension with the above carriers.
[0149] "Pharmaceutically acceptable carrier" refers to a non-toxic, inert, solid, semi-solid substance or liquid filler, diluent, encapsulating material or auxiliary formulation or any type of excipient that is compatible with a patient, such as a mammal, such as a human, and is suitable for delivering an active agent to a target site without terminating the activity of the agent.
[0150] The “active substance of the present application” or “active compound of the present application” refers to the compound of formula (I) of the present application, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, which has high TrkA selective inhibitory activity.
[0151] The compositions of the present application are formulated, dosed and administered in a manner consistent with medical practice. The "therapeutically effective amount" of the compound administered is determined by factors such as the condition to be treated, the individual being treated, the cause of the condition, the target of the drug, and the mode of administration.
[0152] "Therapeutically effective amount" refers to the amount of the compound of the present invention that will induce a biological or medical response in a subject, such as reducing or inhibiting enzyme or protein activity or improving symptoms, alleviating symptoms, slowing or delaying disease progression, or preventing disease.
[0153] The therapeutically effective amount of the compound of the present application or its pharmaceutically acceptable salt, or its stereoisomer contained in the pharmaceutical composition or the pharmaceutical composition of the present application is, for example, 0.1 mg / kg to 5 g / kg body weight.
[0154] "Patient" refers to an animal, such as a mammal, for example, a human. The term "mammal" refers to warm-blooded vertebrate mammals, including cats, dogs, rabbits, bears, foxes, wolves, monkeys, deer, mice, pigs and humans.
[0155] "Treatment" refers to alleviating, slowing the progression of, attenuating, preventing, or maintaining an existing disease or condition (eg, cancer). Treatment also includes curing, preventing the development of, or alleviating to some extent, one or more symptoms of a disease or condition.
[0156] The term "pharmaceutically acceptable salt" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts. Pharmaceutically acceptable acid addition salts are salts formed with inorganic or organic acids that retain the biological effectiveness of the free base without other side effects. Inorganic acid salts include, but are not limited to, hydrobromide, sulfate, and phosphate; organic acid salts include, but are not limited to, acetate, propionate, glycolate, gluconate, lactate, and oxalate. These salts can be prepared by methods known in the art.
[0157] "Pharmaceutically acceptable base addition salts" include, but are not limited to, salts with inorganic bases such as sodium, potassium, calcium, and magnesium salts. They also include, but are not limited to, salts with organic bases such as ammonium, triethylamine, lysine, and arginine salts. These salts can be prepared by methods known in the art.
[0158] When the compound shown in the formula (I) of the present application contains one or more chiral centers, it can exist in different optically active forms. When the compound of formula (I) contains more than one chiral center, the compound comprises enantiomers and diastereomers. All enantiomers and diastereomers of the compound, as well as mixtures of enantiomers, mixtures of diastereomers, and mixtures of enantiomers and diastereomers are also within the scope of protection of the present application. Enantiomers and diastereomers can be separated by methods known in the art, such as crystallization and preparative chromatography. Stereoisomers of the compound of formula (I) include trans single isomers and cis single isomers.
[0159] Unless otherwise specified, use wedge-shaped solid key and dotted wedge key To indicate the absolute configuration of a stereocenter, use a straight solid bond and straight dashed key Indicates the relative configuration of a stereocenter.
[0160] In the compound structure of the present application, a group of substituents on the isoxazolidine in the ortho position are used. and The chemical bond of indicates that the relative configuration between the two groups connected is trans, which is expressed as a trans racemate. and The chemical bond of indicates that the two groups connected are trans to each other, indicating a trans single isomer. and Or use and The chemical bond of indicates that the relative configuration between the two groups connected is cis, which is expressed as a cis racemate. and Or use and The chemical bond represents that the two groups connected are cis to each other, and is represented as a cis single isomer. The compound shown in formula (I) of the present application can exist in the form of a mixture containing trans and cis configurations, or exist in a cis single isomer configuration, or exist in a cis racemate form, or exist in a trans single isomer configuration, or exist in a trans racemate form. Wherein the cis racemate represents a mixture containing a pair of cis single isomers, and the trans racemate represents a mixture containing a pair of trans single isomers. In some embodiments, it exists in a trans single isomer configuration. In some embodiments, it exists in a trans racemate form. In addition, the pair of chemical bonds connected on the ortho position of isoxazolidine in the compound structure are or or both or When , it indicates cis configuration. The pair of chemical bonds connected to the ortho position of isoxazolidine are and or respectively and , it indicates the trans configuration.
[0161] Preparation method
[0162] The application provides a preparation method of a compound of formula (I), which can be synthesized using standard synthesis techniques known to those skilled in the art or using methods known in the art in combination with the method described herein. The solvent, temperature, and other reaction conditions provided herein can be changed according to the art. The reactions can be used in sequence to provide compounds of the application, or they can be used to synthesize fragments, which are subsequently added by methods described herein and methods known in the art.
[0163] The compound described in this application can use the illustrative method described in the following similar method or embodiment, or the relevant open literature used by those skilled in the art, by using appropriate selectable starting material synthetic compound. The starting material for synthesizing the compound described in this application can be synthesized or can be obtained from commercial sources. The compound described in this application and other related compounds with different substituents can be synthesized using technology and raw materials known to those skilled in the art. The general method for preparing the compound of the application can be from reactions known in the art, and the reaction can be modified by those skilled in the art to consider appropriate reagents and conditions to introduce the various parts in the molecule provided by the application.
[0164] The present application will be further described below in conjunction with the examples. It should be understood that these examples are intended to illustrate the present application only and are not intended to limit the scope of the present application. The experimental methods for which the conditions are not specified in the following examples are generally based on conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight. Unless otherwise defined, the terms used herein have the same meaning as those familiar to those skilled in the art. In addition, any method and material similar or equivalent to the described content can be applied to the present application.
[0165] Known starting materials can be synthesized by methods known in the art, or can be purchased from companies such as ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, and Darui Chemicals.
[0166] Unless otherwise specified, the reactions in the examples were carried out under nitrogen or argon atmosphere.
[0167] DCM: dichloromethane, TEA: triethylamine, TFA: trifluoroacetic acid, NaHMDS: sodium bis(trimethylsilyl)amide, DMF: dimethylformamide, DMSO: dimethyl sulfoxide, THF: tetrahydrofuran, DIEA: N,N-diisopropylethylamine, EA: ethyl acetate, PE: petroleum ether, DMAP: 4-dimethylaminopyridine, TsCl: 4-toluenesulfonyl chloride, HATU: 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, DMF-DMA: N,N-dimethylformamide dimethyl acetal, LDA: lithium diisopropylamide, MCPBA: m-chloroperbenzoic acid, TMSCN: trimethylsilyl cyanide, TMSCl: trimethylchlorosilane, BINAP: (2R,3S)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, NBS: N-bromosuccinimide, NCS: N-chlorosuccinimide, Pd2(dba)3: tris(dibenzylideneacetone)dipalladium, Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, Pd(dppf)Cl2: [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium, DPPA: diphenylphosphoryl azide, Grubb's 2 Catalyst: 1,3-bis(2,4,6-trimethylphenyl)-2-(imidazolidinylidene)(dichlorobenzylidene)(tricyclohexylphosphine)ruthenium, PMBCl: p-methoxybenzyl chloride, TfOH: trifluoromethanesulfonic acid, DBU: 1,8-diazabicycloundec-7-ene, TBAF: tetrabutylammonium fluoride, Na Ascorbate: sodium ascorbate, t-BuXPhosPd-G3: methanesulfonic acid (2-di-tert-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium(II), MeCN: acetonitrile, t-BuONa: sodium tert-butoxide, NH2OH·HCl: hydroxylamine hydrochloride, EtOAc: ethyl acetate, LiHMDS: lithium bis(trimethylsilyl)amide, HOAc: acetic acid, EtOH: ethanol, NaH: sodium hydride, MeOH: methanol, POCl3: phosphorus oxychloride, Cs2CO3: cesium carbonate, NH4HCO3: ammonium bicarbonate, combiflash: rapid preparative chromatography, DIPEA: N,N-diisopropylethylamine, LiOH: lithium hydroxide, SOCl2: thionyl chloride, H2O2: hydrogen peroxide, t-BuOH: tert-butanol, Boc2O: di-tert-butyl dicarbonate, NH2Boc: tert-butyl carbamate, ACN: acetonitrile, Pd / C: palladium on carbon, Ac2O: acetic anhydride, SnCl2: stannous chloride, Pd(OAc)2: palladium acetate, dioxane: dioxane, Methanol: methanol, Na2SO3: sodium sulfite, Ammonia: ammonia water, BH3: borane, DAST: diethylaminosulfur trifluoride.
[0168] The percentages mentioned in this application, unless otherwise specified, refer to mass percentages for solid-liquid mixtures and solid-solid mixtures, and volume percentages for liquid-liquid mixtures. Unless otherwise specified, the solvent is water.
[0169] As used herein, room temperature refers to about 20°C to about 30°C.
[0170] As used herein, "overnight" means from about 10 h to about 16 h.
[0171] The configurations of the following examples of the present application and their intermediates are as described in detail in the examples. In the compound structure, a pair of isoxazolidines at the ortho position are used. and The relative configuration between the chemically bonded groups is trans, indicating a trans racemic form. and The configuration represented by the chemical bonds is the trans single isomer configuration.
[0172] Intermediate 1
[0173] Step 1: Dissolve cycloheptane-1,3-dione (1 g, 8 mmol) in 3 mL of DMF-DMA and reflux at 95°C for 2 h. After cooling to room temperature, add ethanol solution (twice) and concentrate under reduced pressure to obtain compound 1-1 (1.4 g, orange-red solid). Yield: 100%. MS m / z (ESI): 182.3 [M+H] + .
[0174] Step 2: Dissolve compound 1-1 (1.4 g, 8 mmol) in ethanol (30 mL). Add acetamidine hydrochloride (1.46 g, 15 mmol) and triethylamine (2.33 g, 23 mmol) sequentially. Reflux at 95°C for 16 h. Concentrate the reaction mixture and purify it by reverse phase chromatography (A: H2O; B: MeCN) to obtain compound 1-2 (1.13 g, red oil) in an 83% yield. 1 HNMR (400MHz, CDCl3) δ (ppm): 8.93 (s, 1H), 3.19-3.11 (m, 2H), 2.89-2.77 (m, 5H), 2.07-1.94 (m, 4H). MS m / z(ESI):177.2[M+H] + .
[0175] Step 3: Dissolve compound 1-2 (1.13 g, 6 mmol) and ethyl formate (0.95 g, 13 mmol) in a toluene solution (25 mL). Slowly add t-BuONa (1.23 g, 13 mmol) at 0°C and react at room temperature for 1 h. Extract the reaction mixture with water (30 mL), acetic acid (4 mL), and ethyl acetate (50 mL x 3). The organic layer is washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain compound 1-3 (1.4 g, orange oil). MS m / z (ESI): 205.3 [M+H] + .
[0176] Step 4: Dissolve compound 1-3 (1.4 g, 7 mmol) and NH2OH·HCl (947 mg, 14 mmol) in acetic acid solution (6 mL) and reflux at 90°C for 1 h. Concentrate the mixture, add saturated sodium bicarbonate solution (50 mL), and extract with ethyl acetate (50 mL x 2). The organic layer is washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain compound 1-4 (1.07 g, yellow solid) in a yield of 78%. MS m / z (ESI): 202.3 [M+H] + .
[0177] Step 5: Compound 1-4 (1.07 g, 5 mmol) was dissolved in methanol / ether (1:1, 10 mL), and 5N MeONa (2.13 mL, 11 mmol) was added at room temperature. The mixture was reacted at room temperature for 1 h. Water (50 mL) was added, and the pH was adjusted to 5 with acetic acid solution. The reaction mixture was extracted with ethyl acetate (50 mL × 3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain compound 1-5 (1.19 g, dark yellow oil). MS m / z (ESI): 202.3 [M+H] + .
[0178] Step 6: Dissolve intermediate 1-5 (1.19 g, 6 mmol) and phenylhydrazine (1.16 mL, 12 mmol) in ethanol, add 4 drops of concentrated hydrochloric acid, and react at 95°C for 3 h. Concentrate under reduced pressure and purify by reverse phase chromatography (A: H2O; B: MeCN) to afford compound 1-6 (0.92 g, yellow solid) in a 54% yield. MS m / z (ESI): 292.4 [M+H] + .
[0179] Step 7: Compound 1-6 (100 mg, 0.34 mmol) was dissolved in DCM (4 mL), pyridine (0.25 mL) was added, and phenyl chloroformate (80.36 mg, 0.51 mmol) was added dropwise. The mixture was reacted at room temperature for 1 h. Dichloromethane (40 mL) was added, and the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, wet loaded, and passed through a silica gel column (PE:EA = 2:1) to afford Intermediate 1 (90 mg, white solid). Yield: 50%. MS m / z (ESI): 412.5 [M+H]. + .
[0180] Intermediate 2
[0181] Step 1: Dissolve cycloheptane-1,3-dione (2.6 g, 20.61 mmol) in 1,1-dimethoxy-N,N-dimethylmethanamine (7.37 g, 61.83 mmol). Stir the reaction mixture at 90°C for 3 hours and spin dry to obtain compound 1-1 (3.74 g, yellow oil). Yield: 100%. MS m / z (ESI): 182.1 [M+H] + .
[0182] Step 2: Dissolve compound 1-1 (3.74 g, 20.64 mmol) and tert-butyl N-(methylamino)carbamate (3.02 g, 20.64 mmol) in toluene (5 mL). Stir the reaction mixture at 100°C for 16 hours. After the reaction, the solvent was dried and filtered through a column (PE / EtOAc = 3 / 2) to obtain compound 2-2 (1.7 g, yellow solid). Yield: 50.17%. MS m / z (ESI): 165.1 [M+H] + .
[0183] Step 3: Dissolve compound 2-2 (1.2 g, 7.31 mmol) in THF (15 mL). The reaction mixture was then cooled to -78°C, and LiHMDS (1 M, 8.77 mL) was added. The mixture was stirred at -78°C for 1 hour, followed by the addition of p-toluenesulfonylcarbonitrile (1.99 g, 10.96 mmol), and stirred at -78°C for another 1 hour. After completion of the reaction, the mixture was quenched with saturated ammonium chloride, extracted with ethyl acetate, and dried over anhydrous sodium sulfate. The solvent was evaporated and passed through a column chromatography (PE / EtOAc = 3 / 2) to afford compound 2-3 (1.1 g, yellow solid). Yield: 79.55%. MS m / z (ESI): 190.1 [M+H] + .
[0184] Step 4: Dissolve compound 2-3 (1.1 g, 5.81 mmol) and phenylhydrazine (943.02 mg, 8.72 mmol) in HOAc (3 mL) and EtOH (10 mL). Stir the reaction mixture at 90°C for 4 hours. Dry the solvent and filter through a column (PE / EtOAc = 1 / 1) to obtain compound 2-4 (1.6 g, yellow solid). Yield: 98.53%. MS m / z (ESI): 280.2 [M+H] + .
[0185] Step 5: Compound 2-4 (70 mg, 0.25 mmol) was dissolved in DCM (5 mL), and pyridine (59 mg, 0.75 mmol) was added. The reaction solution was cooled to 0°C, and phenyl chloroformate (47 mg, 0.30 mmol) was added dropwise. The reaction solution was stirred at room temperature for 1 hour. After the reaction was complete, the solvent was evaporated under reduced pressure to obtain intermediate 2 (50 mg, yellow solid). Yield: 50.12%. MS m / z (ESI): 400.1 [M+H] + .
[0186] Intermediate 3
[0187] Step 1: Dissolve cycloheptane-1,3-dione (9 g, 71.34 mmol) in DCM (4.78 mL), then add DMF (5.21 g, 71.34 mmol, 5.52 mL). Cool the reaction mixture to 0°C, then add oxalyl chloride (10.87 g, 85.61 mmol). Stir the reaction mixture at 0°C for half an hour. Spin dry to obtain compound 3-1 (10.32 g, yellow oil). Yield: 100%. MS m / z (ESI): 145.2 [M+H] + .
[0188] Step 2: Dissolve 2-cyanoacetamide (12.00 g, 142.74 mmol) in DMF (30 mL), cool to 0°C, add NaH (6.28 g, 157.01 mmol, 60% purity), and stir at 0°C for half an hour. Then, add compound 3-1 (10.32 g, 71.37 mmol). The reaction mixture is stirred at room temperature for half an hour. The DMF is dried and quenched with water. The mixture is extracted with ethyl acetate. The aqueous phase is acidified with 2M HCl and extracted three times with DCM / MeOH (10 / 1). The combined extracts are dried over anhydrous sodium sulfate. The product is dried and passed through a column chromatography (PE / EtOAc = 2 / 3) to afford compound 3-2 (8 g, yellow oil). Yield: 58.32%. MS m / z (ESI): 193.1 [M+H]. + .
[0189] Step 3: Dissolve 1,1-dimethoxy-N,N-dimethylmethanamine (7.44 g, 62.43 mmol) in DMF (50 mL), then add compound 3-2 (8 g, 41.62 mmol). The reaction mixture was stirred at 50°C for 4 hours. The DMF was evaporated, quenched with water, and the aqueous phase was acidified with 2M HCl and filtered. Compound 3-3 (6.1 g, yellow solid) was obtained in a yield of 72.48%. MS m / z (ESI): 203.1 [M+H] + .
[0190] Step 4: Dissolve compound 3-3 (6 g, 29.67 mmol) in 50% H2SO4 (50 mL) and heat to 130°C. Stir the reaction mixture at 130°C for 16 hours. Quench with saturated potassium carbonate and remove water by spin drying. Purify the mixture by column chromatography (DCM / MeOH = 20 / 1) to afford compound 3-4 (2.8 g, yellow solid). Yield: 53.25%. MS m / z (ESI): 178.1 [M+H] + .
[0191] Step 5: Compound 3-4 (1 g, 5.64 mmol) was dissolved in POCl₃ (2.60 g, 16.93 mmol), and the reaction mixture was stirred at 90°C for 3 hours. The POCl₃ was evaporated to dryness, quenched with ice water, and the aqueous phase was made alkaline with saturated sodium bicarbonate. The extracts were extracted three times with DCM, combined, and dried over anhydrous sodium sulfate. The product was dried and purified by column chromatography (PE / EtOAc = 2 / 1) to afford compound 3-5 (0.9 g, yellow solid). Yield: 81.51%. MS m / z (ESI): 196.0 [M+H] + .
[0192] Step 6: Compound 3-5 (390 mg, 1.99 mmol) and benzyl carbamate (602.66 mg, 3.99 mmol) were dissolved in toluene (10 mL). Cs2CO3 (649.49 mg, 1.99 mmol), Pd2(dba)3 (91.27 mg, 99.67 μmol), and Xantphos (115.34 mg, 199.34 μmol) were then added. The reaction mixture was stirred at 100°C under nitrogen for 16 hours. The mixture was then dried and passed through a column (PE / EtOAc = 2 / 1) to afford compound 3-6 (610 mg, yellow solid). Yield: 98.60%. MS m / z (ESI): 311.1 [M+H] + .
[0193] Step 7: Compound 3-6 (610 mg, 1.97 mmol) was dissolved in THF (5 mL), then cooled to -78°C. LiHMDS (1 M, 5.90 mL) was added and stirred at -78°C for half an hour. Then, p-toluenesulfonylcarbonitrile (712.36 mg, 3.93 mmol) was added. The reaction mixture was stirred at -78°C for 1 hour. The reaction mixture was quenched with ammonium chloride, extracted with ethyl acetate, and dried over anhydrous sodium sulfate. The solvent was dried and passed through a column (PE / EtOAc = 2 / 1) to obtain compound 3-7 (450 mg, yellow solid). Yield: 68.27%. MS m / z (ESI): 336.1 [M+H] + .
[0194] Step 8: Dissolve compound 3-7 (600 mg, 1.79 mmol) and phenylhydrazine (386.96 mg, 3.58 mmol) in HOAc (2 mL) and EtOH (10 mL). Stir the reaction mixture under nitrogen at 90°C for 16 hours. The solvent was evaporated and filtered through a column (PE / EtOAc = 2 / 1) to afford compound 3-8 (290 mg, yellow solid). Yield: 38.10%. MS m / z (ESI): 426.2 [M+H] + .
[0195] Step 9: Compound 3-8 (86 mg, 202.12 μmol) was dissolved in DCM (5 mL), followed by the addition of pyridine (47.96 mg, 606.37 μmol, 48.85 μL) and phenyl chloroformate (63.29 mg, 404.25 μmol). The reaction mixture was stirred under nitrogen at room temperature for 3 hours. The mixture was dried to afford Intermediate 3 (110 mg, yellow solid). Yield: 99.75%. MS m / z (ESI): 546.0 [M+H] + .
[0196] Intermediate 4
[0197] Step 1-5: Refer to the preparation method of compound 1-5, except that (4-methoxybenzyl)hydrazine is used instead of acetamidine hydrochloride to obtain compound 4-5. MS m / z (ESI): 296.0 [M+H] + .
[0198] Step 6: Refer to the preparation method of compound 1-6, except that intermediate 4-5 replaces intermediate 1-5 to obtain compound 4-6 (3.0 g, yellow solid), yield: 50%. MS m / z (ESI): 386.1 [M+H] + .
[0199] Step 7: Dissolve compound 4-6 (3 g, 7.8 mmol) in trifluoroacetic acid (50 mL) and react at 75°C for 24 h. The mixture was concentrated and purified by reverse phase chromatography (A: H2O; B: MeCN) to afford compound 4-7 (1.1 g, brown solid) in a 52% yield. MS m / z (ESI): 266.1 [M+H] + .
[0200] Step 8: Dissolve compound 4-7 (1 g, 3.77 mmol) and DIEA (974.25 mg, 7.54 mmol, 1.31 mL) in DCM (10 mL), cool to 0°C, then add methanesulfonyl chloride (647.64 mg, 5.65 mmol). Stir the reaction mixture at room temperature for 1 hour. Spin dry and pass through a column (PE / EtOAc = 1 / 1) to obtain the crude product, which is then chirally prepared to afford compound 4-8 (366 mg, yellow solid). Yield: 28.28%. MS m / z (ESI): 344.1 [M+H]. + .
[0201] Step 9: Compound 4-8 (68 mg, 198.02 μmol) was dissolved in DCM (5 mL), followed by the addition of pyridine (46.99 mg, 594.05 μmol, 47.86 μL) and phenyl chloroformate (46.50 mg, 297.03 μmol). The reaction mixture was stirred at room temperature for 2 hours. The mixture was dried to afford intermediate 4 (91 mg, yellow solid). Yield: 99.15%. MS m / z (ESI): 464.1 [M+H] + .
[0202] Intermediate 5
[0203] Step 1: 1,1-dimethylhydrazine hydrochloride (3 g, 31.07 mmol) was added to ethanol (50 mL), sodium bicarbonate (2.61 g, 31.07 mmol) was added, and the reaction solution was stirred at room temperature for 30 minutes. Then, cycloheptane-1,3-dione (3.92 g, 31.07 mmol) and indium chloride (687.19 mg, 3.11 mmol) were added. The reaction solution was stirred at room temperature for 2 hours. Water (100 mL) was added and extracted with dichloromethane (100 mL x 3). The organic phase was dried, filtered, and concentrated under reduced pressure to give compound 5-1 (5.2 g, yellow solid). The crude product was used directly in the next step. MS m / z (ESI): 169.1 [M+H] + .
[0204] Step 2: Compound 5-1 (5.2 g, 30.91 mmol) and acrolein (2.60 g, 46.36 mmol) were added to ethanol (50 mL). The reaction mixture was heated to 50°C and stirred for 16 hours. The mixture was concentrated under reduced pressure. The residue was dissolved in dichloromethane (150 mL) and washed sequentially with saturated sodium chloride solution (50 mL) and water (50 mL). The organic phase was dried, filtered, and concentrated under reduced pressure to afford compound 5-2 (6.6 g, yellow oil) in a yield of 84.62%. MS m / z (ESI): 253.2 [M+H] + .
[0205] Step 3: Compound 5-2 (5.6 g, 22.28 mmol) and 10% palladium on carbon (1.3 g, 4.46 mmol) were added to xylene (80 mL). The reaction mixture was stirred at 120°C for 48 hours. Filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using an eluent system (petroleum ether / tetrahydrofuran: 1 / 0 to 1 / 1) to afford compound 5-3 (1.8 g, orange oil) in a yield of 50.12%. MS m / z (ESI): 162.1 [M+H] + .
[0206] Step 4: Compound 5-3 (420 mg, 2.61 mmol) was added to tetrahydrofuran (145 mL). Under argon, the mixture was cooled to -78°C and lithium bis(trimethylsilyl)amide (1 M, 5.21 mL) was added dropwise. The reaction mixture was stirred at -78°C for 1 hour. A solution of 4-methylbenzenesulfonyl cyanide (944.28 mg, 5.21 mmol) in tetrahydrofuran (5 mL) was then added dropwise. The reaction mixture was stirred at -78°C for 1 hour. Saturated ammonium chloride solution (10 mL) was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phase was dried, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using an eluent system (petroleum ether / ethyl acetate: 1 / 0 to 2 / 3) to afford compound 5-4 (80 mg, yellow oil) in a yield of 16.49%. MS m / z (ESI): 187.1 [M+H]. + .
[0207] Step 5: Phenylhydrazine (69.69 mg, 644.44 μmol) and compound 5-4 (80 mg, 429.62 μmol) were added to acetic acid (1 mL) and ethanol (4 mL). The reaction mixture was stirred at 90°C for 2 hours. The mixture was concentrated under reduced pressure and the resulting residue was purified by silica gel column chromatography using a solvent system (petroleum ether / tetrahydrofuran: 1 / 0 to 1 / 1) to afford compound 5-5 (80 mg, yellow oil) in a yield of 67.39%. MS m / z (ESI): 277.1 [M+H] + .
[0208] Step 6: Dissolve compound 5-5 (50 mg, 180.94 μmol) in dichloromethane (10 mL), add phenyl chloroformate (56.66 mg, 361.88 μmol) and pyridine (42.94 mg, 542.82 μmol, 43.73 μL). The reaction solution was stirred at room temperature for 3 hours. Water (20 mL) was added for washing, and the aqueous phase was extracted with dichloromethane (20 mL x 3). The organic phase was dried and filtered. Concentration under reduced pressure gave intermediate 5 (90 mg, light yellow oil), which was used directly in the next step. MS m / z (ESI): 397.1 [M+H] + .
[0209] Intermediate 6
[0210] Step 1: Dissolve 6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-5-one (1 g, 6.20 mmol) in dichloromethane (20 mL) and add m-chloroperbenzoic acid (1.61 g, 9.31 mmol). The reaction mixture was stirred at room temperature for 16 hours. Saturated sodium bicarbonate solution (25 mL) was added and the mixture was extracted with dichloromethane (30 mL x 3). The organic phase was dried, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using an eluent system (dichloromethane / methanol: 1 / 0 to 10 / 1) to afford compound 6-1 (890 mg, white solid) in a yield of 80.96%. MS m / z (ESI): 178.1 [M+H] + .
[0211] Step 2: Compound 6-1 (890 mg, 5.02 mmol) was added to phosphorus oxychloride (8 mL), and the reaction mixture was stirred at 120°C for 3 hours. The mixture was concentrated under reduced pressure. The residual solution was quenched with ice water, and the pH was adjusted to neutral by adding saturated sodium bicarbonate solution. The mixture was extracted with dichloromethane (30 mL x 3). The organic phase was dried, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using an eluent system (petroleum ether / ethyl acetate: 1 / 0 to 3 / 1) to obtain compound 6-2 (420 mg, light yellow oil) in a yield of 42.74%. MS m / z (ESI): 196.1 [M+H] + .
[0212] Step 3: Benzyl carbamate (356.96 mg, 2.36 mmol) and compound 6-2 (420 mg, 2.15 mmol) were added to toluene (20 mL), followed by cesium carbonate (839.34 mg, 2.58 mmol), tris(dibenzylideneacetone)dipalladium (98.29 mg, 107.34 μmol), and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (124.21 mg, 214.67 μmol). The reaction mixture was stirred at 105°C under nitrogen for 16 hours. The mixture was filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using a solvent system (petroleum ether / ethyl acetate: 1 / 0 to 3 / 1) to afford compound 6-3 (520 mg, light yellow oil) in a yield of 78.05%. MS m / z (ESI): 311.1 [M+H] + .
[0213] Step 4: Compound 6-3 (520 mg, 1.68 mmol) was added to THF (20 mL). Under argon, the mixture was cooled to -78°C and lithium bis(trimethylsilyl)amide (1 M, 5.03 mL) was added dropwise. The reaction mixture was stirred at -78°C for 1 hour. A solution of 4-methylbenzenesulfonyl cyanide (607.26 mg, 3.35 mmol) in tetrahydrofuran (10 mL) was then added dropwise. The reaction mixture was stirred at -78°C for 1 hour. The mixture was quenched by addition of saturated ammonium chloride (20 mL), the pH was adjusted to 5 with hydrochloric acid, and the mixture was extracted with ethyl acetate (30 mL x 3). The organic phase was dried, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using a solvent system (petroleum ether / tetrahydrofuran: 1 / 0 to 3 / 1) to afford compound 6-4 (490 mg, light yellow oil) in an 87.20% yield. MS m / z (ESI): 336.1 [M+H]. + .
[0214] Step 5: Compound 6-4 (490 mg, 1.46 mmol) and phenylhydrazine (237.01 mg, 2.19 mmol) were added to acetic acid (4 mL) and ethanol (12 mL). The reaction mixture was stirred at 90°C for 16 hours. The mixture was concentrated under reduced pressure and the resulting residue was purified by silica gel column chromatography using a solvent system (petroleum ether / tetrahydrofuran: 1 / 0 to 3 / 1) to afford compound 6-5 (600 mg, yellow solid) in a yield of 96.51%. MS m / z (ESI): 426.2 [M+H] + .
[0215] Step 6: Dissolve compound 6-5 (50 mg, 117.51 μmol) in dichloromethane (10 mL), add pyridine (27.89 mg, 352.54 μmol, 28.40 μL), and then add phenyl chloroformate (55.20 mg, 352.54 μmol). The reaction mixture was stirred at room temperature for 3 hours. Concentration under reduced pressure gave intermediate 6 (64 mg, yellow oil), which was used directly in the next step. MS m / z (ESI): 546.0 [M+H] + .
[0216] Preparation of compound C2
[0217] Step 1: Dissolve 5-amino-4-methyl-1-phenyl-1H-pyrazol-3-ol (0.95 g, 5.02 mmol) in DMF (15 mL), add N-ethyl-N-isopropylpropan-2-amine (1.30 g, 10.04 mmol, 1.75 mL) and 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (1.79 g, 5.02 mmol), and stir at room temperature overnight. Concentrate under reduced pressure to obtain a yellow oil, which is then purified by combiflash (0-50% EA / PE) to afford product C2-1 (1.4 g, 4.36 mmol, 86.79% yield). MS m / z (ESI): 322.1 [M+H] + .
[0218] Step 2: Compound C2-1 (1.28 g, 3.99 mmol) was dissolved in water (2 mL), and (2-methylpyrimidin-5-yl)boronic acid (0.55 g, 3.99 mmol), potassium carbonate (551.11 mg, 3.99 mmol), bis(2-diphenylphosphorylcyclopentyl-2,4-dien-1-yl)iron, dichloropalladium (291.76 mg, 398.75 μmol), and dioxane (20 mL) were added. The mixture was stirred at 100°C overnight under nitrogen. The mixture was concentrated under reduced pressure to obtain a yellow solid. The solid was purified by combiflash (0-60% EA / PE) to give product C2-2 (0.9 g, 3.39 mmol, yield 85.07%). MS m / z (ESI): 266.1 [M+H] + .
[0219] Step 3: Dissolve compound C2-2 (300 mg, 1.13 mmol) in dichloromethane (15 mL), add phenyl chloroformate (177.04 mg, 1.13 mmol) and pyridine (268.32 mg, 3.39 mmol, 273.27 μL), and stir at room temperature for 2 hours. Concentrate under reduced pressure to obtain phenyl (4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl) carbamate (350 mg, 908.11 μmol, 80.31% yield) as a yellow solid. Compound H-25-e (200 mg, 771.45 μmol) was dissolved in acetonitrile (15 mL), and phenyl (4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl) carbamate (297.33 mg, 771.45 μmol) and N-ethyl-N-isopropylpropan-2-amine (299.11 mg, 2.31 mmol, 403.12 μL) were added. The mixture was stirred at 80°C for 2 hours. The mixture was concentrated under reduced pressure to afford a yellow solid. The solid was purified by combiflash (0-30% MEOH / DCM) to afford a yellow solid. The solid was then purified by pre-HPLC to afford compound C2 (trans racemate, 52.67 mg, 95.76 μmol, 12.40% yield, 100% purity). MS m / z (ESI): 551.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ9.01(s,2H),8.20(s,1H),7.89-7.95(m,2H),7.56-7.58(m,2H),7.47-7.51(m,2H),7.35-7 .38(m,2H),4.32(s,1H),4.32(s,1H),3.51-3.47(m,3H),3.25(s,3H),3.04-3.02(m,3H),2.66(s,3H),2.09(s,3H).
[0220] Example 1: Preparation of Compound H-1
[0221] Step 1: Dissolve 6-fluoronicotinaldehyde (5 g, 39.97 mmol) in DCM (10 mL), add ethyl acetate (triphenylphosphoranilide) (16.71 g, 47.96 mmol), and stir at room temperature overnight. Concentrate under reduced pressure to obtain a yellow solid. The yellow solid is purified by column chromatography (0-30% EA / PE) to obtain compound H-1-a (7 g, 35.86 mmol, 89.73% yield) as a white solid. MS m / z (ESI): 196.1 [M+H] + .
[0222] Step 2: Dissolve compound H-1-a (500 mg, 2.56 mmol) in toluene (4.14 mL), add N-(2-methoxyethyl)hydroxylamine hydrochloride (233.38 mg, 2.56 mmol), paraformaldehyde (230.74 mg, 7.68 mmol) and triethylamine (777.63 mg, 7.68 mmol, 1.07 mL), and stir at 70°C overnight. Concentrate under reduced pressure to obtain a yellow solid. The solid is purified by column chromatography (0-50% EA / PE) to obtain compound H-1-b (trans racemate, 650 mg, 2.18 mmol, 85.06% yield) as a white oil. MS m / z (ESI): 299.1 [M+H] + .
[0223] Step 3: Dissolve compound H-1-b (700 mg, 2.35 mmol) in H2O (1 mL) and THF (10 mL), add lithium hydroxide (168.59 mg, 7.04 mmol), and stir at room temperature for 2 hours. Add 3N hydrochloric acid solution to adjust the pH to 1, add dichloromethane to extract, extract the organic phase, dry it over anhydrous sodium sulfate, and concentrate under reduced pressure to obtain compound H-1-c (trans racemate, 500 mg, 1.85 mmol, 78.84% yield) as a white solid. MS m / z (ESI): 271.1 [M+H] + .
[0224] Step 4: Dissolve compound H-1-c (500 mg, 1.85 mmol) in tert-butanol (9.59 mL), add triethylamine (374.42 mg, 3.70 mmol, 516.09 μL) and DPPA (899.89 mg, 3.70 mmol), and stir at 100°C overnight. Concentrate under reduced pressure to obtain a yellow oil. The oil is purified by column chromatography (0-60% PE / EA) to obtain compound H-1-d (trans racemate, 120 mg, 351.52 μmol, 19.00% yield) as a yellow oil. MS m / z (ESI): 342.1 [M+H] + .
[0225] Step 5: Dissolve compound H-1-d (120 mg, 351.52 μmol) in dioxane (4 mL), add HCl (12.82 mg, 351.52 μmol), and stir at room temperature for 2 hours. Concentrate under reduced pressure to obtain a yellow solid. The solid was used directly in the next reaction to obtain compound H-1-e (trans racemate, 63 mg, 264.03 μmol, 70.75% yield) as a yellow solid. MS m / z (ESI): 242.1 [M+H] + .
[0226] Step 6: Compound H-1-e (63.70 mg, 264.03 μmol) was dissolved in MeCN (9.89 mL), and intermediate 1 (108.63 mg, 264.03 μmol) and triethylamine (80.15 mg, 792.08 μmol, 110.48 μL) were added. The mixture was stirred at 80°C for 3 hours. The mixture was concentrated under reduced pressure to obtain a yellow solid. Pre-HPLC analysis yielded compound H-1 (trans racemate, 24.62 mg, 39.53 μmol, 14.97% yield). MS m / z (ESI): 559.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.14-8.12 (m, 2H), 7.91-7.88 (m, 1H), 7.59-7.48 (m, 4H), 7.41-7.37 (m, 1H), 7.27-7.25 (m, 1H), 7.1 5-7.13(m,1H),4.65(s,1H),4.32(s,1H),3.52-3.49(m,3H),3.24(s,3H ),3.06-3.01(m,4H),2.66-2.63(m,3H),2.58(s,3H),1.97-1.95(m,2H).
[0227] Example 2: Preparation of Compound H-2
[0228] Step 1: Dissolve 6-bromonicotinaldehyde (1.5 g, 8.06 mmol) in DCM (15 mL), add ethyl acetate (triphenylphosphoranilide) (3.37 g, 9.68 mmol), and stir at room temperature overnight. Concentrate under reduced pressure to obtain a yellow solid. The solid is purified by column chromatography (0-40% EA / PE) to obtain compound H-2-a (1.7 g, 6.64 mmol, 82.32% yield) as a white solid. MS m / z (ESI): 256.1 [M+H] + .
[0229] Step 2: Dissolve compound H-2-a (1.7 g, 6.64 mmol) in toluene (20 mL), add N-(2-methoxyethyl)hydroxylamine hydrochloride (604.79 mg, 6.64 mmol), paraformaldehyde (678.23 mg, 19.91 mmol), and triethylamine (2.02 g, 19.91 mmol, 2.78 mL), and stir overnight at 70°C under nitrogen. Concentrate under reduced pressure to obtain a yellow solid. The solid is purified by column chromatography (0-40% EA / PE) to obtain compound H-2-b (trans racemate, 1.8 g, 5.01 mmol, 75.49% yield) as a yellow oil. MS m / z (ESI): 359.1 [M+H] + .
[0230] Step 3: Dissolve compound H-2-b (1.8 g, 5.01 mmol) in water (1 mL) and methanol (10 mL), add lithium hydroxide (360.01 mg, 15.03 mmol), and stir at room temperature for 2 hours. Add 3N hydrochloric acid to adjust the pH to 1, extract with dichloromethane, dry over anhydrous sodium sulfate, and concentrate under reduced pressure to obtain compound H-2-c (trans racemate, 1.4 g, 4.23 mmol, 84.37% yield) as a white solid. MS m / z (ESI): 331.1 [M+H] + .
[0231] Step 4: Dissolve compound H-2-c (1.4 g, 4.23 mmol) in tert-butanol (20 mL), add DPPA (2.06 g, 8.46 mmol) and triethylamine (1.28 g, 12.68 mmol, 1.77 mL), and stir at 100°C overnight. Concentrate under reduced pressure to obtain a yellow solid. The solid is purified by column chromatography (0-50% EA / PE) to obtain compound H-2-d (trans racemate, 120 mg, 298.30 μmol, 7.06% yield) as a yellow oil. MS m / z (ESI): 402.1 [M+H] + .
[0232] Step 5: Compound H-2-d (110 mg, 273.44 μmol) was dissolved in dioxane (10 mL), and tert-butyl carbamate (48.05 mg, 410.16 μmol), Xantphos (15.85 mg, 27.34 μmol), cesium carbonate (178.18 mg, 546.88 μmol), and Pd2(dba)3 (25.04 mg, 27.34 μmol) were added. The mixture was incubated at 100°C overnight under nitrogen and concentrated under reduced pressure to obtain a black solid. The solid was purified by column chromatography (0-50% EA / PE) to obtain compound H-2-e (trans racemate, 100 mg, 228.04 μmol, 83.40% yield) as a yellow solid. MS m / z (ESI): 439.1 [M+H] + .
[0233] Step 6: Dissolve compound H-2-e (100 mg, 228.04 μmol) in dioxane (4 mL), add hydrogen chloride (83.15 mg, 2.28 mmol) at 0°C, and stir at room temperature for 2 hours. Concentrate under reduced pressure to obtain a yellow solid compound H-2-f (trans racemate, 40 mg, 167.87 μmol, 73.61% yield). MS m / z (ESI): 239.1 [M+H] + .
[0234] Step 7: Compound H-2-f (40 mg, 167.87 μmol) was dissolved in acetonitrile (10 mL), and intermediate 1 (69.07 mg, 167.87 μmol) and triethylamine (50.96 mg, 503.60 μmol, 70.24 μL) were added and stirred at 80°C for 2 hours. The mixture was concentrated under reduced pressure to obtain a yellow oil. Pre-HPLC analysis yielded compound H-2 (trans racemate, 15 mg, 26.24 μmol, 15.63% yield). MS m / z (ESI): 556.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.24 (s, 1H), 8.02 (s, 1H), 7.80 (s, 1H), 7.51-7.30 (M, 6H), 7.11-7.09 (d, J = 8Hz, 1H), 6.41-6.39 (d, J = 8Hz, 1 H),5.94(s,2H),4.42-4.29(m,2H),3.47-3.44(m,2H),3.23(s,3H),3.05-2.92(m,5H),2.63-2.61(m,3H),2.57(s,3H),1.96-1.95(m,2H).
[0235] Example 3: Preparation of Compound H-3
[0236] Step 1: Dissolve 5-fluoronicotinaldehyde (1 g, 7.99 mmol) in acetic acid (15 mL), add ammonium acetate (1.23 g, 15.99 mmol) and nitromethane (2.93 g, 47.96 mmol), and stir at 90°C for 4 hours. Pour into ice water, extract with ethyl acetate, dry the organic phase over anhydrous sodium sulfate, and concentrate under reduced pressure to obtain a brown oil. The oil is purified by column chromatography (0-80% EA / PE) to obtain compound H-3-a (0.9 g, 5.35 mmol, 66.97% yield) as a yellow solid. MS m / z (ESI): 169.1 [M+H] + .
[0237] Step 2: Dissolve compound H-3-a (0.9 g, 5.35 mmol) in toluene (15 mL), add paraformaldehyde (182.32 mg, 5.35 mmol), N-(2-methoxyethyl)hydroxylamine hydrochloride (731.58 mg, 8.03 mmol), and triethylamine (1.63 g, 16.06 mmol, 2.24 mL), and stir at 70°C for 2 hours. Concentrate under reduced pressure to obtain a yellow oil. The oil is purified by column chromatography (0-80% EA / PE) to obtain compound H-3-b (trans racemate, 0.6 g, 2.21 mmol, 41.32% yield) as a yellow oil. MS m / z (ESI): 272.1 [M+H] + .
[0238] Step 3: Dissolve compound H-3-b (200 mg, 0.74 mmol) in HCl (5 mL), add stannous chloride (0.5 g, 2.21 mmol), and stir at 50°C for 2 hours. Pour into saturated sodium bicarbonate solution, adjust the pH to 8 with sodium bicarbonate, extract with dichloromethane / methanol (10 / 1), dry over anhydrous sodium sulfate, and concentrate under reduced pressure to obtain a yellow solid compound H-3-c (trans racemate, 40 mg, 165.80 μmol, yield 22.49%). MS m / z (ESI): 242.1 [M+H] + .
[0239] Step 4: Dissolve compound H-3-c (40 mg, 165.80 μmol) in acetonitrile (10 mL), add intermediate 1 (68.22 mg, 165.80 μmol) and triethylamine (50.33 mg, 497.39 mmol, 69.37 μL), and stir at 80°C for 2 hours. Concentrate under reduced pressure to obtain a yellow solid. Pre-HPLC analysis yielded compound H-3 (trans racemate, 9.73 mg, 17.42 μmol, 10.51% yield). MS m / z (ESI): 559.1 [M+H] +. 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.47-8.39 (m, 2H), 8.13 (s, 1H), 7.62-7.27 (m, 7H), 4.70 (s, 1H), 4.3 5(s,1H),3.54-3.50(m,2H),3.25(s,3H),3.05-3.02(m,5H),2.66-2.63(m,3H),2.58(s,3H),2.31-2.28(m,2H).
[0240] Example 4: Preparation of Compound H-4
[0241] Step 1: Dissolve nicotinaldehyde (2 g, 18.67 mmol) in acetic acid (15 mL), add ammonium acetate (2.88 g, 37.34 mmol) and nitromethane (6.84 g, 112.03 mmol), and stir at 90°C for 4 hours. Pour into ice water, extract with ethyl acetate, dry the organic phase over anhydrous sodium sulfate, and concentrate under reduced pressure to obtain a brown oil. The oil is purified by column chromatography (0-80% EA / PE) to obtain compound H-4-a (1.2 g, 7.99 mmol, 42.81% yield) as a yellow solid. MS m / z (ESI): 151.1 [M+H] + .
[0242] Step 2: Dissolve compound H-4-a (1.2 g, 7.99 mmol) in toluene (11.66 mL), add paraformaldehyde (272.22 mg, 7.99 mmol), N-(2-methoxyethyl)hydroxylamine hydrochloride (873.86 mg, 9.59 mmol) and triethylamine (2.43 g, 23.98 mmol, 3.34 mL), and stir at 70°C for 2 hours. Concentrate under reduced pressure to obtain a yellow oil. The oil is purified by column chromatography (0-80% EA / PE) to obtain compound H-4-b (trans racemate, 0.4 g, 1.58 mmol, 19.76% yield) as a yellow oil. MS m / z (ESI): 254.1 [M+H] + .
[0243] Step 3: Dissolve compound H-4-b (400 mg, 1.58 mmol) in HCl (10 mL), add stannous chloride (1.07 g, 4.74 mmol), and stir at 50°C for 2 hours. Pour into saturated sodium bicarbonate solution, adjust the pH to 8 with sodium bicarbonate, extract with dichloromethane / methanol (10 / 1), dry over anhydrous sodium sulfate, and concentrate under reduced pressure to obtain a yellow solid compound H-4-c (trans racemate, 110 mg, 492.68 μmol, 31.19% yield). MS m / z (ESI): 224.1 [M+H] + .
[0244] Step 4: Dissolve compound H-4-c (110 mg, 492.68 μmol) in acetonitrile (10 mL), add intermediate 1 (202.71 mg, 492.68 μmol) and triethylamine (149.56 mg, 1.48 mmol, 206.15 μL), and stir at 80°C for 2 hours. Concentrate under reduced pressure to obtain a yellow solid. Pre-HPLC analysis yielded compound H-4 (trans racemate, 9.86 mg, 17.85 μmol, 3.62% yield). MS m / z (ESI): 541.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.51-8.47 (m, 2H), 8.11 (s, 1H), 7.59-7..57 (m, 1H), 7.52-7.36 (m, 4H), 7.35-7.24 (m, 3 H),4.65(s,2H),4.35(s,2H),3.51-3.49(m,2H),3.25(s,3H),3.04-3.01(m,4H),2.63-2.60(m,2H),2.49(s,3H),1.97-1.95(m,2H).
[0245] Example 5: Preparation of Compound H-5
[0246] Step 1: Dissolve 6-chloro-5-fluoronicotinaldehyde (1 g, 4.75 mmol) in acetonitrile (20 mL), add methyl prop-2-enoate (409.11 mg, 4.75 mmol), diacetoxypalladium (0.107 g, 0.475 mmol), tri-o-tolylphosphine (0.145 g, 0.475 mmol), and N,N-diethylethylamine (480.87 mg, 4.75 mmol, 662.81 μL). Stir at 90°C overnight under nitrogen. Filter and concentrate under reduced pressure to obtain a yellow solid. The solid was purified by column chromatography (0-40% EA / PE) to obtain compound H-5-a (1 g, 4.64 mmol, 97.60% yield) as a yellow solid. MS m / z (ESI): 230.1 [M+H] + .
[0247] Step 2: Dissolve compound H-5-a (1 g, 4.64 mmol) in toluene (20 mL), add N-(2-methoxyethyl)hydroxylamine hydrochloride (633.85 mg, 6.96 mmol), paraformaldehyde (315.92 mg, 9.28 mmol) and triethylamine (1.41 g, 13.91 mmol, 1.94 mL), and stir at 70°C for 4 hours. Concentrate under reduced pressure to obtain a yellow solid. The solid is purified by column chromatography (0-50% EA / PE) to obtain compound H-5-b (trans racemate, 1 g, 3.14 mmol, 67.65% yield) as a yellow solid. MS m / z (ESI): 333.1 [M+H] + .
[0248] Step 3: Dissolve compound H-5-b (1 g, 3.14 mmol) in H2O (2 mL), add lithium hydroxide (225.41 mg, 9.41 mmol) and methanol (20 mL), and stir at room temperature for 2 hours. Add 3N hydrochloric acid solution to adjust the pH to 4, extract with dichloromethane, dry the organic phase over anhydrous sodium sulfate, and concentrate under reduced pressure to obtain a yellow solid compound H-5-c (trans racemate, 0.8 g, 2.63 mmol, 83.68% yield). MS m / z (ESI): 305.1 [M+H] + .
[0249] Step 4: Compound H-5-c (0.8 g, 2.63 mmol) was dissolved in tert-butanol (10 mL), and [azido(phenyl)phosphoryl]benzene (1.28 g, 5.25 mmol), triethylamine (531.35 mg, 5.25 mmol, 732.40 μL), and tert-butyl tert-butyloxycarbonyl carbonate (859.52 mg, 3.94 mmol) were added. Under nitrogen protection, the mixture was stirred at 90°C overnight. The mixture was concentrated under reduced pressure to obtain a yellow solid. The solid was purified by column chromatography (0-80% EA / PE) to obtain compound H-5-d (trans racemate, 0.22 g, 585.38 μmol, 22.30% yield) as a yellow oil. MS m / z (ESI): 376.1 [M+H] + .
[0250] Step 5: Dissolve compound H-5-d (0.22 g, 585.38 μmol) in dioxane (6 mL), add hydrogen chloride (106.72 mg, 2.93 mmol), and stir at room temperature for 2 hours. Concentrate under reduced pressure to obtain compound H-5-e (trans racemate, 130 mg, 471.52 μmol, 80.55% yield) as a yellow oil. MS m / z (ESI): 276.1 [M+H] + .
[0251] Step 6: Dissolve compound H-5-e (0.12 g, 435.25 μmol) in acetonitrile (10 mL), add intermediate 1 (179.08 mg, 435.25 μmol) and triethylamine (132.13 mg, 1.31 mmol, 182.12 μL), and stir at 80°C for 2 hours. Concentrate under reduced pressure to obtain a yellow solid. Pre-HPLC analysis yielded compound H-5 (trans racemate, 10.91 mg, 17.56 μmol, 4.03% yield). MS m / z (ESI): 593.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.21 (s, 2H), 7.84-7.81 (m, 1H), 7.60-7.49 (m, 4H), 7.40-7.29 (m, 2H), 4.68 (s ,1H),4.34(s,1H),3.52-3.50(m,3H),3.25(s,3H),3.06-3.03(m,5H),2.68-2.65(m,2H),2.49(s,3H),1.97-1.95(m,2H).
[0252] Example 6: Preparation of Compound H-6
[0253] Step 1: Dissolve 6-chloro-5-methylnicotinaldehyde (1 g, 4.75 mmol) in acetonitrile (20 mL). Add methyl prop-2-enoate (409.11 mg, 4.75 mmol), diacetoxypalladium (0.107 g, 0.475 mmol), tri-o-tolylphosphine (0.145 g, 0.475 mmol), and N,N-diethylethylamine (480.87 mg, 4.75 mmol, 662.81 μL). Stir overnight at 90°C under nitrogen. Filter and concentrate under reduced pressure to obtain a yellow solid. The solid was purified by column chromatography (0-40% EA / PE) to afford compound H-6-a (1 g, 4.64 mmol, 97.60% yield) as a yellow solid. MS m / z (ESI): 226.1 [M+H] + .
[0254] Step 2: Dissolve compound H-6-a (1 g, 4.64 mmol) in toluene (20 mL), add N-(2-methoxyethyl)hydroxylamine hydrochloride (633.85 mg, 6.96 mmol), paraformaldehyde (315.92 mg, 9.28 mmol) and triethylamine (1.41 g, 13.91 mmol, 1.94 mL), and stir at 70°C for 4 hours. Concentrate under reduced pressure to obtain a yellow solid. The solid is purified by column chromatography (0-50% EA / PE) to obtain compound H-6-b (trans racemate, 1 g, 3.14 mmol, 67.65% yield) as a yellow solid. MS m / z (ESI): 329.1 [M+H] + .
[0255] Step 3: Dissolve compound H-6-b (1 g, 3.14 mmol) in H2O (2 mL), add lithium hydroxide (225.41 mg, 9.41 mmol) and methanol (20 mL), and stir at room temperature for 2 hours. Add 3N hydrochloric acid solution to adjust the pH to 4, extract with dichloromethane, dry the organic phase over anhydrous sodium sulfate, and concentrate under reduced pressure to obtain a yellow solid compound H-6-c (trans racemate, 0.8 g, 2.63 mmol, 83.68% yield). MS m / z (ESI): 301.1 [M+H] + .
[0256] Step 4: Compound H-6-c (0.8 g, 2.63 mmol) was dissolved in tert-butanol (10 mL), and [azido(phenyl)phosphoryl]benzene (1.28 g, 5.25 mmol), triethylamine (531.35 mg, 5.25 mmol, 732.40 μL), and tert-butyl tert-butyloxycarbonyl carbonate (859.52 mg, 3.94 mmol) were added. Under nitrogen protection, the mixture was stirred at 90°C overnight. The mixture was concentrated under reduced pressure to obtain a yellow solid. The solid was purified by column chromatography (0-80% EA / PE) to obtain compound H-6-d (trans racemate, 0.22 g, 585.38 μmol, 22.30% yield) as a yellow oil. MS m / z (ESI): 372.1 [M+H] + .
[0257] Step 5: Dissolve compound H-6-d (0.16 g, 430.38 μmol) in dioxane (6 mL), add hydrogen chloride (106.72 mg, 2.93 mmol), and stir at room temperature for 2 hours. Concentrate under reduced pressure to obtain compound H-6-e (trans racemate, 80 mg, 294.40 μmol, 68.42% yield) as a yellow oil. MS m / z (ESI): 272.1 [M+H] + .
[0258] Step 6: Compound H-6-e (0.08 g, 294.40 μmol) was dissolved in acetonitrile (10 mL), and intermediate 1 (121.13 mg, 294.40 μmol) and triethylamine (89.37 mg, 0.883 mmol, 123.18 μL) were added and stirred at 80°C for 2 hours. The mixture was concentrated under reduced pressure to obtain a yellow solid. Pre-HPLC analysis yielded compound H-6 (trans racemate, 39.50 mg, 60.41 μmol, 20.52% yield). MS m / z (ESI): 589.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.14 (s, 2H), 7.71-7.41 (m, 5H), 7.39-7.26 (m, 2H), 4.61 (s, 1H), 4.32 (s, 1 H),3.51-3.47(m,3H),3.49(s,3H),3.08-3.02(m,5H),2.63-2.60(m,2H),2.45(s,3H),2.30(s,3H),1.98-1.95(m,2H).
[0259] Example 7: Preparation of Compound H-7
[0260] Step 1: Dissolve ethoxycarbonylmethylenetriphenylphosphine (56.4 g, 161.8 mmol) in DCM (200 mL). Slowly add 3,4-difluorobenzaldehyde (23 g, 161.8 mmol) under ice-cooling. Stir at room temperature overnight and concentrate. The remaining yellow oily solid is washed with 200 mL (petroleum ether / ethyl acetate = 3 / 1). A large amount of solid (triphenylphosphine oxide) precipitates. Filter and concentrate the filtrate. The product is purified by column chromatography (petroleum ether / ethyl acetate = 6 / 1) to obtain compound H-7-a (31 g, 90% yield) as a colorless oil. MS m / z (ESI): 213.0 [M+H] + .
[0261] Step 2: Compound H-7-a (4.24 g, 20 mmol) and triethylamine (6 g, 60 mmol) were dissolved in toluene (70 mL), and paraformaldehyde (1.8 g, 60 mmol) and N-(2-methoxyethyl)hydroxylamine hydrochloride (2.54 g, 20 mmol) were added. The temperature was raised to 70°C and stirred overnight. The reaction solution was cooled, filtered, and the filtrate was concentrated. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain compound H-7-b (trans racemic form, 5 g, yield 79%) as a yellow oil. MS m / z (ESI): 316.0 [M+H] + .
[0262] Step 3: Dissolve compound H-7-b (1.0 g, 3.17 mmol) in THF / MeOH / H2O (20 mL / 5 mL / 5 mL), add lithium hydroxide (0.39 g, 9.51 mmol), stir at room temperature for 1 hour, concentrate, and remove the organic phase. The residue is diluted with water (15 mL), adjusted to pH 3-4 with 3M hydrochloric acid, and extracted three times with dichloromethane. The combined organic phases are dried and concentrated, and the residue H-7-c is used directly in the next step. MS m / z (ESI): 288.0 [M+H] + .
[0263] Step 4: Compound H-7-c (1.44 g, 5 mmol) was dissolved in tert-butanol (25 mL), and DPPA (2 g, 7.5 mmol), triethylamine (1 g, 10 mmol), and Boc anhydride (1.64 g, 7.5 mmol) were added. The atmosphere was replaced with argon three times, and the mixture was heated to 95°C and stirred overnight. The mixture was cooled and concentrated, and the residue was purified by column chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain compound H-7-d (trans racemate, 0.3 g, yield 16.8%) as a yellow oil. MS m / z (ESI): 359.1 [M+H] + .
[0264] Step 5: To a solution of compound H-7-d (0.06 g, 0.18 mmol) in dichloromethane (6 mL) was added a 4 M solution of hydrogen chloride in dioxane. The mixture was stirred at room temperature for 1 hour and concentrated. The residue, compound H-7-e (trans racemate, 42 mg, 91.3% yield), was used directly in the next step. MS m / z (ESI): 259.1 [M+H] + .
[0265] Step 6: Compound H-7-e (45 mg, 0.21 mmol) and intermediate 2 (84 mg, 0.21 mmol) were dissolved in acetonitrile, and DIPEA (82 mg, 0.63 mmol) was added. The mixture was then heated to 70°C and stirred for 2 hours. The reaction solution was concentrated, and the residue was purified by preparative HPLC to give compound H-7 (trans racemate, 40 mg, yield 33.9%). MS m / z (ESI): 564.3 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 7.99 (s, 1H), 7.67 (s, 1H), 7.56-7.49 (m, 2H), 7.45-7.43 (m, 2H), 7.40-7.28 (m, 3H), 7.14-7.12 (m ,2H),4.59(s,1H),4.29(s,1H),3.73(s,3H),3.52-3.50(m,2H),3.25(s,3H),3.01-2.98(m,6H),2.56-2.54(m,2H),1.92(s,2H).
[0266] Example 8: Preparation of Compound H-8
[0267] Step 1: Dissolve ethoxycarbonylmethylenetriphenylphosphine (35 g, 100 mmol) in DCM (100 mL). Slowly add 3-fluorobenzaldehyde (12.4 g, 100 mmol) under ice-cooling. Stir at room temperature overnight and concentrate. The remaining yellow oily solid is washed with (petroleum ether / ethyl acetate = 3 / 1). A large amount of solid (triphenylphosphine oxide) precipitates. Filter and concentrate the filtrate. The product is purified by column chromatography (petroleum ether / ethyl acetate = 6 / 1) to obtain compound H-8-a (17 g, 88% yield) as a colorless oil. MS m / z (ESI): 195.1 [M+H] + .
[0268] Step 2: Compound H-8-a (3.88 g, 20 mmol) and triethylamine (6 g, 60 mmol) were dissolved in toluene (70 mL), and paraformaldehyde (1.8 g, 60 mmol) and N-(2-methoxyethyl)hydroxylamine hydrochloride (2.54 g, 20 mmol) were added. The mixture was heated to 70°C and stirred overnight. The reaction solution was cooled, filtered, and the filtrate was concentrated. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain compound H-8-b (trans racemic form, 4 g, yield 67.3%) as a yellow oil. MS m / z (ESI): 298.1 [M+H] + .
[0269] Step 3: Dissolve compound H-8-b (1.0 g, 3.36 mmol) in THF / MeOH / H2O (20 mL / 5 mL / 5 mL), add lithium hydroxide (0.42 g, 10 mmol), stir at room temperature for 1 hour, concentrate and remove the organic phase, dilute the residue with water (15 mL), adjust the pH to 3-4 with 3M hydrochloric acid, and extract three times with dichloromethane. The combined organic phases are dried and concentrated, and the residue H-8-c is used directly in the next step. MS m / z (ESI): 270.1 [M+H] + .
[0270] Step 4: Compound H-8-c (0.8 g, 3 mmol) was dissolved in tert-butanol (20 mL), and DPPA (1.46 g, 6 mmol), triethylamine (0.9 g, 9 mmol), and Boc anhydride (1.3 g, 6 mmol) were added. The atmosphere was replaced with argon three times, and the mixture was heated to 95°C and stirred overnight. The mixture was cooled and concentrated, and the residue was purified by column chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain compound H-8-d (trans racemate, 0.2 g, yield 19.6%) as a yellow oil. MS m / z (ESI): 341.1 [M+H] + .
[0271] Step 5: To a solution of compound H-8-d (0.06 g, 0.18 mmol) in dichloromethane (6 mL) was added a 4 M solution of hydrogen chloride in dioxane. The mixture was stirred at room temperature for 1 hour and concentrated. The residue, compound H-8-e (trans racemate, 40 mg, 95.2% yield), was used directly in the next step. MS m / z (ESI): 241.1 [M+H] + .
[0272] Step 6: Compound H-8-e (40 mg, 0.17 mmol) and intermediate 2 (68 mg, 0.17 mmol) were dissolved in acetonitrile, and DIPEA (44 mg, 0.34 mmol) was added. The mixture was then heated to 70°C and stirred for 2 hours. The reaction solution was concentrated, and the residue was purified by preparative HPLC to give compound H-8 (trans racemate, 20 mg, yield 21.6%). MS m / z (ESI): 546.3 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 7.98 (s, 1H), 7.56-7.49 (m, 2H), 7.45-7.43 (m, 2H), 7.40-7.27 (m, 2H), 7.13-7.11 (m, 4H), 4.6 3(s,1H),4.31(s,1H),3.73(s,3H),3.52-3.50(m,2H),3.25(s,3H),3.01-2.99(m,7H),2.56-2.54(m,2H),1.93-1.91(m,2H).
[0273] Example 9: Preparation of Compound H-9
[0274] Step 1: 5-Fluoro-2-formaldehyde pyridine (1.2 g, 9.59 mmol) and triethylamine (1.94 g, 19.18 mmol) were dissolved in DCM (20 mL), nitromethane (878.27 mg, 14.39 mmol) was added, and the mixture was stirred at room temperature for 1 hour. LCMS showed that the starting material disappeared. The reaction solution was concentrated, and the residue was dissolved in glacial acetic acid (20 mL). DMAP (117 mg, 0.96 mmol) was added and stirred at room temperature for 1 hour. The reaction solution was concentrated, and the residue was purified by column chromatography (PE / EA=8 / 1) to give a yellow solid compound H-9-a (1.2 g, yield 74%).
[0275] Step 2: Compound H-9-a (1.68 g, 10 mmol) and triethylamine (3.1 g, 30 mmol) were dissolved in toluene (50 mL), and paraformaldehyde (0.9 g, 30 mmol) and N-(2-methoxyethyl)hydroxylamine hydrochloride (1.27 g, 10 mmol) were added. The temperature was raised to 70°C and stirred overnight. The reaction solution was cooled, filtered, and the filtrate was concentrated. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain compound H-9-b (trans racemic form, 2.1 g, yield 77.8%) as a yellow oil. MS m / z (ESI): 272.1 [M+H] + .
[0276] Step 3: Compound H-9-b (0.2 g, 0.74 mmol) was suspended in concentrated hydrochloric acid (20 mL), and stannous chloride (0.5 g, 2.2 mmol) was added. The mixture was heated to 50°C and stirred for 2 hours. After cooling, the mixture was neutralized with sodium carbonate in an ice bath and extracted with dichloromethane. The combined organic phases were dried and concentrated. The residue, H-9-c (trans racemate, 0.1 g, yield 56.2%), was used directly in the next step. MS m / z (ESI): 242.1 [M+H] + .
[0277] Step 4: Compound H-9-c (40 mg, 0.17 mmol) and intermediate 1 (68 mg, 0.17 mmol) were dissolved in acetonitrile, and DIPEA (44 mg, 0.34 mmol) was added. The mixture was then heated to 70°C and stirred for 2 hours. The reaction solution was concentrated, and the residue was purified by preparative HPLC to obtain compound H-9 (trans racemate, 30 mg, yield 31.6%). MS m / z (ESI): 559.3 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.24 (s, 1H), 8.54-8.49 (m, 1H), 8.07 (s, 1H), 7.7 2-7.70(m,1H),7.61-7.55(m,2H),7.55-7.45(m,3H),7.44-7.35(m,1H),7.24(d, J=7.8Hz,1H),4.76(s,1H),4.60-4.58(m,1H),3.50-3.48(m,2H),3.31-3.28(m,2 H),3.24(s,3H),3.08-2.98(m,4H),2.65-2.63(m,2H),2.58(s,3H),1.95(s,2H).
[0278] Example 10: Preparation of Compound H-10
[0279] Step 1: 6-Fluoro-2-formaldehyde pyridine (1.25 g, 10 mmol) and triethylamine (2 g, 20 mmol, 2.68 mL) were dissolved in DCM (20 mL), nitromethane (0.92 g, 15 mmol) was added, and the mixture was stirred at room temperature for 1 hour. LCMS showed that the starting material disappeared. The reaction solution was concentrated, and the residue was dissolved in glacial acetic acid (20 mL). DMAP (244 mg, 2 mmol) was added and stirred at room temperature for 1 hour. The reaction solution was concentrated, and the residue was purified by column chromatography (PE / EA = 8 / 1) to give a yellow solid compound H-10-a (1.1 g, yield 65.5%).
[0280] Step 2: Compound H-10-a (1.0 g, 5.95 mmol) and triethylamine (1.8 g, 17.8 mmol) were dissolved in toluene (30 mL), and paraformaldehyde (0.54 g, 17.9 mmol) and N-(2-methoxyethyl)hydroxylamine hydrochloride (0.76 g, 5.95 mmol) were added. The temperature was raised to 70°C and stirred overnight. The reaction solution was cooled, filtered, and the filtrate was concentrated. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain compound H-10-b (trans racemic form, 1.2 g, yield 75%) as a yellow oil. MS m / z (ESI): 272.1 [M+H] + .
[0281] Step 3: Compound H-10-b (0.3 g, 1.1 mmol) was suspended in concentrated hydrochloric acid (15 mL), and stannous chloride (0.75 g, 3.3 mmol) was added. The mixture was heated to 50°C and stirred for 2 hours. After cooling, the mixture was neutralized with sodium carbonate in an ice bath and extracted with dichloromethane. The combined organic phases were dried and concentrated. The residue, H-10-c (trans racemate, 0.2 g, yield 75.5%), was used directly in the next step. MS m / z (ESI): 242.1 [M+H] + .
[0282] Step 4: Compound H-10-c (40 mg, 0.17 mmol) and intermediate 1 (68 mg, 0.17 mmol) were dissolved in acetonitrile, and DIPEA (44 mg, 0.34 mmol) was added. The mixture was then heated to 70°C and stirred for 2 hours. The reaction solution was concentrated, and the residue was purified by preparative HPLC to obtain compound H-10 (trans racemic form, 27 mg, yield 28.4%). MS m / z (ESI): 559.3 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.11-8.06 (m, 1H), 7.99-7.97 (m, 1H), 7.61-7.46 (m, 4H), 7.46-7.33 (m, 2H), 7.26 (d, J = 7.8Hz, 1H), 7.1 0(d,J=7.6Hz,1H),4.70(s,2H),3.54-3.46(m,2H),3.24(s,3H),3.05-3.0 2(m,4H),2.66-2.64(m,2H),2.58(s,3H),2.51(s,2H),2.01-1.92(m,2H).
[0283] Example 11: Preparation of Compound H-11
[0284] Step 1: Dissolve 5-bromo-3-chloro-2-methylpyridine (2.06 g, 10 mmol), methyl acrylate (2.58 g, 30 mmol), triethylamine (3.03 g, 30 mmol), tris(o-methylphenyl)phosphine (0.3 g, 1.0 mmol), and palladium acetate (113 mg, 0.5 mmol) in CH3CN (20 mL). Replace the atmosphere with argon three times, heat to 90°C, stir overnight, cool, and concentrate. The residue is purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to give compound H-11-a (1.1 g, yield 52%) as a yellow oil. MS m / z (ESI): 212.0 [M+H] + .
[0285] Step 2: Compound H-11-a (1.1 g, 5.2 mmol) and triethylamine (1.58 g, 15.6 mmol) were dissolved in toluene (30 mL), and paraformaldehyde (0.47 g, 15.6 mmol) and N-(2-methoxyethyl)hydroxylamine hydrochloride (0.66 g, 5.2 mmol) were added. The temperature was raised to 70°C and stirred overnight. The reaction solution was cooled, filtered, and the filtrate was concentrated. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain compound H-11-b (trans racemic form, 0.8 g, yield 49%) as a yellow oil. MS m / z (ESI): 315.0 [M+H] + .
[0286] Step 3: Dissolve compound H-11-b (0.8 g, 2.55 mmol) in THF / H2O (10 mL / 3 mL), add lithium hydroxide (0.32 g, 7.64 mmol), stir at room temperature for 2 hours, concentrate, and dilute the residue with water (20 mL), adjust the pH to 4 with 3M hydrochloric acid, and extract three times with dichloromethane. The combined organic phases are dried and concentrated. The residue H-11-c (trans racemate, 0.7 g, yield 91.5%) is used directly in the next step. MS m / z (ESI): 301.0 [M+H] + .
[0287] Step 4: Compound H-11-c (0.7 g, 2.33 mmol) was dissolved in tert-butanol (16 mL), and DPPA (1.15 g, 4.2 mmol), triethylamine (0.71 g, 7 mmol), and Boc anhydride (0.92 g, 4.2 mmol) were added. The atmosphere was replaced with argon three times, and the mixture was heated to 95° C. and stirred overnight. The mixture was cooled and concentrated. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain compound H-11-d (trans racemic form, 0.2 g, yield 23.1%) as a yellow oil. MS m / z (ESI): 372.1 [M+H] + .
[0288] Step 5: To a solution of compound H-11-d (0.07 g, 0.19 mmol) in dichloromethane (6 mL) was added a 4 M solution of hydrogen chloride in dioxane (1.5 mL). The mixture was stirred at room temperature for 1 hour and concentrated. The residue, H-11-e (trans racemic form, 50 mg, 98% yield), was used directly in the next step. MS m / z (ESI): 272.1 [M+H] + .
[0289] Step 6: Compound H-11-e (50 mg, 0.18 mmol) and intermediate 1 (76 mg, 0.18 mmol) were dissolved in acetonitrile, and DIPEA (70 mg, 0.54 mmol) was added. The mixture was then heated to 70°C and stirred for 2 hours. The reaction solution was concentrated, and the residue was purified by preparative HPLC to obtain compound H-11 (trans racemic form, 10 mg, yield 9.5%). MS m / z (ESI): 589.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.33 (d, J = 1.8Hz, 1H), 8.12 (s, 1 H),7.76(d,J=1.5Hz,1H),7.62-7.55(m,2H),7.51-7.49(m,2H),7.43-7.35(m ,1H),7.27-7.25(m,1H),4.62(s,1H),4.33(s,1H),3.52-3.50(m,2H),3.25(s ,3H),3.13-2.97(m,6H),2.65(s,2H),2.58(s,3H),2.51(s,3H),1.98(s,2H).
[0290] Example 12: Preparation of Compound H-12
[0291] Step 1: 3-Bromo-4-fluoropyridine (2.8 g, 15.9 mmol), methyl acrylate (4.1 g, 47.7 mmol), triethylamine (4.82 g, 47.7 mmol), tri(o-methylphenyl)phosphine (0.48 g, 1.59 mmol), and palladium acetate (179 mg, 0.8 mmol) were dissolved in CH3CN (70 mL). The atmosphere was replaced with argon three times, and the temperature was raised to 90°C, stirred overnight, cooled, and concentrated. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to give compound H-12-a (2 g, yield 69.4%) as a yellow oil. MS m / z (ESI): 182.1 [M+H] + .
[0292] Step 2: Compound H-12-a (2 g, 11 mmol) and triethylamine (3.35 g, 33 mmol) were dissolved in toluene (40 mL), and paraformaldehyde (0.99 g, 33 mmol) and N-(2-methoxyethyl)hydroxylamine hydrochloride (1.40 g, 11 mmol) were added. The temperature was raised to 70°C and stirred overnight. The reaction solution was cooled, filtered, and the filtrate was concentrated. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain compound H-12-b (trans racemic form, 1.4 g, yield 44.9%) as a yellow oil. MS m / z (ESI): 285.1 [M+H] + .
[0293] Step 3: Dissolve compound H-12-b (1.4 g, 4.91 mmol) in THF / H2O (20 mL / 5 mL), add lithium hydroxide (0.62 g, 14.7 mmol), stir at room temperature for 2 hours, concentrate, and dilute the residue with water (20 mL), adjust the pH to 4 with 3M hydrochloric acid, and extract three times with dichloromethane. The combined organic phases are dried and concentrated. The residue H-12-c (trans racemate, 0.3 g, yield 22.6%) is used directly in the next step. MS m / z (ESI): 271.0 [M+H] + .
[0294] Step 4: Compound H-12-c (0.7 g, 2.33 mmol) was dissolved in tert-butanol (16 mL), and DPPA (1.15 g, 4.2 mmol), triethylamine (0.71 g, 7 mmol), and Boc anhydride (0.92 g, 4.2 mmol) were added. The atmosphere was replaced with argon three times, and the mixture was heated to 60°C and stirred overnight. The mixture was cooled and concentrated, and the residue was purified by column chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain compound H-12-d (trans racemic form, 0.1 g, yield 12.6%) as a yellow oil. MS m / z (ESI): 342.1 [M+H] + .
[0295] Step 5: To a solution of compound H-12-d (0.07 g, 0.19 mmol) in dichloromethane (6 mL) was added a 4 M solution of hydrogen chloride in dioxane (1.5 mL). The mixture was stirred at room temperature for 1 hour and concentrated. The residue, H-12-e (trans racemate, 50 mg, 98% yield), was used directly in the next step. MS m / z (ESI): 242.1 [M+H] + .
[0296] Step 6: Compound H-12-e (40 mg, 0.16 mmol) and intermediate 1 (68 mg, 0.16 mmol) were dissolved in acetonitrile, and DIPEA (62 mg, 0.48 mmol) was added. The mixture was then heated to 60°C and stirred for 2 hours. The reaction solution was concentrated, and the residue was purified by preparative HPLC to obtain compound H-12 (trans racemic form, 4 mg, yield 4.5%). MS m / z (ESI): 559.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.24 (s, 1H), 8.64 (d, J = 10.0Hz, 1H), 8.55-8.53 (m, 1H), 8.07 (s, 1H), 7.58-7.45 (m, 4H), 7.43-7.37 (m, 1H), 7.32 -7.30(m,2H),4.85(s,1H),4.52(s,1H),3.51-3.49(m,2H),3.24(s,3H) ,3.08-3.00(m,4H),2.58(s,5H),2.52-2.50(m,2H),2.01-1.91(m,2H).
[0297] Example 13: Preparation of Compound H-13
[0298] Step 1: Dissolve 2,3-difluoro-4-iodopyridine (2.41 g, 10 mmol), methyl acrylate (2.58 g, 30 mmol), triethylamine (3.03 g, 30 mmol), tris(o-methylphenyl)phosphine (0.3 g, 1.0 mmol), and palladium acetate (113 mg, 0.5 mmol) in DMF (30 mL). Replace the atmosphere with argon three times, heat to 90°C, stir overnight, cool, and concentrate. The residue is purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to give compound H-13-a (1.7 g, yield 85.4%) as a yellow oil. MS m / z (ESI): 200.0 [M+H] + .
[0299] Step 2: Compound H-13-a (1.7 g, 8.5 mmol) and triethylamine (2.59 g, 25.6 mmol) were dissolved in toluene (40 mL), and paraformaldehyde (0.76 g, 25.6 mmol) and N-(2-methoxyethyl)hydroxylamine hydrochloride (1.08 g, 8.5 mmol) were added. The mixture was heated to 70°C and stirred overnight. The reaction solution was cooled, filtered, and the filtrate was concentrated. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain compound H-13-b (trans racemic form, 1.9 g, yield 73.9%) as a yellow oil. MS m / z (ESI): 303.0 [M+H] + .
[0300] Step 3: Compound H-13-b (1.9 g, 6.29 mmol) was dissolved in THF / H2O (20 mL / 5 mL), and lithium hydroxide (0.79 g, 18.8 mmol) was added. The mixture was stirred at room temperature for 2 hours and concentrated. The residue was diluted with water (30 mL), adjusted to pH 4 with 3M hydrochloric acid, and extracted three times with dichloromethane. The combined organic phases were dried and concentrated. The residue, H-13-c (trans racemate, 1.7 g, yield 94.4%), was used directly in the next step. MS m / z (ESI): 289.0 [M+H] + .
[0301] Step 4: Compound H-13-c (576 mg, 2.0 mmol) was dissolved in tert-butanol (20 mL), and DPPA (0.88 g, 3.2 mmol), triethylamine (0.6 g, 6 mmol), and Boc anhydride (0.7 g, 3.2 mmol) were added. The atmosphere was replaced with argon three times, and the mixture was heated to 95°C and stirred overnight. The mixture was cooled and concentrated, and the residue was purified by column chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain compound H-13-d (trans racemic form, 0.22 g, yield 30.6%) as a yellow oil. MS m / z (ESI): 360.2 [M+H] + .
[0302] Step 5: To a solution of compound H-13-d (70 mg, 0.19 mmol) in dichloromethane (6 mL) was added a 4 M solution of hydrogen chloride in dioxane (1.5 mL). The mixture was stirred at room temperature for 1 hour and concentrated. The residue, H-13-e (trans racemate, 40 mg, 80% yield), was used directly in the next step. MS m / z (ESI): 260.1 [M+H] + .
[0303] Step 6: Compound H-13-e (50 mg, 0.19 mmol) and intermediate 1 (79 mg, 0.19 mmol) were dissolved in acetonitrile, and DIPEA (74 mg, 0.57 mmol) was added. The mixture was then heated to 70°C and stirred for 2 hours. The reaction solution was concentrated, and the residue was purified by preparative HPLC to obtain compound H-13 (trans racemic form, 50 mg, yield 45.9%). MS m / z (ESI): 577.3 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.14 (s, 1H), 8.04-7.98 (m, 1H), 7.58-7.56 (m, 2H), 7.51-7.49 (m, 2H), 7.46-7.34 (m, 3H), 4.9 9(s,1H),4.49(s,1H),3.53-3.51(m,2H),3.25(s,3H),3.10-3.01(m, 4H),2.66-2.64(m,2H),2.58(s,3H),2.50-2.48(m,2H),1.96(s,2H).
[0304] Example 14: Preparation of Compound H-14
[0305] Step 1: Dissolve 5-bromo-2-chloro-3-fluoro-pyridine (10.5 g, 49.90 mmol), methyl acrylate (12.89 g, 149.69 mmol), tri-o-methylphenylphosphine (1.52 g, 4.99 mmol), triethylamine (15.15 g, 149.69 mmol, 20.88 mL), and palladium acetate (560.12 mg, 2.49 mmol) in acetonitrile (50 mL). Stir the reaction mixture under nitrogen at 90°C for 16 hours. Dried solvent was evaporated, water was added, and the mixture was extracted with ethyl acetate and dried over anhydrous sodium sulfate. The dried solvent was purified by column chromatography (PE / EtOAc = 3 / 1) to afford compound H-14-a (8 g, yellow solid). Yield: 74.36%. MS m / z (ESI): 216.0 [M+H]. + .
[0306] Step 2: Dissolve compound H-14-a (8 g, 37.10 mmol) in MeOH (10 mL), THF (20 mL), and H₂O (20 mL), then add LiOH (2.67 g, 111.31 mmol). Stir the reaction mixture at room temperature for 3 hours. Remove the solvent by evaporation, add water, adjust the pH to 3 with 1 M hydrochloric acid, and filter. Dry the filter cake to obtain compound H-14-b (7.2 g, yellow solid). Yield: 96.26%. MS m / z (ESI): 202.0 [M+H]+ .
[0307] Step 3: Dissolve compound H-14-b (5 g, 24.80 mmol) in DCM (50 mL). Then add SOCl2 (3.54 g, 29.76 mmol, 2.16 mL). Stir the reaction mixture at 50°C for 1 hour. The solvent is evaporated to give compound H-14-c (5.18 g, yellow solid). Yield: 94.91%. MS m / z (ESI): 220.1 [M+H] + .
[0308] Step 4: (4R)-4-phenyloxazolidin-2-one (1.48 g, 9.09 mmol) was dissolved in THF (1.61 mL), cooled to -78°C, and LiHMDS (1 M, 9.09 mL) was added dropwise. The reaction was stirred at -78°C for 1 hour. Compound H-14-c (2 g, 9.09 mmol) was added dropwise and stirred at -78°C for 2 hours. The reaction was quenched with aqueous solution, extracted with ethyl acetate, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography (petroleum ether containing 60% ethyl acetate) to afford compound H-14-d (2.1 g, yellow solid). Yield: 66.63%. MS m / z (ESI): 347.1 [M+H]. + .
[0309] Step 5: Compound H-14-d (2 g, 5.77 mmol) was dissolved in toluene (10 mL), and triethylamine (583.67 mg, 5.77 mmol, 804.50 μL), N-(2-methoxyethyl)hydroxylamine hydrochloride (735.82 mg, 5.77 mmol, HCl), and paraformaldehyde (519.57 mg, 17.30 mmol) were added. The reaction was stirred at 70°C for 16 hours. The solvent was evaporated under reduced pressure, and the crude product was purified by column chromatography (petroleum ether containing 60% ethyl acetate) to afford compound H-14-e (1.2 g, yellow solid). Yield: 46.25%. MS m / z (ESI): 450.1 [M+H]. + .
[0310] Step 6: Compound H-14-e (1.2 g, 2.67 mmol) was dissolved in THF (10 mL) and H₂O (2 mL), and then LiOH (191.66 mg, 8.00 mmol) and H₂O₂ (0.1 mL) were added. The reaction was stirred at room temperature for 3 hours. After the reaction, water was added to the reaction solution and extracted with ethyl acetate. The aqueous phase was acidified with 1 M HCl, extracted with DCM, and dried over anhydrous sodium sulfate. The DCM was evaporated to obtain compound H-14-f (trans single isomer, 650 mg, yellow solid). Yield: 79.97%. MS m / z (ESI): 305.1 [M+H] + .
[0311] Step 7: Compound H-14-f (650 mg, 2.13 mmol) was dissolved in t-BuOH (10 mL), and DPPA (1.04 g, 4.27 mmol), TEA (431.72 mg, 4.27 mmol, 595.07 μL), and Boc2O (931.16 mg, 4.27 mmol) were added. The reaction was stirred at 95°C for 16 hours. The solvent was evaporated under reduced pressure, and the crude product was purified by column chromatography (petroleum ether containing 40% ethyl acetate) to afford compound H-14-g (trans single isomer, 120 mg, yellow solid). Yield: 14.97%. MS m / z (ESI): 376.1 [M+H]. + .
[0312] Step 8: Compound H-14-g (60 mg, 159.65 μmol) was dissolved in toluene (5 mL), and Cs2CO3 (52.02 mg, 159.65 μmol), NH2Boc (37.41 mg, 319.30 μmol), Pd2(dba)3 (14.62 mg, 15.97 μmol), and Xantphos (18.48 mg, 31.93 μmol) were added. The reaction was stirred at 150°C in a microwave oven for 1 hour. The solvent was evaporated under reduced pressure, and the crude product was purified by column chromatography (petroleum ether containing 80% ethyl acetate) to afford compound H-14-h (trans single isomer, 30 mg, yellow solid). Yield: 52.73%. MS m / z (ESI): 357.2 (M+H-100). + .
[0313] Step 9: Dissolve compound H-14-h (30 mg, 84.18 μmol) in HCl / dioxane (2 mL) and MeOH (2 mL). Stir the reaction mixture at room temperature for 2 hours. Spin dry to obtain compound H-14-i (trans isomer, 16 mg, yellow solid). Yield: 74.17%. MS m / z (ESI): 257.2 [M+H]+ .
[0314] Step 10: Intermediate 1 (20 mg, 48.61 μmol) and compound H-14-i were dissolved in ACN (2 mL), followed by the addition of DIEA (12.56 mg, 97.22 μmol, 16.93 μL). The reaction mixture was stirred under nitrogen at 80°C for 2 hours and monitored by LC-MS. After completion of the reaction, the mixture was concentrated under reduced pressure and the residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH₄HCO₃H₂O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain the desired product, compound H-14 (trans isomer, 5.00 mg). Yield: 16.68%. MS m / z (ESI): 574.3 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.06 (s, 1H), 7.67 (s, 1H), 7.55 (d, J = 8.0Hz, 2H ),7.49(t,J=8.0Hz,2H),7.39(t,J=8.0Hz,1H),7.28(d,J=12.0Hz,1H),7.14(d,J=8.0Hz,1H ),6.21(s,2H),4.48(s,1H),4.30(s,1H),3.53-3.43(m,2H),3.24(s,3H),3.05-3.03(m,2H ),3.00-2.94(m,2H),2.68-2.59(m,2H),2.58(s,3H),2.52-2.49(m,2H),2.01-1.90(m,2H).
[0315] Example 15: Preparation of Compound H-15
[0316] Intermediate 2 (50 mg, 125.17 μmol) and compound H-25-e (trans racemate, 32.45 mg, 125.17 μmol) were dissolved in ACN (10 mL), followed by the addition of DIEA (32.35 mg, 250.35 μmol, 43.61 μL). The reaction mixture was stirred at 80°C under nitrogen for 2 hours. After completion of the reaction, the mixture was concentrated under reduced pressure and the resulting residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH₄HCO₃H₂O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain the desired product, compound H-15 (trans racemate, 5.00 mg). The yield was 6.95%. MS m / z (ESI): 565.3 [M+H]+ . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 8.03 (s, 1H), 7.95-7.91 (m, 2H), 7.66 (d, J = 4.0Hz, 1H), 7.52 (d, J = 8.0Hz, 2H), 7.47-7.41 (m, 2H), 7.30 (t, J = 8.0Hz, 1H) ),7.18(s,1H),4.65(s,1H),4.34(s,1H),3.73(s,3H),3.51(t,J=6.0Hz,2 H),3.25(s,3H),3.05-2.95(m,4H),2.65-2.50(m,4H),1.96-1.89(m,2H).
[0317] Example 16: Preparation of Compound H-16
[0318] Step 1: Intermediate 3 (55 mg, 100.81 μmol) and compound H-8-e (trans racemate, 36.33 mg, 151.21 μmol) were dissolved in ACN (5 mL). DIEA (26.06 mg, 201.62 μmol, 35.12 μL) was then added. The reaction mixture was stirred at 80°C under nitrogen for 2 hours. The mixture was dried to afford compound H-16-a (trans racemate, 40 mg, yellow solid). Yield: 57.36%. MS m / z (ESI): 692.0 [M+H] + .
[0319] Step 2: Compound H-16-a (40 mg, 57.82 μmol) was dissolved in EtOH (5 mL), followed by the addition of 10% Pd / C (6.13 mg, 57.82 μmol). The reaction mixture was stirred under hydrogen at room temperature for 2 hours. LC-MS monitoring was performed. After completion of the reaction, the mixture was filtered, concentrated under reduced pressure, and the resulting residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH₄HCO₃H₂O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain the target product, compound H-16 (trans racemate, 12 mg). Yield: 34.60%. MS m / z (ESI): 558.3 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ (ppm): 8.43 (s, 1H), 8.35 (s, 1H), 7.98 (s, 2H), 7.57 (d ,J=7.7Hz,2H),7.49(t,J=7.8Hz,2H),7.43-7.29(m,3H),7.20-7.02(m,3H),6 .84(s,1H),4.69(s,1H),4.34(s,1H),3.53(d,J=5.7Hz,4H),3.26(s,3H),3.1 1(s,2H),2.87(d,J=9.0Hz,2H),2.63(d,J=14.7Hz,2H),1.93(d,J=4.0Hz,2H).
[0320] Example 17: Preparation of Compound H-17
[0321] Step 1: Intermediate 3 (53 mg, 97.14 μmol) and compound H-7-e (trans racemate, 30.11 mg, 116.57 μmol) were dissolved in acetonitrile (5 mL). DIEA (25.11 mg, 194.29 μmol, 33.84 μL) was then added. The reaction mixture was stirred at 80°C under nitrogen for 2 hours. The mixture was dried to afford compound H-17-a (trans racemate, 40 mg, yellow solid). Yield: 58.02%. MS m / z (ESI): 710.0 [M+H] + .
[0322] Step 2: Compound H-17-a (40 mg, 56.36 μmol) was dissolved in EtOH (5 mL), followed by the addition of 10% Pd / C (597.40 μg, 5.64 μmol). The reaction mixture was stirred under hydrogen at room temperature for 2 hours. LC-MS monitoring was performed. After completion of the reaction, the mixture was filtered, concentrated under reduced pressure, and the resulting residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH₄HCO₃H₂O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain the desired product H-17 (trans racemic form, 6.67 mg). Yield: 19.77%. MS m / z (ESI): 576 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ (ppm): 8.57 (s, 1H), 8.00 (s, 1H), 7.59-7.53 (m, 2H), 7. 48-7.44(m,2H),7.41-7.29(m,3H),7.19-7.10(m,2H),6.25(s,1H),5.90(s,2H) ,4.60(s,1H),4.29(s,1H),3.51(t,J=6.0Hz,2H),3.27(s,2H),3.25(s,3H),3.0 2(t,J=6.0Hz,2H),2.71-2.64(m,2H),2.56(t,J=6.0Hz,2H),1.91-1.84(m,2H).
[0323] Example 18: Preparation of Compound H-18
[0324] Step 1: Dissolve 3-fluoropyridine-4-carboxaldehyde (1 g, 7.99 mmol) and nitromethane (585.51 mg, 9.59 mmol) in DCM (10 mL). Then add TEA (1.62 g, 15.99 mmol, 2.23 mL). The reaction mixture is stirred at room temperature for 1 hour. The solvent is evaporated, and AcO (10 mL) is added. The reaction mixture is then cooled to 0°C and DMAP (97.66 mg, 799.36 μmol) is added. The reaction mixture is stirred at room temperature for another 1 hour. The solvent is evaporated and the mixture is purified by column chromatography (PE / EtOAc = 2 / 1) to afford compound H-18-a (740 mg, yellow solid). Yield: 55.06%. MS m / z (ESI): 169.1 [M+H]. + .
[0325] Step 2: Add N-(2-methoxyethyl)hydroxylamine hydrochloride (254.95 mg, 2.00 mmol, HCl) to toluene (20.79 mL), followed by paraformaldehyde (60.02 mg, 2.00 mmol) and DIEA (606.69 mg, 6.00 mmol, 836.24 μL). Under argon, the reaction mixture was heated to 70°C and stirred for 1 hour. The temperature was then lowered to below 50°C, and compound H-18-a (336 mg, 2.00 mmol) was added. Stirring was continued at 70°C for 2 hours. The mixture was then dried and passed through a column (PE / EtOAc = 2 / 1) to afford compound H-18-b (trans racemic, 320 mg, yellow oil). Yield: 59.03%. MS m / z (ESI): 272.1 [M+H]. + .
[0326] Step 3: Dissolve compound H-18-b (320 mg, 1.18 mmol) in HCl (10 mL), then add SnCl2 (798.63 mg, 3.54 mmol). Stir the reaction mixture at 50°C for 2 hours. Neutralize the mixture with NaHCO3 until alkaline, extract with DCM, and dry over anhydrous sodium sulfate. Spin dry to obtain compound H-18-c (trans racemate, 80 mg, yellow oil). Yield: 28.11%. MS m / z (ESI): 242.2 [M+H]. + .
[0327] Step 4: Intermediate 1 (80 mg, 194.43 μmol) and compound H-18-c (56.29 mg, 233.32 μmol) were dissolved in ACN (5 mL), followed by the addition of DIEA (50.26 mg, 388.86 μmol, 67.73 μL). The reaction mixture was stirred at 80°C under nitrogen for 2 hours. After completion of the reaction, the mixture was concentrated under reduced pressure and the resulting residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH₄HCO₃H₂O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain the desired product H-18 (trans racemic form, 28.64 mg). Yield: 26.30%. MS m / z (ESI): 559.3 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.52 (s, 1H), 8.41 (d, J = 4.9Hz, 1H), 8.10 (s, 1H), 7.60-7.46 (m, 5H), 7.43-7.35 (m, 2H), 4.92 (s, 1H),4.47(s,1H),3.52(t,J=6.0Hz,2H),3.32(s,2H),3.25(s,3H),3.0 9-3.00(m,4H),2.64(t,J=6.0Hz,2H),2.58(s,3H),2.00-1.93(m,2H).
[0328] Example 19: Preparation of Compound H-19
[0329] Step 1: Dissolve 4-bromo-2-fluoropyridine (50 g, 284.11 mmol), methyl acrylate (48.92 g, 568.23 mmol), tri(o-methylphenyl)phosphine (1.73 g, 5.68 mmol), TEA (57.50 g, 568.23 mmol, 79.25 mL), and Pd(OAc)2 (1.28 g, 5.68 mmol) in ACN. Stir the reaction mixture under nitrogen at 90°C for 16 hours. The solvent was evaporated and filtered through a column (PE / EtOAc = 3 / 1) to afford compound H-19-a (45 g, yellow solid). Yield: 87.43%. MS m / z (ESI): 182.1 [M+H]. + .
[0330] Step 2: Add N-(2-methoxyethyl)hydroxylamine hydrochloride (14.17 g, 111.12 mmol, HCl) to toluene (150 mL), followed by paraformaldehyde (9.10 g, 303.04 mmol) and TEA (30.66 g, 303.04 mmol, 42.27 mL). Under argon, heat the reaction mixture to 70°C and stir for 1 hour. Cool the mixture to below 50°C, add compound H-19-a (18.3 g, 101.01 mmol), and continue stirring at 70°C for 2 hours. The solvent was evaporated and filtered through a column (PE / EtOAc = 2 / 1) to afford compound H-19-b (trans racemic, 5.3 g, yellow liquid). Yield: 18.46%. MS m / z (ESI): 285.2 [M+H]. + .
[0331] Step 3: Dissolve compound H-19-b (5.3 g, 18.64 mmol) in MeOH (10 mL) and H2O (10 mL), then add LiOH (893.02 mg, 37.29 mmol). Stir the reaction mixture at room temperature for 2 hours. Drain the methanol and adjust the mixture to a weakly acidic state with hydrochloric acid. Extract with dichloromethane and dry over anhydrous sodium sulfate. Drain the solvent to obtain compound H-19-c (trans racemate, 4.4 g, 16.28 mmol, 87.33% yield) as a yellow solid. Yield: 87.33%. MS m / z (ESI): 271.1 [M+H]. + .
[0332] Step 4: Dissolve DPPA (5.94 g, 24.42 mmol), Boc2O (5.33 g, 24.42 mmol), TEA (4.94 g, 48.84 mmol, 6.81 mL), and compound H-19-c (4.4 g, 16.28 mmol) in t-BuOH (108.67 mL). Stir the reaction mixture at 95°C for 16 hours. The solvent was evaporated and filtered through a column (PE / EtOAc = 2 / 1) to afford compound H-19-d (trans racemate, 1.05 g, yellow oil). Yield: 18.89%. MS m / z (ESI): 342.1 [M+H] + .
[0333] Step 5: Dissolve compound H-19-d (1.05 g, 3.08 mmol) in dioxane (3.33 mL) and HCl (1.67 mL) and stir at room temperature for 3 hours. The solvent was evaporated to give compound H-19-e (trans racemate, 813 mg, yellow solid). Yield: 95.18%. MS m / z (ESI): 242.1 [M+H] + .
[0334] Step 6: Intermediate 1 (1.39 g, 3.37 mmol) and compound H-19-e (813 mg, 3.37 mmol) were dissolved in ACN (10 mL), followed by the addition of DIEA (871.02 mg, 6.74 mmol, 1.17 mL). The reaction mixture was stirred at 80°C under nitrogen for 2 hours. After completion of the reaction, the mixture was concentrated under reduced pressure and the resulting residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH₄HCO₃H₂O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain the desired product H-19 (trans racemic form, 1.08 g). Yield: 57.37%. MS m / z (ESI): 559.1 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ (ppm): 9.33 (s, 1H), 8.31 (s, 1H), 8.15 (d, J = 6.0Hz, 1H), 7.6 1(d,J=8.0Hz,2H),7.51(t,J=8.0Hz,2H),7.40(dd,J=16.0,8.0Hz,2H),7.26(s,1H), 7.04(s,1H),4.68(s,1H),4.33(s,1H),3.53(d,J=6.0Hz,2H),3.43(s,2H),3.26(s,3 H), 3.05 (d, J = 8.0Hz, 4H), 2.68 (t, J = 6.0Hz, 2H), 2.58 (s, 3H), 1.98 (d, J = 4.0Hz, 2H).
[0335] Example 20: Preparation of Compound H-20
[0336] Intermediate 4 and compound H-8-e (trans racemate, 50.80 mg, 211.43 μmol) were dissolved in ACN (10 mL), followed by the addition of DIEA (39.04 mg, 302.04 μmol, 52.61 μL). The reaction mixture was stirred at 80°C under nitrogen for 2 hours. After completion of the reaction, the mixture was concentrated under reduced pressure and the resulting residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH₄HCO₃H₂O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain the desired product H-20 (trans racemate, 56.56 mg). The yield was 60.91%. MS m / z (ESI): 610.3 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 8.34 (s, 1H), 8.05 (s, 1H), 7.56-7.44 (m, 4H), 7.39-7.31 (m, 2H), 7.22- 7.03(m,4H),4.64(s,1H),4.31(s,1H),3.59-3.44(m,5H),3.30(s,2H),3.25(s,3H),3.02(t,J=5.8Hz,4H),2.65(s,2H),1.98-1.87(m,2H).
[0337] Example 21: Preparation of Compound H-21
[0338] Intermediate 4 (67 mg, 144.55 μmol) and compound H-7-e (trans racemate, 41.0.077 mg, 159.00 μmol) were dissolved in ACN (10 mL), followed by the addition of DIEA (37.36 mg, 289.10 μmol, 50.35 μL). The reaction mixture was stirred at 80°C under nitrogen for 2 hours. After completion of the reaction, the mixture was concentrated under reduced pressure and the resulting residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH₄HCO₃H₂O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain the desired product H-21 (trans racemate, 43.87 mg). The yield was 48.23%. MS m / z (ESI): 628.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 8.36 (s, 1H), 8.08 (s, 1H), 7.59-7.45 (m, 4H), 7.39-7.32 (m, 3H), 7.26-7.12 (m, 2H), 4.61 ( s,1H),4.29(s,1H),3.60-3.48(m,5H),3.39-3.34(m,2H),3.26(s,3H),3.03(t,J=6.0Hz,4H),2.66(s,2H),1.95(s,2H).
[0339] Example 22: Preparation of Compounds H-22-a and H-22-b
[0340] Compound HH-1-19 (trans racemate, 2.2 g, 3.94 mmol) was chirally resolved (instrument: SFC-150 (Thar, Waters), column type: IC 20×250 mm, 10 μm (Daicel), column temperature: 35°C, mobile phase: CO2 / (MeOH / ACN (0.2% Methanol Ammonia) = 1:1) = 50 / 50, flow rate: 120 g / min, back pressure: 100 bar, detection wavelength: 214 nm, cycle time: 3.0 min, sample diluent: 2300 mg dissolved in 60 mL Methanol, injection volume: 1.0 mL) and then lyophilized to obtain the target product H-22-a (trans single isomer, retention time: 1.476 min, 1.1 g). MS m / z (ESI): 559.3 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ (ppm): 9.26 (s, 1H), 8.25-8.08 (m, 2H), 7.60 (d, J = 7.5Hz, 2H), 7.51 (t, J = 7.8Hz, 2H), 7.43-7.31 (m, 2H), 7.25 (s, 1H),7.03(s,1H),4.67(s,1H),4.32(s,1H),3.53(s,2H),3.25(s,3H),3.04(s,4H),2.68(s,2H),2.58(s,3H),2.48(s,2H),1.97(s,2H).
[0341] and H-22-b (trans single isomer, retention time: 2.522 min, 1.0 g). MS m / z (ESI): 559.3 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.26 (s, 1H), 8.25-8.08 (m, 2H), 7.60 (d, J = 8.0Hz, 2H), 7.51 (t, J = 8.0Hz, 2H), 7.43-7.31 (m, 2H),7.25(s,1H),7.03(s,1H),4.67(s,1H),4.32(s,1H),3.53(s,2H),3.25(s,3H),3.04(s,4H),2.68(s,2H),1.97(s,2H).
[0342] Example 23: Preparation of Compound H-23
[0343] Step 1: Dissolve 2,6-fluoro-4-iodopyridine (10 g, 41.50 mmol), methyl acrylate (10.72 g, 124.49 mmol), tri(o-methylphenyl)phosphine (631.51 mg, 2.07 mmol), TEA (12.60 g, 124.49 mmol, 17.36 mL), and Pd(OAc)2 (465.83 mg, 2.07 mmol) in DMF (50 mL). Stir the reaction mixture under nitrogen at 70°C for 16 hours. The solvent was dried and purified by column chromatography (PE / EtOAc = 5 / 1) to afford compound H-23-a (7 g, yellow solid). Yield: 84.70%. MS m / z (ESI): 200.1 [M+H]. + .
[0344] Step 2: Add N-(2-methoxyethyl)hydroxylamine hydrochloride (5.38 g, 42.18 mmol, HCl) to toluene (35.22 mL), followed by paraformaldehyde (3.17 g, 105.45 mmol) and TEA (10.67 g, 105.45 mmol, 14.71 mL). Under argon, heat the reaction mixture to 70°C and stir for 1 hour. Cool the mixture to below 50°C, add compound H-23-a (7 g, 35.15 mmol), and continue stirring at 70°C for 2 hours. The solvent was evaporated and filtered through a column (PE / EtOAc = 2 / 1) to afford compound H-23-b (trans racemic, 5.7 g, yellow oil). Yield: 53.65%. MS m / z (ESI): 303.1 [M+H]. + .
[0345] Step 3: Dissolve compound H-23-b (5.7 g, 18.86 mmol) in THF (20 mL) and H₂O (20 mL), then add LiOH (903.26 mg, 37.71 mmol). Stir the reaction mixture at room temperature for 2 hours. Neutralize the mixture with concentrated hydrochloric acid to a weak acidic state, extract with DCM, and dry over anhydrous sodium sulfate. The solvent is evaporated to dryness to afford compound H-23-c (trans racemate, 5.4 g, yellow oil). Yield: 99.35%. MS m / z (ESI): 289.1 [M+H] + .
[0346] Step 4: Dissolve DPPA (9.62 g, 39.55 mmol), Boc2O (8.63 g, 39.55 mmol), TEA (6.00 g, 59.32 mmol, 8.27 mL), and compound H-23-c (5.7 g, 19.77 mmol) in t-BuOH (1.89 mL). Stir the reaction mixture at 95°C for 16 hours. The solvent was evaporated and filtered through a column (PE / EtOAc = 2 / 1) to afford compound H-23-d (trans racemate, 1.6 g, yellow oil). Yield: 22.51%. MS m / z (ESI): 360.1 [M+H]. + .
[0347] Step 5: Dissolve compound H-23-d (1.6 g, 4.45 mmol) in DCM (10 mL), then add HCl (10 mL). Stir the reaction mixture at room temperature for 1 hour. The solvent is evaporated to dryness to afford compound H-23-e (trans racemate, 1.15 g, yellow solid). Yield: 100%. MS m / z (ESI): 260.1 [M+H] + .
[0348] Step 6: Intermediate 1 (1.52 g, 3.70 mmol) and compound H-23-e (1.15 g, 4.44 mmol) were dissolved in ACN (20 mL), followed by the addition of DIEA (955.48 mg, 7.39 mmol, 1.29 mL). The reaction mixture was stirred at 80°C under nitrogen for 2 hours. After completion of the reaction, the mixture was concentrated under reduced pressure and the resulting residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH₄HCO₃H₂O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain the desired product H-23 (trans racemic form, 1.2 g). Yield: 55.01%. MS m / z (ESI): 577.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.26 (s, 1H), 8.21 (s, 1H), 7.61 (d, J = 8.0Hz, 2H), 7.50 (t, J = 8.0Hz, 2H), 7.37 (dd, J = 16, 8.0Hz, 2H), 7.04 (s, 2H), 4.71 (s ,1H),4.35(s,1H),3.61-3.45(m,2H),3.33-3.29(m,2H),3.28-3.23(m,3H) ,3.12-2.93(m,4H),2.69(t,J=6.0Hz,2H),2.58(s,3H),2.06-1.90(m,2H).
[0349] Example 24: Preparation of Compound H-24
[0350] Compound H-7-e (trans racemate, 41.00 mg, 158.75 μmol) and intermediate 1 (56 mg, 136.10 μmol) were added to acetonitrile (10 mL), followed by N,N-diisopropylethylamine (52.77 mg, 408.31 μmol). The reaction mixture was stirred at 80°C for 2 hours. After concentration under reduced pressure, the residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain product H-24 (trans racemate, 36.50 mg) in a yield of 45.09%. MS m / z (ESI): 576.0 [M+H]. 1H NMR (400MHz, CD3OD) δ (ppm): 9.32 (s, 1H), 8.10 (s, 1H), 7.61 (d, J = 7.5Hz, 2H), 7. 52(t,J=7.7Hz,2H),7.43(t,J=7.3Hz,2H),7.23-7.17(m,2H),7.11(s,1H),4.59( s,1H),4.42(s,1H),3.63-3.58(m,2H),3.37(s,3H),3.31(s,2H),3.18-3.14(m,2 H), 3.10 (t, J = 5.5Hz, 2H), 2.79 (t, J = 6.4Hz, 2H), 2.67 (s, 3H), 2.15-2.07 (m, 2H).
[0351] Example 25: Preparation of Compound H-25
[0352] Step 1: Under argon, 5-bromo-2,3-difluoro-pyridine (772.21 mg, 3.98 mmol) and ethyl 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-acrylate (900 mg, 3.98 mmol) were dissolved in dioxane (20 mL) and water (5 mL). [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (291.29 mg, 398.10 μmol) and cesium carbonate (2.60 g, 7.96 mmol) were then added. The reaction was stirred at 90°C for 16 hours. The mixture was filtered and the solvent was evaporated under reduced pressure to afford the crude product. The residue was purified by silica gel column chromatography using a solvent system (petroleum ether / ethyl acetate: 1 / 0 to 3 / 1) to afford compound H-25-a (580 mg, white solid) in a yield of 68.34%. MS m / z(ESI):214.0[M+H] + .
[0353] Step 2: Add N-(2-methoxyethyl)hydroxylamine hydrochloride (480 mg, 3.76 mmol) to toluene (15 mL), followed by triethylamine (1.57 mL, 11.29 mmol), paraformaldehyde (338.98 mg, 11.29 mmol), and compound H-25-a (802.12 mg, 3.76 mmol). Under argon, the reaction mixture was heated to 75°C and stirred for 16 hours. The mixture was concentrated under reduced pressure and the resulting residue was purified by silica gel column chromatography using a solvent system (petroleum ether / ethyl acetate: 1 / 0 to 3 / 1) to afford compound H-25-b (trans racemic form, 1.05 g, colorless oil) in a yield of 88.23%. MS m / z (ESI): 317.1 [M+H] + .
[0354] Step 3: Dissolve compound H-25-b (1.05 g, 2.79 mmol) in tetrahydrofuran (10 mL), methanol (2 mL), and water (2 mL), and add lithium hydroxide monohydrate (209.61 mg, 5.00 mmol). The reaction mixture was stirred at room temperature for 1 hour. The organic solvent was removed by vortexing under reduced pressure, and 10 mL of water was added. The pH was adjusted to 2 with 1N hydrochloric acid, and the mixture was extracted with dichloromethane (30 mL x 3). The organic phase was dried, filtered, and concentrated to obtain compound H-25-c (trans racemate, 782 mg, light yellow oil) in a yield of 81.47%. MS m / z (ESI): 289.1 [M+H] + .
[0355] Step 4: Compound H-25-c (782 mg, 2.71 mmol), diphenylphosphoryl azide (989.68 mg, 4.07 mmol), and triethylamine (686.31 mg, 6.78 mmol, 945.98 μL) were added to tert-butanol (15 mL). Under argon, the mixture was heated to 95°C and stirred for 16 hours. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using a solvent system (petroleum ether / ethyl acetate: 1 / 0 to 2 / 1) to afford compound H-25-d (trans racemate, 220 mg, light yellow oil) in a yield of 22.57%. MS m / z (ESI): 360.2 [M+H] + .
[0356] Step 5: Dissolve compound H-25-d (220 mg, 612.19 μmol) in methanol (6 mL), then add 4N hydrochloric acid in 1,4-dioxane (4 mL). Stir the reaction mixture at room temperature for 2 hours. Concentrate under reduced pressure to obtain compound H-25-e (trans racemate, 140 mg, light yellow oil) in a yield of 88.21%. MS m / z (ESI): 260.0 [M+H] + .
[0357] Step 6: Compound H-25-e (41.16 mg, 158.75 μmol) and intermediate 1 (56 mg, 136.10 μmol) were added to acetonitrile (10 mL), followed by N,N-diisopropylethylamine (52.77 mg, 408.31 μmol). The reaction mixture was stirred at 80°C for 2 hours. After concentration under reduced pressure, the residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain product H-25 (trans racemic form, 21.33 mg) in a yield of 26.48%. MS m / z (ESI): 577.0 [M+H] +. 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.26 (s, 1H), 8.15 (s, 1H), 7.93 (dd, J = 18.2, 7.5Hz, 2H) ,7.59(d,J=7.5Hz,2H),7.50(t,J=7.9Hz,2H),7.38(t,J=7.3Hz,1H),7.29(d,J=7.0Hz ,1H),4.67(s,1H),4.33(s,1H),3.51(d,J=5.4Hz,2H),3.29-3.27(m,2H),3.25(s,3H) ,3.04(dd,J=12.0,7.0Hz,4H),2.66(t,J=6.0Hz,2H),2.58(s,3H),2.01-1.92(m,2H).
[0358] Example 26: Preparation of Compound H-26
[0359] Step 1: Dissolve compound H-7-a (1.5 g, 7.07 mmol) in tetrahydrofuran (20 mL), methanol (5 mL), and water (5 mL). Then add lithium hydroxide monohydrate (444.96 mg, 10.60 mmol). Stir the reaction mixture at room temperature for 2 hours. Remove the organic solvent by vortexing, add 15 mL of water, and adjust the pH to 2 with 4N hydrochloric acid solution. A white solid precipitates. Filter, wash the solid with water, and dry to obtain the product compound H-26-a (1.25 g, white solid) in a yield of 96.03%. MS m / z (ESI): 185.0 [M+H] + .
[0360] Step 2: Add thionyl chloride (969.13 mg, 8.15 mmol, 591.66 μL) and compound H-26-a (1.25 g, 6.79 mmol) to dichloromethane (15 mL), and add 3 drops of N,N-dimethylformamide dropwise. Reflux the reaction mixture at 50°C for 2 hours. Concentrate under reduced pressure to obtain compound H-26-b (1.38 g, white solid). The crude product is used directly in the next step. MS m / z (ESI): 199.0 [M+H] + (methyl ester).
[0361] Step 3: (R)-4-phenyloxazolidin-2-one (1.11 g, 6.81 mmol) was dissolved in tetrahydrofuran (20 mL), cooled to -78°C, and lithium bis(trimethylsilyl)amide (2 M, 3.75 mL) was added dropwise. The mixture was stirred at -78°C for 1 hour. Compound H-26-b (1.38 g, 6.81 mmol) was then added dropwise. The reaction was stirred at -78°C for 2 hours. The mixture was quenched with aqueous solution and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using a solvent system (petroleum ether / ethyl acetate: 1 / 0 to 1 / 1) to afford compound H-26-c (1.28 g, yellow solid) in a yield of 57.06%. MS m / z (ESI): 330.0 [M+H]. + .
[0362] Step 4: Add N-(2-methoxyethyl)hydroxylamine hydrochloride (545.46 mg, 4.28 mmol) to toluene (25 mL), followed by triethylamine (1.63 mL, 11.29 mmol), paraformaldehyde (350.19 mg, 11.66 mmol), and compound H-26-c (1.28 g, 3.89 mmol). Under argon, the reaction mixture was heated to 80°C and stirred for 16 hours. The mixture was concentrated under reduced pressure and the resulting residue was purified by silica gel column chromatography using a solvent system (petroleum ether / ethyl acetate: 1 / 0 to 1 / 1) to afford compound H-26-d (760 mg, colorless oil) in a yield of 45.22%. MS m / z (ESI): 433.2 [M+H] + .
[0363] Step 5: Compound H-26-d (760 mg, 1.76 mmol) was added to tetrahydrofuran (10 mL) and water (5 mL). Lithium hydroxide monohydrate (147.51 mg, 3.52 mmol) was added, followed by dropwise addition of hydrogen peroxide (59.78 mg, 1.76 mmol, 0.5 mL). The reaction mixture was stirred at room temperature for 0.5 hours. The reaction was quenched by the addition of a 2.0 M aqueous solution of Na2SO3 (5 mL). After stirring for 10 minutes, water (10 mL) was added and the mixture was extracted with ethyl acetate (30 mL x 2). The aqueous phase was retained and the pH was adjusted to 2 with 1N HCl. The aqueous phase was then extracted with DCM (30 mL x 3). The organic phase from the second extraction was concentrated under reduced pressure to afford compound H-26-e (trans single isomer, 310 mg, colorless oil) in a yield of 61.40%. MS m / z (ESI): 288.1 [M+H] + .
[0364] Step 6: Compound H-26-e (310 mg, 1.08 mmol), diphenylphosphoryl azide (393.68 mg, 1.62 mmol), and triethylamine (273.00 mg, 2.70 mmol, 376.30 μL) were added to tert-butanol (8 mL). Under argon, the mixture was heated to 95°C and stirred for 16 hours. The mixture was concentrated under reduced pressure. The residue was purified by preparative thin-layer chromatography (petroleum ether / ethyl acetate: 2:1) to afford compound H-26-f (trans single isomer, 45 mg, colorless oil) in a yield of 11.64%. MS m / z (ESI): 359.2 [M+H] + .
[0365] Step 7: Dissolve compound H-26-f (45 mg, 125.57 μmol) in methanol (2 mL), then add 4N hydrochloric acid in 1,4-dioxane (2 mL). Stir the reaction mixture at room temperature for 1 hour. Concentrate under reduced pressure to obtain compound H-26-g (trans single isomer, 32 mg, light yellow oil) in a yield of 98.68%. MS m / z (ESI): 259.1 [M+H] + .
[0366] Step 8: Compound H-26-g (32 mg, 158.75 μmol) and intermediate 1 (56 mg, 136.10 μmol) were added to acetonitrile (10 mL), followed by N,N-diisopropylethylamine (48.04 mg, 371.71 μmol). The reaction mixture was stirred at 80°C for 2 hours. After concentration under reduced pressure, the residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain product H-26 (trans single isomer, 23.18 mg) in a yield of 31.83%. MS m / z (ESI): 576.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.11 (s, 1H), 7.59 (d, J = 8.0Hz, 2 H),7.50(t,J=7.8Hz,2H),7.44-7.29(m,3H),7.22(d,J=7.8Hz,1H),7.15(s,1 H),4.59(s,1H),4.28(s,1H),3.51(t,J=5.7Hz,2H),3.30(s,2H),3.25(s,3H ), 3.03 (dd, J = 15.0, 8.9Hz, 4H), 2.65 (s, 2H), 2.58 (s, 3H), 2.01-1.91 (m, 2H).
[0367] Example 27: Preparation of Compound H-27
[0368] Compound H-7-e (trans racemate, 45 mg, 152.68 μmol) and intermediate 5 (45 mg, 87.12 μmol) were added to acetonitrile (10 mL), followed by N,N-diisopropylethylamine (33.78 mg, 261.35 μmol). The reaction mixture was stirred at 80°C for 6 hours. After concentration under reduced pressure, the residue was purified by preparative liquid chromatography (preparative column: 21.2×250 mm C18 column; system: 10 mM NH₄HCO₃H₂O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain product H-27 (trans racemate, 5.09 mg) in a yield of 9.97%. MS m / z (ESI): 561.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 8.44-8.39 (m, 1H), 8.36 (dd, J = 4.7, 1.6Hz, 1H), 8.09 (s, 1 H),7.59(d,J=7.6Hz,2H),7.49(t,J=7.8Hz,2H),7.41-7.26(m,4H),7.23(d,J=7.6Hz,1H) ,7.15(s,1H),4.60(s,1H),4.29(s,1H),3.50(d,J=5.8Hz,2H),3.29-3.27(m,2H),3.25( s, 3H), 3.08 (d, J = 10.2Hz, 2H), 3.02 (t, J = 5.7Hz, 2H), 2.64 (d, J = 6.7Hz, 2H), 1.98 (s, 2H).
[0369] Example 28: Preparation of Compound H-28
[0370] Compound H-8-e (trans racemate, 70 mg, 252.95 μmol) and intermediate 5 (45 mg, 87.12 μmol) were added to acetonitrile (10 mL), followed by N,N-diisopropylethylamine (56.30 mg, 435.95 μmol). The reaction mixture was stirred at 80°C for 6 hours. After concentration under reduced pressure, the residue was purified by preparative liquid chromatography (preparative column: 21.2×250 mm C18 column; system: 10 mM NH₄HCO₃H₂O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain product H-28 (trans racemate, 10.43 mg) in a yield of 20.24%. MS m / z (ESI): 543.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 8.42 (dd, J=7.9, 1.6Hz, 1H), 8.36 (dd, J=4.7, 1.7Hz, 1H), 8.09 (s, 1H), 7.5 9(d,J=7.7Hz,2H),7.49(t,J=7.8Hz,2H),7.36(dt,J=15.0,7.7Hz,2H),7.29(dd,J=7.9,4.7Hz,1H),7.23 (d,J=7.9Hz,1H),7.15-7.06(m,3H),4.63(s,1H),4.31(s,1H),3.51(t,J=5.6Hz,2H),3.30-3.28(m,2H), 3.24(d,J=4.2Hz,3H), 3.12-3.05(m,2H), 3.03(t,J=5.8Hz,2H), 2.65(t,J=6.2Hz,2H), 2.03-1.93(m,2H).
[0371] Example 29: Preparation of Compound H-29
[0372] Step 1: Intermediate 6 (64 mg, 117.30 μmol) and compound H-8-e (trans racemate, 40 mg, 166.48 μmol) were added to acetonitrile (10 mL), followed by N,N-diisopropylethylamine (45.48 mg, 351.91 μmol, 61.30 μL). The reaction mixture was stirred at 80°C for 4 hours. The mixture was concentrated under reduced pressure to afford compound H-29-a (trans racemate, 80 mg, light yellow oil). The crude product was used directly in the next step. MS m / z (ESI): 692.1 [M+H] + .
[0373] Step 2: Dissolve compound H-29-a (80 mg, 115.65 μmol) in ethanol (10 mL) and add 10% palladium on carbon (50 mg, 115.65 μmol). Stir the reaction mixture at room temperature for 2 hours under a hydrogen atmosphere. Filter and concentrate under reduced pressure. Purify the resulting residue by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain compound H-29 (trans racemate, 31.26 mg) in a yield of 97.48%. MS m / z (ESI): 558.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 8.06 (d, J = 8.5Hz, 1H), 8.00 (s, 1H), 7.56 (d, J = 7.4Hz, 2H), 7.46 (t, J=7.9Hz,2H),7.34(dd,J=13.4,6.1Hz,2H),7.13(dd,J=16.6,8.9Hz,4H),6.35(d,J=8.5Hz,1H),5. 92(s,2H),4.64(s,1H),4.31(s,1H),3.51(t,J=5.9Hz,2H),3.28(d,J=2.8Hz,2H),3.24(d,J=6.3H z, 3H), 3.02 (t, J = 5.8Hz, 2H), 2.85 (d, J = 10.1Hz, 2H), 2.57 (t, J = 6.3Hz, 2H), 1.90 (d, J = 5.8Hz, 2H).
[0374] Example 30: Preparation of Compound H-30
[0375] Step 1: Intermediate 6 (102 mg, 180.95 μmol) and compound H-7-e (trans racemate, 72.43 mg, 280.43 μmol) were added to acetonitrile (10 mL), followed by N,N-diisopropylethylamine (72.49 mg, 560.86 μmol). The reaction mixture was stirred at 80°C for 4 hours. The mixture was concentrated under reduced pressure to afford compound H-30-a (trans racemate, 132 mg, light yellow oil). The crude product was used directly in the next step. MS m / z (ESI): 710.1 [M+H] + .
[0376] Step 2: Dissolve compound H-30-a (132 mg, 185.98 μmol) in ethanol (20 mL) and add 10% palladium on carbon (80 mg, 115.65 μmol). Stir the reaction mixture at room temperature for 2 hours under a hydrogen atmosphere. Filter and concentrate under reduced pressure. Purify the resulting residue by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain compound H-30 (trans racemic form, 36.00 mg) in a yield of 31.52%. MS m / z (ESI): 576.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 8.06 (d, J = 8.5Hz, 1H), 8.00 (s, 1H), 7.56 (d, J = 7.5Hz, 2H) ,7.46(t,J=7.9Hz,2H),7.41-7.26(m,3H),7.15(d,J=6.8Hz,2H),6.35(d,J=8.5Hz,1H),5 .92(s,2H),4.60(s,1H),4.29(s,1H),3.51(t,J=5.7Hz,2H),3.29(s,2H),3.25(s,3H),3. 02 (t, J = 5.8 Hz, 2H), 2.85 (d, J = 10.3 Hz, 2H), 2.57 (t, J = 6.4 Hz, 2H), 1.92 (d, J = 4.7 Hz, 2H).
[0377] Example 31: Preparation of Compound H-31
[0378] Step 1: Add ammonium acetate (7.39 g, 95.92 mmol) to acetic acid (50 mL). After dissolution and clarification, add 2-fluoropyridine-3-carboxaldehyde (5 g, 39.97 mmol) and nitromethane (14.64 g, 239.81 mmol). The reaction mixture was stirred at 90°C for 4 hours. Water (200 mL) was added and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was dried, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using an eluent system (petroleum ether / ethyl acetate: 1 / 0 to 3 / 1) to obtain compound H-31-a (655 mg, light yellow solid) in a yield of 9.75%. MS m / z (ESI): 169.0 [M+H] + .
[0379] Step 2: Add N-(2-methoxyethyl)hydroxylamine hydrochloride (497.00 mg, 3.90 mmol) to toluene (20 mL), followed by paraformaldehyde (116.98 mg, 3.90 mmol) and triethylamine (1.18 g, 11.69 mmol, 1.63 mL). Under argon, the reaction mixture was heated to 70°C and stirred for 1 hour. The temperature was then lowered to below 50°C, and compound H-31-a (655 mg, 3.90 mmol) was added. Stirring was continued at 70°C for 2 hours. The mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using a solvent system (petroleum ether / ethyl acetate: 1 / 0 to 3 / 1) to afford compound H-31-b (trans racemic, 950 mg, light yellow oil) in a yield of 89.90%. MS m / z (ESI): 272.1 [M+H]. + .
[0380] Step 3: Dissolve compound H-31-b (235.25 mg, 867.31 μmol) in concentrated hydrochloric acid (10 mL), then add stannous chloride dihydrate (587.13 mg, 2.60 mmol). Stir the reaction mixture at 50°C for 2 hours. Neutralize the reaction mixture with sodium bicarbonate until alkaline, filter, extract with dichloromethane, and dry over anhydrous sodium sulfate. Filter and concentrate under reduced pressure to obtain compound H-31-c (trans racemate, 110 mg, brown oil) in a yield of 52.57%. MS m / z (ESI): 242.1 [M+H] + .
[0381] Step 4: Compound H-31-c (61.57 mg, 255.19 μmol) and intermediate 1 (70 mg, 170.13 μmol) were added to acetonitrile (20 mL), followed by N,N-diisopropylethylamine (65.96 mg, 510.38 μmol, 88.90 μL). The reaction mixture was stirred at 80°C for 3 hours. After concentration under reduced pressure, the residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain product H-31 (trans racemic form, 45.95 mg) in a yield of 47.73%. MS m / z (ESI): 559.1 [M+H] + . 1HNMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.16 (d, J = 4.3Hz, 1H), 8.08 (s, 1H), 7. 99(t,J=8.6Hz,1H),7.56(dd,J=8.5,1.1Hz,2H),7.50(dd,J=10.4,5.1Hz,2H),7.43- 7.28(m,3H),4.80(s,1H),4.48(s,1H),3.50(t,J=5.7Hz,2H),3.31(s,2H),3.24(s,3 H), 3.04 (dd, J = 10.7, 4.7Hz, 4H), 2.68-2.60 (m, 2H), 2.58 (s, 3H), 2.02-1.91 (m, 2H).
[0382] Example 32: Preparation of Compound H-32
[0383] Step 1: Dissolve 3-fluoropyridine-2-carbaldehyde (2 g, 15.99 mmol) in dichloromethane (20 mL), add nitromethane (1.17 g, 19.18 mmol) and triethylamine (3.24 g, 31.97 mmol, 4.46 mL). Stir the reaction mixture at room temperature for 1 hour. Concentrate under reduced pressure. Dissolve the residue in dichloromethane (20 mL), add N,N-dimethylpyridin-4-amine (195.31 mg, 1.60 mmol), and then add acetic anhydride (1.96 g, 19.18 mmol) dropwise. Stir the reaction mixture at room temperature under nitrogen for 2 hours. Concentrate under reduced pressure and purify the resulting residue by silica gel column chromatography using a solvent system (petroleum ether / ethyl acetate: 1 / 0 to 3 / 1) to obtain compound H-32-a (890 mg, yellow solid) in a yield of 33.11%. MS m / z(ESI):169.1[M+H] + .
[0384] Step 2: Add N-(2-methoxyethyl)hydroxylamine hydrochloride (675.31 mg, 5.29 mmol) to toluene (25 mL), followed by paraformaldehyde (158.95 mg, 5.29 mmol) and triethylamine (1.61 g, 15.88 mmol, 2.22 mL). Under argon, the reaction mixture was heated to 70°C and stirred for 1 hour. The temperature was then lowered to below 50°C, and compound H-32-a (890 mg, 5.29 mmol) was added. Stirring was continued at 70°C for 2 hours. The mixture was concentrated under reduced pressure and the resulting residue was purified by silica gel column chromatography using a solvent system (petroleum ether / ethyl acetate: 1 / 0 to 3 / 1) to afford compound H-32-b (trans racemic, 1.1 g, light yellow oil) in a yield of 76.61%. MS m / z (ESI): 272.1 [M+H]. + .
[0385] Step 3: Dissolve compound H-32-b (230 mg, 847.94 μmol) in concentrated hydrochloric acid (10 mL), then add stannous chloride dihydrate (574.02 mg, 2.54 mmol). Stir the reaction mixture at 50°C for 2 hours. Neutralize the reaction mixture with sodium bicarbonate until alkaline, filter, extract with dichloromethane, and dry over anhydrous sodium sulfate. Filter and concentrate under reduced pressure to obtain compound H-32-c (trans racemate, 75 mg, brown oil) in a yield of 36.66%. MS m / z (ESI): 242.1 [M+H] + .
[0386] Step 4: Compound H-32-c (61.57 mg, 255.19 μmol) and intermediate 1 (70 mg, 170.13 μmol) were added to acetonitrile (20 mL), followed by the addition of N,N-diisopropylethylamine (65.96 mg, 510.38 μmol, 88.90 μL). The reaction mixture was stirred at 80°C for 3 hours. After concentration under reduced pressure, the residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain product H-32 (trans racemic form, 41.13 mg) in a yield of 43.28%. MS m / z (ESI): 559.1 [M+H] + . 1HNMR (400MHz, DMSO-d6) δ (ppm): 9.23 (s, 1H), 8.43 (d, J = 4.6Hz, 1H), 8.02 (s, 1H), 7.72 (t, J = 8.8Hz, 1H), 7.58-7.52 (m, 2H), 7.50-7.43 (m, 3H), 7.3 9(t,J=7.3Hz,1H),7.25(s,1H),4.96(s,2H),3.48-3.38(m,2H),3.22(s, 3H), 3.01 (dd, J=15.1, 10.0Hz, 6H), 2.64-2.53 (m, 5H), 1.97-1.87 (m, 2H).
[0387] Example 33: Preparation of Compounds H-33-a and H-33-b
[0388] Compound H-25-e (trans racemate, 82 mg, 316.29 μmol) and intermediate 1 (112 mg, 272.20 μmol) were added to acetonitrile (15 mL), followed by N,N-diisopropylethylamine (105.54 mg, 816.61 μmol). The reaction mixture was stirred at 80°C for 2 hours. After concentration under reduced pressure, the resulting residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain the racemic product H-25 (trans racemate, 90 mg). Chiral preparation (instrument: SFC-150 (Thar, Waters), column type: IC 20×250 mm, 10 μm (Daicel), column temperature: 35°C, mobile phase: CO2 / (MeOH / ACN (0.2% Methanol Ammonia) = 1:1) = 50 / 50, flow rate: 120 g / min, back pressure: 100 bar, detection wavelength: 214 nm, cycle time: 3.0 min) was then performed, followed by separation and lyophilization to obtain compound H-33-a (trans single isomer, retention time 1.253 min, 20.45 mg). MS m / z (ESI): 577.0 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.15 (s, 1H), 7.97-7.87 (m, 2H), 7 .59(d,J=7.5Hz,2H),7.50(t,J=7.9Hz,2H),7.38(t,J=7.4Hz,1H),7.30(d,J= 7.0Hz,1H),4.67(s,1H),4.34(s,1H),3.51(s,2H),3.29(s,2H),3.25(s,3H), 3.04(dd,J=11.9,7.1Hz,4H),2.66(t,J=5.8Hz,2H),2.58(s,3H),1.97(s,2H).
[0389] and compound H-33-b (trans single isomer, retention time 1.657 min, 21.57 mg), yield 26.25%. MS m / z (ESI): 577.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.26 (s, 1H), 8.16 (s, 1H), 7.98-7.87 (m, 2H), 7.5 9(d,J=7.9Hz,2H),7.50(t,J=7.9Hz,2H),7.38(t,J=7.3Hz,1H),7.30(d,J=6.8H z,1H),4.66(s,1H),4.33(s,1H),3.51(s,2H),3.30(s,2H),3.25(s,3H),3.04(d d,J=12.1,7.2Hz,4H),2.66(t,J=6.2Hz,2H),2.58(s,3H),1.96(d,J=5.3Hz,2H).
[0390] Example 34: Preparation of Compound H-34
[0391] Step 1: Dissolve 5-bromo-3-fluoro-pyridine-2-carbonitrile (3 g, 14.93 mmol), methyl acrylate (3.85 g, 44.78 mmol), tri(o-methylphenyl)phosphine (454.28 mg, 1.49 mmol), triethylamine (4.53 g, 44.78 mmol, 6.25 mL), and palladium acetate (335.10 mg, 1.49 mmol) in acetonitrile (40 mL). Stir the reaction mixture under nitrogen at 90°C for 16 hours. Concentrate under reduced pressure. The resulting residue is purified by silica gel column chromatography using a solvent system (petroleum ether / ethyl acetate: 1 / 0 to 3 / 1) to afford compound H-34-a (2.8 g, orange-red solid) in a yield of 90.99%. MS m / z (ESI): 207.1 [M+H]. + .
[0392] Step 2: Add N-(2-methoxyethyl)hydroxylamine hydrochloride (1.91 g, 14.94 mmol) to toluene (40 mL), followed by triethylamine (4.12 g, 40.74 mmol, 5.68 mL), paraformaldehyde (1.22 g, 40.74 mmol), and compound H-34-a (2.8 g, 13.58 mmol). Under argon, the reaction mixture was heated to 75°C and stirred for 16 hours. The mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using a solvent system (petroleum ether / ethyl acetate: 1 / 0 to 1 / 1) to afford compound H-34-b (trans racemic, 1.08 g, light yellow oil) in a yield of 25.71%. MS m / z (ESI): 310.1 [M+H] + .
[0393] Step 3: Dissolve compound H-34-b (1.08 g, 3.49 mmol) in water (10 mL) and THF (30 mL), and add lithium hydroxide monohydrate (190.47 mg, 4.54 mmol). Stir the reaction mixture at room temperature for 1 hour. Adjust the pH to 4 with 1N hydrochloric acid, remove the organic solvent under reduced pressure, and extract with dichloromethane (50 mL x 3). The organic phase is dried, filtered, and concentrated to obtain compound H-34-c (trans racemate, 727 mg, light yellow oil) in a yield of 70.51%. MS m / z (ESI): 296.1 [M+H] + .
[0394] Step 4: Compound H-34-c (630 mg, 2.13 mmol) was added to tert-butyl alcohol (10 mL), followed by diphenylphosphoryl azide (778.36 mg, 3.20 mmol) and triethylamine (539.77 mg, 5.33 mmol, 743.99 μL). Under argon, the mixture was heated to 95°C and stirred for 16 hours. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using an eluent system (petroleum ether / ethyl acetate: 1 / 0 to 1 / 1) to afford compound H-34-d (trans racemate, 310 mg, yellow solid) in a yield of 39.65%. MS m / z (ESI): 367.2 [M+H] + .
[0395] Step 5: Dissolve compound H-34-d (70 mg, 191.06 μmol) in dichloromethane (5 mL), then add trifluoroacetic acid (2.5 mL). Stir the reaction mixture at room temperature for 1.5 hours. Concentrate under reduced pressure to obtain compound H-34-e (trans racemate, 50 mg, yellow oil) in a yield of 98.29%. MS m / z (ESI): 267.1 [M+H] + .
[0396] Step 6: Compound H-34-e (50 mg, 187.78 μmol) and intermediate 1 (70 mg, 170.13 μmol) were added to acetonitrile (20 mL), followed by N,N-diisopropylethylamine (65.96 mg, 510.38 μmol, 88.90 μL). The reaction mixture was stirred at 80°C for 2 hours. After concentration under reduced pressure, the residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain product H-34 (trans racemic form, 44.69 mg) in a yield of 45.01%. MS m / z (ESI): 584.1 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ (ppm): 9.26 (s, 1H), 8.54 (s, 1H), 8.20 (s, 1H), 7.94 (d, J = 10.0Hz, 1H), 7.63-7.58 (m, 2H), 7.51 (dd, J = 10.6, 5.2Hz, 2H),7.41-7.34(m,2H),4.78(s,1H),4.35(s,1H),3.53(t,J=5.2Hz,2H),3.29(s,2H),3.26(s,3H),3.05(t,J=6.8Hz,4H),2.68(t,J=6.2Hz, 2H), 2.58 (s, 3H), 1.98 (d, J = 5.3Hz, 2H).
[0397] Example 35: Preparation of Compound H-35
[0398] Step 1: Dissolve 4-bromo-2-fluoro-3-methylpyridine (2 g, 10.53 mmol), methyl acrylate (2.72 g, 31.58 mmol), tris(o-methylphenyl)phosphine (320.36 mg, 1.05 mmol), triethylamine (3.20 g, 31.58 mmol, 4.40 mL), and palladium acetate (236.31 mg, 1.05 mmol) in acetonitrile (30 mL). Stir the reaction mixture under nitrogen at 90°C for 16 hours. Concentrate under reduced pressure. The residue is purified by silica gel column chromatography using a solvent system (petroleum ether / ethyl acetate: 1 / 0 to 3 / 1) to afford compound H-35-a (2 g, yellow solid) in a yield of 97.35%. MS m / z (ESI): 196.1 [M+H]. + .
[0399] Step 2: Add N-(2-methoxyethyl)hydroxylamine hydrochloride (1.36 g, 10.67 mmol) to toluene (40 mL), followed by triethylamine (2.94 g, 29.10 mmol, 4.06 mL), paraformaldehyde (873.93 mg, 29.10 mmol), and compound H-35-a (1.89 g, 9.70 mmol). Under argon, the reaction mixture was heated to 75°C and stirred for 16 hours. The mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using a solvent system (petroleum ether / ethyl acetate: 1 / 0 to 3 / 1) to afford compound H-35-b (trans racemic form, 2.4 g, light yellow oil) in a yield of 82.94%. MS m / z (ESI): 299.1 [M+H] + .
[0400] Step 3: Dissolve compound H-35-b (2.31 g, 7.76 mmol) in water (10 mL) and THF (30 mL), and add lithium hydroxide monohydrate (488.43 mg, 11.64 mmol). Stir the reaction mixture at room temperature for 1 hour. Adjust the pH to 4 with 1N hydrochloric acid, remove the organic solvent under reduced pressure, and extract with dichloromethane (50 mL x 3). The organic phase is dried, filtered, and concentrated to obtain compound H-35-c (trans racemate, 2.1 g, yellow oil) in a yield of 95.20%. MS m / z (ESI): 285.1 [M+H] + .
[0401] Step 4: Compound H-35-c (665 mg, 2.34 mmol) was added to tert-butyl alcohol (10 mL), followed by diphenylphosphoryl azide (853.35 mg, 3.51 mmol) and triethylamine (591.76 mg, 5.85 mmol, 815.66 μL). Under argon, the mixture was heated to 95°C and stirred for 16 hours. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using an eluent system (petroleum ether / ethyl acetate: 1 / 0 to 2 / 1) to afford compound H-35-d (trans racemate, 128 mg, yellow solid) in a yield of 15.40%. MS m / z (ESI): 356.2 [M+H] + .
[0402] Step 5: Add compound H-35-d (66 mg, 185.70 μmol) to a 4N hydrochloric acid solution in 1,4-dioxane (10 mL). Stir the reaction mixture at room temperature for 1 hour. Concentrate under reduced pressure to obtain compound H-35-e (trans racemate, 54 mg, white solid) in a yield of 99.67%. MS m / z (ESI): 256.1 [M+H] + .
[0403] Step 6: Compound H-35-e (54 mg, 211.53 μmol) and intermediate 1 (77 mg, 187.14 μmol) were added to acetonitrile (20 mL), followed by N,N-diisopropylethylamine (72.56 mg, 561.42 μmol, 97.79 μL). The reaction mixture was stirred at 80°C for 2 hours. After concentration under reduced pressure, the residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain product H-35 (trans racemic form, 53.03 mg) in a yield of 49.23%. MS m / z (ESI): 573.0 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.15 (s, 1H), 8.00 (d, J = 5.1Hz, 1H), 7.6 0-7.56(m,2H),7.50(dd,J=10.4,5.0Hz,2H),7.40(dd,J=16.2,8.9Hz,3H),4.94(s, 1H),4.34(s,1H),3.53(t,J=5.5Hz,2H),3.29(s,2H),3.26(d,J=4.6Hz,3H),3.06(d d,J=11.5,6.1Hz,4H),2.66-2.62(m,2H),2.58(s,3H),2.00(dd,J=25.6,8.2Hz,5H).
[0404] Example 36: Preparation of Compound H-36
[0405] Step 1: Compound H-8-d (trans racemate, 15 g, 62.43 mmol) was separated by chiral preparative liquid chromatography (instrument: SFC-150 (Thar, Waters) column type: IC 20×250 mm, 10 μm (Daicel), column temperature: 35° C., mobile phase: CO 2 / (MeOH / ACN (0.2% Methanol Ammonia)=1:1)=50 / 50, flow rate: 120 g / min, back pressure: 100 bar, detection wavelength: 214 nm, cycle time: 3.0 min) to obtain a trans single isomer compound (retention time:
[0406] 2.25 min, 7 g, 20.86 mmol, light yellow solid, yield 33.41%). MS m / z (ESI): 341.1 [M+H] + .
[0407] Step 2: Dissolve the trans-isomer obtained in Step 1 (3.2 g, 9.40 mmol) in dichloromethane and add hydrochloric acid (4 M, 35.25 mL). Stir the reaction at 26°C for 2 hours. Dry the mixture under reduced pressure to obtain the de-Boc-protected trans-isomer (2.2 g, 9.16 mmol) in a 97.40% yield. The crude product was used directly in the next step. MS m / z (ESI): 241.1 [M+H] + .
[0408] Step 3: The de-Boc-protected trans single isomer (100 mg, 416.19 μmol) obtained in Step 2 and Intermediate 1 (221.23 mg, 416.19 μmol) were dissolved in acetonitrile (10 mL), and N,N-diisopropylethylamine (107.58 mg, 832.39 μmol, 144.99 μL) was added. The reaction was stirred at 80°C for 12 hours. After concentration under reduced pressure, the product was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain compound H-36 (trans single isomer, 151.3 mg, 271.33 μmol) in a yield of 65.19%. MS m / z(ESI):558.1[M+H] + . 1 HNMR (400MHz, DMSO-d6) δ (ppm): 9.26 (s, 1H), 8.10 (s, 1H), 7.59 (d, J = 8.0Hz, 2H ),7.50(t,J=7.8Hz,2H),7.37(dt,J=14.2,7.5Hz,2H),7.23(d,J=7.6Hz,1H),7 .12(t,J=8.8Hz,3H),4.64(s,1H),4.31(s,1H),3.51(t,J=5.6Hz,2H),3.25(s, 3H), 3.04 (dd, J=13.2, 7.8Hz, 5H), 2.66 (s, 3H), 2.58 (s, 3H), 2.01-1.93 (m, 2H).
[0409] Example 37: Preparation of Compound H-37
[0410] Step 1: Acetic acid (50 mL) was added to ammonium acetate (5.99 g, 77.71 mmol), followed by 6-chloronicotinaldehyde (5 g, 35.32 mmol) and nitromethane (12.94 g, 211.93 mmol). The mixture was heated to 90°C and stirred for 18 hours. After cooling to room temperature, the reaction mixture was poured onto crushed ice and extracted with ethyl acetate. The mixture was washed with saturated brine, dried, and dried under reduced pressure. The resulting residue was purified by silica gel column chromatography using a 6 / 1 ratio of petroleum ether to ethyl acetate to afford compound H-37-a (0.5 g, 2.71 mmol, yield: 7.67%).
[0411] Step 2: Add N-(2-methoxyethyl)hydroxylamine hydrochloride (0.6 g, 4.70 mmol) to toluene (12 mL), followed by triethylamine (1.43 g, 14.11 mmol, 1.97 mL), paraformaldehyde (141.24 mg, 4.70 mmol), and compound H-37-a (868.14 mg, 4.70 mmol). Under argon, the reaction mixture was heated to 70°C and stirred for 16 hours. The mixture was concentrated under reduced pressure and the resulting residue was purified by silica gel column chromatography using a 3 / 1 solvent system (petroleum ether / ethyl acetate) to afford compound H-37-b (trans racemic, 0.3 g, 1.04 mmol, colorless oil) in a yield of 22.17%. MS m / z (ESI): 288.7 [M+H]. + .
[0412] Step 3: Compound H-37-b (280 mg, 973.24 μmol) was dissolved in hydrochloric acid (8 mL), and stannous chloride dihydrate (768.64 mg, 3.41 mmol) was added. The reaction was stirred at 70°C for 3 hours. The mixture was cooled to room temperature, adjusted to pH 9 with aqueous ammonia, filtered, and the filtrate was extracted with dichloromethane, washed with brine, dried, and dried under reduced pressure to afford compound H-37-c (trans racemate, 100 mg, 0.389 mmol, light yellow oil) in a 40% yield. MS m / z (ESI): 258.1 [M+H] + .
[0413] Step 4: Compound H-37-c (100 mg, 389 μmol) and intermediate 1 (159.65 mg, 388.02 μmol) were dissolved in acetonitrile (5 mL), and N,N-diisopropylethylamine (50.15 mg, 388.02 μmol, 67.59 μL) was added. The reaction was stirred at 80°C for 12 hours. After concentration under reduced pressure, the product was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain compound H-37 (trans racemate, 60.24 mg, 103.57 μmol) in a yield of 26.69%. MS m / z (ESI): 575.3 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.31 (d, J = 2.1Hz, 1H), 8.12 (s, 1H), 7.81- 7.74(m,1H),7.58(d,J=8.1Hz,2H),7.55-7.44(m,3H),7.39(t,J=7.3Hz,1H),7.26(d,J =7.2Hz,1H),4.65(s,1H),4.32(s,1H),3.51(t,J=5.7Hz,2H),3.29(s,2H),3.25(s,3H ), 3.04 (dd, J = 12.7, 7.1 Hz, 4H), 2.65 (t, J = 6.2 Hz, 2H), 2.58 (s, 3H), 2.03-1.91 (m, 2H).
[0414] Example 38: Preparation of Compound H-38
[0415] Step 1: Pyridine-2-carboxaldehyde (3 g, 28.01 mmol) was dissolved in dichloromethane (12 mL), followed by the addition of nitromethane (1.71 g, 28.01 mmol) and triethylamine (5.66 g, 56.02 mmol, 7.79 mL). The reaction was stirred at 26°C for 1 hour, and the reaction was monitored for completion by LC-MS. The solvent was evaporated under reduced pressure, and the crude product was dissolved in dichloromethane (12.40 mL). N,N-dimethylpyridin-4-amine (342.17 mg, 2.80 mmol) and acetic anhydride (3.43 g, 33.61 mmol) were added at 0°C and stirred at 26°C for 2 hours. The mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using a 2 / 1 system of petroleum ether / ethyl acetate to afford compound H-38-a (1.3 g, 8.66 mmol, colorless oil) in a yield of 30.92%. MS m / z(ESI):151.0[M+H] + .
[0416] Step 2: Add N-(2-methoxyethyl)hydroxylamine hydrochloride (1.2 g, 9.41 mmol) to toluene (10 mL), followed by triethylamine (1.43 g, 14.11 mmol, 1.97 mL), paraformaldehyde (141.24 mg, 4.70 mmol), and compound H-38-a (706.13 mg, 4.70 mmol). Under argon, the reaction mixture was heated to 70°C and stirred for 16 hours. The mixture was concentrated under reduced pressure and the resulting residue was purified by silica gel column chromatography using a 3 / 1 solvent system (petroleum ether / ethyl acetate) to afford compound H-38-b (trans racemate, 0.5 g, 1.97 mmol) in a yield of 41.98%. MS m / z (ESI): 254.1 [M+H]+ .
[0417] Step 3: Dissolve compound H-38-b (500.00 mg, 1.97 mmol) in hydrochloric acid (8 mL), then add stannous chloride dihydrate (1.56 g, 6.91 mmol). Stir the reaction at 50°C for 2 hours. Cool to room temperature, adjust the pH to 9 with aqueous ammonia, filter, and extract the filtrate with dichloromethane, wash with brine, dry, and evaporate to dryness under reduced pressure to afford compound H-38-c (trans racemate, 0.12 g, 0.53 mmol, light yellow oil) in a yield of 27.3%. MS m / z (ESI): 224.1 [M+H] + .
[0418] Step 4: Compound H-38-c (159.65 mg, 388.02 μmol) and intermediate 1 (86.63 mg, 388.02 μmol) were dissolved in acetonitrile (10 mL), and N,N-diisopropylethylamine (100.30 mg, 776.05 μmol, 135.17 μL) was added. The reaction was stirred at 80°C for 12 hours. After concentration under reduced pressure, the product was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to afford compound H-38 (trans racemate, 71.1 mg, 119.19 μmol) in a yield of 30.72%. MS m / z (ESI): 541.3 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.50 (s, 1H), 8.07 (s, 1H), 7.78 (td, J = 7.7, 1.8Hz, 1H), 7. 61-7.55(m,2H),7.49(t,J=7.8Hz,2H),7.40(dd,J=16.4,8.8Hz,2H),7.34-7.28(m,1H),7.24(d,J=7. 7Hz,1H),4.75(s,1H),4.60(d,J=11.6Hz,1H),3.51(dd,J=10.9,4.9Hz,2H),3.29(s,2H),3.25(d,J=3 .9Hz,3H),3.03(dd,J=11.6,8.1Hz,4H),2.64(dd,J=10.8,5.6Hz,2H),2.58(s,3H),2.00-1.91(m,2H).
[0419] Example 39: Preparation of Compound H-39
[0420] Step 1: Dissolve 5-bromo-2-fluoro-3-methyl-pyridine (1.9 g, 10.00 mmol), methyl 2-enoate (2.58 g, 30.00 mmol), tri(o-tolyl)phosphine (608.68 mg, 2.00 mmol), triethylamine (3.04 g, 30.00 mmol, 4.18 mL), and palladium acetate (224.49 mg, 999.93 μmol) in acetonitrile (10 mL). Stir the reaction mixture under argon at 90°C for 16 hours. The solvent was evaporated under reduced pressure to afford the crude product. The residue was purified by silica gel column chromatography using a 3 / 1 system of petroleum ether / ethyl acetate to afford compound H-39-a (1.2 g, 6.15 mmol) in a yield of 61.48%. MS m / z (ESI): 196.1 [M+H]. + .
[0421] Step 2: Add N-(2-methoxyethyl)hydroxylamine hydrochloride (1.53 g, 11.99 mmol) to toluene (10 mL), followed by triethylamine (3.03 g, 29.97 mmol, 4.18 mL), paraformaldehyde (900.02 mg, 29.97 mmol), and compound H-39-a (1.95 g, 9.99 mmol). Under argon, the reaction mixture was heated to 70°C and stirred for 16 hours. The mixture was concentrated under reduced pressure and the resulting residue was purified by silica gel column chromatography using a 3 / 1 solvent system (petroleum ether / ethyl acetate) to afford compound H-39-b (trans racemate, 2 g, 6.70 mmol, yellow solid) in a yield of 67.11%. MS m / z (ESI): 299.1 [M+H] + .
[0422] Step 3: Dissolve compound H-39-b (1 g, 3.35 mmol) in water (2 mL) and tetrahydrofuran (8 mL), then add lithium hydroxide monohydrate (140.79 mg, 3.35 mmol). Stir the reaction at 26°C for 2 hours. Adjust the pH to approximately 6 with 2N hydrochloric acid, evaporate the solvent, extract with dichloromethane, dry over anhydrous sodium sulfate, and evaporate to dryness under reduced pressure to obtain compound H-39-c (trans racemate, 0.6 g, 2.11 mmol) in a yield of 62.96%. MS m / z (ESI): 285.1 [M+H] + .
[0423] Step 4: Dissolve compound H-39-c (0.6 g, 2.11 mmol), [azido(phenyl)phosphoryl]benzene (769.94 mg, 3.17 mmol), tert-butyl carbonate (921.25 mg, 4.22 mmol), and triethylamine (639.50 mg, 6.33 mmol) in tert-butanol (10 mL). Stir the reaction at 95°C for 12 hours. The solvent was evaporated under reduced pressure. Purify the product by silica gel column chromatography using a 1 / 1 solvent system (petroleum ether / ethyl acetate) to obtain compound H-39-d (trans racemate, 200 mg, 562.74 μmol) in a yield of 26.66%. MS m / z (ESI): 356.1 [M+H]. + .
[0424] Step 5: Compound H-39-d (200 mg, 562.74 μmol) was dissolved in dichloromethane (10 mL) and hydrochloric acid (4 M, 4.22 mL) was added. The reaction was stirred at 26°C for 3 hours. The crude product (trans racemate, 143 mg, 560.15 μmol) was obtained by vacuum drying. The yield was 99.54%. The crude product was used directly in the next step. MS m / z (ESI): 256.1 [M+H] + .
[0425] Step 6: Compound H-39-e (100 mg, 391.71 μmol) and intermediate 1 (241.76 mg, 587.57 μmol) were dissolved in acetonitrile (10 mL), and N,N-diisopropylethylamine (151.88 mg, 1.18 mmol, 204.69 μL) was added. The reaction was stirred at 80°C for 12 hours. After concentration under reduced pressure, the product was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain compound H-39 (trans racemate, 59.62 mg, 101.46 μmol) in a yield of 25.90%. MS m / z (ESI): 573.1 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.10 (s, 1H), 7.93 (s, 1H), 7.75 (d, J = 9.7Hz, 1H),7.62-7.55(m,2H),7.50(t,J=7.8Hz,2H),7.39(t,J=7.3Hz,1H),7.24(d,J=7.4Hz,1 H),4.62(s,1H),4.32(s,1H),3.50(t,J=5.7Hz,2H),3.29(s,2H),3.25(s,3H),3.03(dd, J=14.0,8.1Hz,4H),2.65(t,J=6.1Hz,2H),2.58(s,3H),2.21(s,3H),2.01-1.92(m,2H).
[0426] Example 40: Preparation of Compound H-40
[0427] Step 1: Dissolve 5-bromo-2-methyl-3-fluoro-pyridine (1.90 g, 10.00 mmol), methyl 2-enoate (2.58 g, 30.00 mmol), tri(o-tolyl)phosphine (608.68 mg, 2.00 mmol), triethylamine (3.04 g, 30.00 mmol, 4.18 mL), and palladium acetate (224.49 mg, 999.93 μmol) in acetonitrile (10 mL). Stir the reaction mixture under argon at 90°C for 16 hours. The solvent was evaporated under reduced pressure to afford the crude product. The resulting residue, compound H-40-a (1 g, 5.12 mmol), was purified by silica gel column chromatography using a 3 / 1 solvent system (petroleum ether / ethyl acetate). Yield: 51.24%. MS m / z (ESI): 196.1 [M+H]. + .
[0428] Step 2: Add N-(2-methoxyethyl)hydroxylamine hydrochloride (784.28 mg, 6.15 mmol) to toluene (12 mL), followed by triethylamine (1.56 g, 15.37 mmol, 2.14 mL), paraformaldehyde (461.55 mg, 15.37 mmol), and compound H-40-a (1 g, 5.12 mmol). Under argon, the reaction mixture was heated to 70°C and stirred for 16 hours. The mixture was concentrated under reduced pressure and the resulting residue was purified by silica gel column chromatography using a 3 / 1 solvent system (petroleum ether / ethyl acetate) to afford compound H-40-b (trans racemate, 1 g, 3.35 mmol) as a yellow solid in a yield of 65.43%. MS m / z (ESI): 299.1 [M+H] + .
[0429] Step 3: Dissolve compound H-40-b (1 g, 3.35 mmol) in water (2 mL) and tetrahydrofuran (8 mL), then add lithium hydroxide monohydrate (211.19 mg, 5.03 mmol). Stir the reaction at 26°C for 2 hours. Adjust the pH to approximately 6 with 2N hydrochloric acid, evaporate the solvent under reduced pressure, extract with dichloromethane, dry over anhydrous sodium sulfate, and evaporate to dryness under reduced pressure to obtain compound H-40-c (trans racemate, 500 mg, 1.76 mmol) in a yield of 52.47%. MS m / z (ESI): 285.1 [M+H] + .
[0430] Step 4: Dissolve compound H-40-c (500 mg, 1.76 mmol), [azido(phenyl)phosphoryl]benzene (641.61 mg, 2.64 mmol), tert-butyl carbonate (767.72 mg, 3.52 mmol), and triethylamine (532.92 mg, 5.28 mmol) in tert-butanol (10 mL). Stir the reaction at 95°C for 12 hours. The solvent was evaporated under reduced pressure. Purify the product by silica gel column chromatography using a 1 / 1 solvent system (petroleum ether / ethyl acetate) to obtain compound H-40-d (trans racemate, 80 mg, 225.10 μmol) in a yield of 12.80%. MS m / z (ESI): 356.1 [M+H]. + .
[0431] Step 5: Compound H-40-d (50.00 mg, 140.69 μmol) was dissolved in dichloromethane (10 mL) and hydrochloric acid (4 M, 1.06 mL) was added. The reaction was stirred at 26°C for 3 hours. The crude product (trans racemate, 35 mg, 137.10 μmol) was obtained by vacuum drying. The yield was 97.45%. The crude product was used directly in the next step. MS m / z (ESI): 256.1 [M+H] + .
[0432] Step 6: Compound H-40-e (30 mg, 117.51 μmol) and intermediate 1 (48.35 mg, 117.51 μmol) were dissolved in acetonitrile (10 mL), and N,N-diisopropylethylamine (45.56 mg, 352.54 μmol, 61.41 μL) was added. The reaction was stirred at 80°C for 12 hours. After concentration under reduced pressure, the product was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to afford compound H-40 (trans racemate, 13.19 mg, 22.48 μmol) in a yield of 19.13%. MS m / z (ESI): 573.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.25 (s, 1H), 8.23 (s, 1H), 8.12 (s, 1H), 7.58 (d, J = 8.1Hz ,2H),7.51(dd,J=13.0,5.4Hz,3H),7.39(t,J=7.3Hz,1H),7.26(d,J=7.2Hz,1H),4.64(s ,1H),4.33(s,1H),3.50(t,J=5.6Hz,2H),3.27(s,2H),3.25(s,3H),3.03(dd,J=13.3,7 .7Hz, 4H), 2.65 (t, J = 6.0Hz, 2H), 2.58 (s, 3H), 2.41 (d, J = 2.8Hz, 3H), 2.01-1.92 (m, 2H).
[0433] Example 41: Preparation of Compound H-41
[0434] Step 1: Dissolve lithium bis(trimethylsilyl)amide (2M, 5.00 mL) in THF (30 mL), cool to -78°C, and add 2-fluoro-6-(trifluoromethyl)pyridine (1.65 g, 9.99 mmol) dropwise. The reaction is stirred at -78°C for 2 hours. A solution of elemental iodine (2.54 g, 9.99 mmol) in tetrahydrofuran is added dropwise to the reaction mixture. Stir at -78°C for 2 hours. Quench with brine, wash with aqueous sodium bisulfite, dry, and evaporate to dryness under reduced pressure. The crude product is purified by column chromatography (petroleum ether containing 35% ethyl acetate) to afford compound H-41-a (1.5 g, 5.15 mmol) in a yield of 51.58%. MS m / z (ESI): 291.7 [M+H]. + .
[0435] Step 2: Dissolve lithium bistrimethylsilylamide (2M, 13.99 mL) in THF (40 mL), cool to -78°C, and add compound H-41-a (3.7 g, 12.72 mmol) dropwise. The reaction is stirred at -78°C for 0.5 hours. Quench with brine, wash with aqueous sodium bisulfite, dry, and evaporate to dryness under reduced pressure. The crude product is purified by column chromatography (petroleum ether containing 35% ethyl acetate) to afford compound H-41-b (2.5 g, 8.59 mmol) in a yield of 67.57%.
[0436] Step 3: Dissolve compound H-41-b (1.3 g, 4.47 mmol), methyl 2-enoate (384.61 mg, 4.47 mmol), tri(o-tolyl)phosphine (271.96 mg, 893.52 μmol), triethylamine (1.36 g, 13.40 mmol, 1.87 mL), and palladium acetate (100.30 mg, 446.76 μmol) in dimethylformamide (10 mL). Stir the reaction mixture under argon at 90°C for 16 hours. The solvent was evaporated under reduced pressure to afford the crude product. Purification by silica gel column chromatography using a 3 / 1 solvent system (petroleum ether / ethyl acetate) afforded compound H-41-c (0.6 g, 2.41 mmol) in a yield of 53.90%.
[0437] Step 4: Add N-(2-methoxyethyl)hydroxylamine hydrochloride (368.64 mg, 2.89 mmol) to toluene (12 mL), followed by triethylamine (731.02 mg, 7.22 mmol, 1.01 mL), paraformaldehyde (216.94 mg, 7.22 mmol), and compound H-41-c (0.6 g, 2.41 mmol). Under argon, the reaction mixture was heated to 70°C and stirred for 16 hours. The mixture was concentrated under reduced pressure and the resulting residue was purified by silica gel column chromatography using a 3 / 1 system of petroleum ether / ethyl acetate to afford compound H-41-d (trans racemate, 0.5 g, 1.42 mmol) in a yield of 58.94%. MS m / z (ESI): 353.0 [M+H]. + .
[0438] Step 5: Dissolve compound H-41-d (1 g, 2.84 mmol) in water (2 mL) and tetrahydrofuran (8 mL), then add lithium hydroxide monohydrate (178.83 mg, 4.26 mmol). The reaction is stirred at 26°C for 2 hours. Adjust the pH to approximately 6 with 2N hydrochloric acid, evaporate the solvent under reduced pressure, extract with dichloromethane, dry over anhydrous sodium sulfate, and filter. Reduce pressure and evaporate to dryness to obtain compound H-41-e (trans racemate, 0.6 g, 1.77 mmol) in a yield of 62.49%. The crude product is used directly in the next step. MS m / z (ESI): 339.1 [M+H] + .
[0439] Step 6: Dissolve compound H-41-e (0.6 g, 1.77 mmol), [azido(phenyl)phosphoryl]benzene (647.09 mg, 2.66 mmol), tert-butyl carbonate (774.27 mg, 3.55 mmol), and triethylamine (537.47 mg, 5.32 mmol) in tert-butanol (10 mL). Stir the reaction at 95°C for 12 hours. The solvent was evaporated under reduced pressure. Purify the product by silica gel column chromatography using a 1 / 1 solvent system (petroleum ether / ethyl acetate) to obtain compound H-41-f (trans racemate, 150 mg, 366.41 μmol) in a yield of 20.66%. MS m / z (ESI): 410.0 [M+H]. + .
[0440] Step 7: Compound H-41-f (100 mg, 244.27 μmol) was dissolved in dichloromethane (5 mL) and hydrochloric acid (4 M, 1.22 mL) was added. The reaction was stirred at 26°C for 3 hours. The crude product (trans racemate, 75 mg, 242.52 μmol) was obtained by vacuum drying. The yield was 99.28%. The crude product was used directly in the next step. MS m / z (ESI): 310.1 [M+H] + .
[0441] Step 8: Compound H-41-g (75.00 mg, 242.52 μmol) and intermediate 1 (99.78 mg, 242.52 μmol) were dissolved in acetonitrile (10 mL), and N,N-diisopropylethylamine (94.03 mg, 727.55 μmol, 126.72 μL) was added. The reaction was stirred at 80°C for 12 hours. After concentration under reduced pressure, the mixture was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to afford compound H-41 (trans racemate, 52.62 mg, 83.98 μmol). Yield: 34.63%. MS m / z (ESI): 627.3 [M+H]. + . 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.26 (s, 1H), 8.23 (s, 1H), 7.84 (s, 1H), 7.61 (d, J = 7.5 Hz,2H),7.50(dd,J=10.7,5.1Hz,2H),7.42(s,1H),7.37(dd,J=10.5,4.2Hz,2H),4.77 (s,1H),4.37(s,1H),3.52(dt,J=9.9,5.0Hz,2H),3.28(s,2H),3.26(s,3H),3.07(dt, J=21.9,9.9Hz,4H),2.69(t,J=6.1Hz,2H),2.58(s,3H),1.99(dd,J=10.7,5.3Hz,2H).
[0442] Example 42: Preparation of Compound H-42
[0443] Step 1: 5-Bromopyridine-2-carboxamide (2.01 g, 10 mmol), methyl acrylate (2.58 g, 30 mmol), triethylamine (3.03 g, 30 mmol), tri(o-methylphenyl)phosphine (0.3 g, 1.0 mmol) and palladium acetate (113 mg, 0.5 mmol) were dissolved in CH3CN (50 mL), replaced with argon three times, heated to 90°C, stirred overnight, cooled and concentrated, and the residue was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to give a yellow oil H-42-a (1 g, yield: 48%), MS m / z (ESI): 207.0 [M+H] + .
[0444] Step 2: Compound H-42-a (1.0 g, 4.8 mmol) and triethylamine (1.48 g, 14.6 mmol) were dissolved in toluene (30 mL), and paraformaldehyde (0.44 g, 14.6 mmol) and N-(2-methoxyethyl)hydroxylamine hydrochloride (0.61 g, 4.8 mmol) were added. The mixture was heated to 70°C and stirred overnight. The reaction solution was cooled, filtered, and the filtrate was concentrated. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain a yellow oil H-42-b (trans racemic compound, 1.1 g, yield: 74%). MS m / z (ESI): 310.1 [M+H] + .
[0445] Step 3: Compound H-42-b (1.1 g, 3.56 mmol) was dissolved in THF / H2O (15 mL / 5 mL), and lithium hydroxide (0.30 g, 7.12 mmol) was added. The mixture was stirred at room temperature for 2 hours and concentrated. The residue was diluted with water (20 mL), adjusted to pH 4 with 3M hydrochloric acid, and extracted three times with dichloromethane. The combined organic phases were dried and concentrated. The residue, H-42-c (trans racemate, 0.7 g, yield: 70%), was used directly in the next step. MS m / z (ESI): 296.1 [M+H] + .
[0446] Step 4: Compound H-42-c (0.7 g, 2.37 mmol) was dissolved in tert-butanol (16 mL), and DPPA (1.17 g, 4.27 mmol), triethylamine (0.71 g, 7.11 mmol), and Boc anhydride (0.93 g, 4.27 mmol) were added. The atmosphere was replaced with argon three times, and the mixture was heated to 95°C and stirred overnight. The mixture was cooled and concentrated, and the residue was purified by column chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain a yellow oil H-42-d (trans racemic form, 0.11 g, yield: 12.7%). MS m / z (ESI): 367.2 [M+H] + .
[0447] Step 5: To a solution of compound H-42-d (0.06 g, 0.16 mmol) in dichloromethane (4 mL) was added a 4 M solution of hydrogen chloride in dioxane (1 mL). The mixture was stirred at room temperature for 1 hour and concentrated. The residue, H-42-e (trans racemate, 40 mg, yield: 98%), was used directly in the next step. MS m / z (ESI): 267.1 [M+H] + .
[0448] Step 6: Compound H-42-e (40 mg, 0.15 mmol) and intermediate 1 (61 mg, 0.15 mmol) were dissolved in acetonitrile, and DIPEA (58 mg, 0.45 mmol) was added. The mixture was then heated to 70°C and stirred for 2 hours. The reaction solution was concentrated, and the residue was purified by preparative HPLC (preparative column: 21.2×250 mm C18 column; system: 10 mM NH₄HCO₃H₂O; wavelength: 254 / 214 nm; gradient: 30% to 60% acetonitrile) to obtain compound H-42 (trans racemate, 12 mg, yield: 14.1%). MS m / z (ESI): 584.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ9.25(s,1H),8.56-8.51(m,1H),8.14(s,1H),8.04(d,J=2.6Hz,1H ),7.97(d,J=8.0Hz,1H),7.87(d,J=8.3Hz,1H),7.62-7.55(m,3H),7.52-7.51(m,2H),7.4 2-7.36(m,1H),7.30(d,J=7.6Hz,1H),4.73(s,1H),4.36(s,1H),3.53-3.51(m,2H),3.29- 3.27(m,2H)3.25(s,3H),3.06-3.04(m,4H),2.65(s,2H),2.58(s,3H),2.02-1.88(m,2H).
[0449] Example 43: Preparation of Compound H-43
[0450] Step 1: 5-Bromo-3-fluoropicolinic acid (4.4 g, 20 mmol), N,O-dimethylhydroxylamine hydrochloride (2.94 g, 30 mmol), triethylamine (4 g, 40 mmol), and HATU (9.12 g, 24 mmol) were dissolved in DMF (50 mL) and stirred at room temperature overnight. The mixture was concentrated, and the residue was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to afford compound H-43-a (2.3 g, yield: 43.7%) as a yellow solid. MS m / z (ESI): 262.9 [M+H] + .
[0451] Step 2: Compound H-43-a (2.3 g, 8.74 mmol) was dissolved in dry THF (350 mL), cooled to -70°C under argon, and a THF solution of BH3 (1 M, 26 mL, 26 mmol) was added dropwise. The mixture was stirred at low temperature for 1.5 hours, quenched with water, and concentrated. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 5 / 1) to give a yellow oil H-43-b (1.2 g, yield: 67%). MS m / z (ESI): 203.9 [M+H] + .
[0452] Step 3: Compound H-43-b (1.2 g, 5.9 mmol), methyl acrylate (1.52 g, 17.7 mmol), triethylamine (1.78 g, 17.7 mmol), tri(o-methylphenyl)phosphine (0.18 g, 0.59 mmol), and palladium acetate (75 mg, 0.295 mmol) were dissolved in CH3CN (30 mL). The atmosphere was replaced with argon three times, the temperature was raised to 90°C, and the mixture was stirred overnight. After cooling, the mixture was concentrated. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to give a yellow oil H-43-c (1 g, yield: 81.9%). MS m / z (ESI): 210.0 [M+H] + .
[0453] Step 4: Dissolve compound H-43-c (1 g, 4.78 mmol) in DCM (20 mL), slowly add DAST (1.54 g, 9.56 mmol), stir for 1 hour, concentrate, and purify the residue by column chromatography (petroleum ether / ethyl acetate = 4 / 1) to obtain a yellow oil H-43-d (1 g, yield: 90.9%). MS m / z (ESI): 232.1 [M+H] + .
[0454] Step 5: Compound H-43-d (1 g, 4.32 mmol) and triethylamine (1.31 g, 12.99 mmol) were dissolved in toluene (30 mL), and paraformaldehyde (0.39 g, 12.99 mmol) and N-(2-methoxyethyl)hydroxylamine hydrochloride (0.55 g, 4.32 mmol) were added. The mixture was heated to 70°C and stirred overnight. The reaction solution was cooled, filtered, and the filtrate was concentrated. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain a yellow oil H-43-e (trans racemic form, 1.1 g, yield: 76.4%). MS m / z (ESI): 335.1 [M+H] + .
[0455] Step 6: Compound H-43-e (1.1 g, 3.29 mmol) was dissolved in THF / H2O (20 mL / 5 mL), and lithium hydroxide (0.27 g, 6.59 mmol) was added. The mixture was stirred at room temperature for 2 hours and concentrated. The residue was diluted with water (150 mL), adjusted to pH 4 with 3M hydrochloric acid, and extracted three times with dichloromethane. The combined organic phases were dried and concentrated. The residue, H-43-f (trans racemate, 0.8 g, yield: 76.2%), was used directly in the next step. MS m / z (ESI): 321.1 [M+H] + .
[0456] Step 7: Compound H-43-f (0.8 g, 2.5 mmol) was dissolved in tert-butanol (20 mL), and DPPA (1.10 g, 4.0 mmol), triethylamine (0.75 g, 7.5 mmol), and Boc anhydride (1 g, 5 mmol) were added. The atmosphere was replaced with argon three times, and the mixture was heated to 90°C and stirred overnight. The mixture was cooled and concentrated, and the residue was purified by column chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain a yellow oil H-43-g (trans racemic compound, 0.11 g, yield: 11.2%). MS m / z (ESI): 392.2 [M+H] + .
[0457] Step 8: To a solution of compound H-43-g (0.06 g, 0.15 mmol) in dichloromethane (6 mL) was added a 4 M solution of hydrogen chloride in dioxane (1.5 mL). The mixture was stirred at room temperature for 1 hour and concentrated. The residue, H-43-h (trans racemate, 40 mg, yield: 88.9%), was used directly in the next step. MS m / z (ESI): 292.1 [M+H] + .
[0458] Step 9: Compound H-43-h (40 mg, 0.14 mmol) and intermediate 1 (56 mg, 0.14 mmol) were dissolved in acetonitrile (10 mL), and DIPEA (54 mg, 0.42 mmol) was added. The mixture was then heated to 60°C and stirred for 2 hours. The reaction solution was concentrated, and the residue was purified by preparative HPLC (preparative column: 21.2×250 mm C18 column; system: 10 mM NH₄HCO₃H₂O; wavelength: 254 / 214 nm; gradient: 30% to 60% acetonitrile) to obtain compound H-43 (trans racemate, 27 mg, yield: 31.76%). MS m / z (ESI): 609.0 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ9.26 (s, 1H), 8.46 (s, 1H), 8.17 (s, 1H), 7.81 (d, J = 11.2 Hz,1H),7.61-7.60(m,2H),7.51-7.49(m,2H),7.42-7.30(m,2H),7.23-6.97(m 1H),4.74(s,1H),4.36(s,1H),3.53-3.51(m,2H),3.32-3.30(m,2H),3.2 5(s,3H),3.09-3.01(m,4H),2.68-2.66(m,2H),2.58(s,3H),1.97(s,2H).
[0459] Example 44: Preparation of Compound H-44
[0460] Step 1: Dissolve 2-fluoro-5-methylisonicotinaldehyde (2.5 g, 10.55 mmol) in acetonitrile (19.19 mL), add methyl prop-2-enoate (908.06 mg, 10.55 mmol), diacetoxypalladium (2.37 g, 10.55 mmol), tri-o-tolylphosphine (3.21 g, 10.55 mmol), and triethylamine (1.07 g, 10.55 mmol, 1.47 mL). Stir at 70°C overnight under nitrogen. Concentrate under reduced pressure to obtain a black solid. The black solid is purified by column chromatography (0-30% EA / PE) to afford compound H-44-a (2 g, 10.25 mmol, 97.14% yield) as a brown solid. MS m / z (ESI): 210.1 [M+H] + .
[0461] Step 2: Dissolve compound H-44-a (1 g, 5.12 mmol) in toluene (19.80 mL), add N-(2-methoxyethyl)hydroxylamine hydrochloride (700.15 mg, 7.68 mmol), paraformaldehyde (348.97 mg, 10.25 mmol), and triethylamine (1.56 g, 15.37 mmol, 2.14 mL), and stir at 70°C overnight. Concentrate under reduced pressure to obtain a yellow solid. The solid is purified by column chromatography (0-50% EA / PE) to obtain compound H-44-b (trans racemate, 1.35 g, 4.53 mmol, yield 88.33%) as a yellow solid. MS m / z (ESI): 313.1 [M+H] + .
[0462] Step 3: Dissolve compound H-44-b (1 g, 3.35 mmol) in H2O (1 mL) and THF (10 mL), add lithium hydroxide (240.84 mg, 10.06 mmol), and stir at room temperature for 2 hours. Add 3N hydrochloric acid solution to adjust the pH to 1, extract with dichloromethane, dry over anhydrous sodium sulfate, and concentrate under reduced pressure to obtain a white solid compound H-44-c (trans racemate, 850 mg, 2.99 mmol, yield 89.19%). MS m / z (ESI): 285.1 [M+H] + .
[0463] Step 4: Dissolve compound H-44-c (850 mg, 2.99 mmol) in tert-butanol (20 mL), add triethylamine (605.11 mg, 5.98 mmol, 516.09 μL) and DPPA (1.45 g, 5.98 mmol), and stir at 90°C overnight. Concentrate under reduced pressure to obtain a yellow oil. The oil is purified by column chromatography (0-60% PE / EA) to obtain a yellow oil, H-44-d (trans racemate, 330 mg, 928.52 μmol, yield 31.05%). MS m / z (ESI): 356.1 [M+H] + .
[0464] Step 5: Dissolve compound H-44-d (330 mg, 878.02 μmol) in dioxane (10 mL), add HCl (96.05 mg, 2.63 mmol), and stir at room temperature for 2 hours. Concentrate under reduced pressure to obtain a yellow solid compound H-44-e (trans racemate, 220 mg, 797.95 μmol, yield 90.87%). The solid was used directly in the next reaction. MS m / z (ESI): 256.1 [M+H] + .
[0465] Step 6: Compound H-44-e (220 mg, 797.95 μmol) was dissolved in MeCN (10 mL), and intermediate 1 (354.58 mg, 861.77 μmol) and triethylamine (261.61 mg, 2.59 mmol, 360.59 μL) were added. The mixture was stirred at 80°C for 3 hours. The mixture was concentrated under reduced pressure to yield a yellow solid. Pre-HPLC (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30% to 60% acetonitrile) gave compound H-44 (trans racemate, 77.30 mg, 132.41 μmol, yield 15.37%). MS m / z (ESI): 573.1 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ9.25(s,1H),8.14(s,1H),7.97(s,1H),7.59-7.57(m,2H),7.52-7.48(m,2H),7.42-7.39(m,2H),7.11(s,1H),4.8 8(s,1H),4.36(s,1H),3.56-3.54(m,2H),3.22(s,3H),3.08-3.04(m, 5H),2.65-2.60(m,3H),2.58(s,3H),2.10(s,3H),1.99-1.96(m,2H).
[0466] Example 45: Preparation of Compounds H-45-a and H-45-b
[0467] Compound H-5 (trans racemate, 90 mg, 151.76 μmol) was subjected to chiral separation (preparation conditions: instrument: SFC-150 (Thar, Waters); column type: IC 20*250 mm, 10 μm (Daicel); column temperature: 35°C; mobile phase: CO2 / (MeOH / ACN (0.2% Methanol Ammonia) = 1:1) = 50 / 50; flow rate: 120 g / min; back pressure: 100 bar; detection wavelength: 214 nm; cycle time: 3.0 min; sample: 2300 mg dissolved in 60 mL methanol; injection volume: 1.0 mL). After separation and lyophilization, compound H-45-a (trans single isomer, retention time: 1.752 min, 34.21 mg, 57.28 μmol, yield 37.75%) was obtained. 1 H NMR(400MHz,DMSO-d6)δ9.25(s,1H),8.20-8.18(m,2H),7.83-7.81(m,1H),7.60-7.58(m,2H),7.52-7.48(m,2H),7.40-7.31(m,2H) ),4.68(s,1H),4.33(s,1H),3.52-3.50(m,2H),3.29(s,3H),3.08-3.03(m,5H),2.48-2.46(m,3H),2.48(s,3H),1.98-1.96(m,2H).
[0468] and compound H-45-b (trans single isomer, retention time: 2.834 min, 29.82 mg, 49.77 μmol, yield 32.80%). 1H NMR(400MHz,DMSO-d6)δ9.25(s,1H),8.20-8.18(m,2H),7.83-7.81(m,1H),7.60-7.48(m,4H),7.40-7.31(m,2H),4.67(s ,1H),4.33(s,1H),3.52-3.49(m,2H),3.29(s,3H),3.08-3.04(m,5H),2.58-2.56(m,3H),2.49(s,3H),1.98-1.96(m,2H).
[0469] Example 46: Preparation of Compound H-46
[0470] Step 1: Dissolve 5-bromopyridine-2-carboxaldehyde (2 g, 10.75 mmol) in dichloromethane (30 mL). Add N-ethyl-N-(trifluorosulfonyl)ethylamine (3.81 g, 23.66 mmol) dropwise at 0°C and stir at room temperature for 4 hours. Concentrate under reduced pressure to obtain a black oil. The oil is purified by column chromatography (0-30% EA / PE) to obtain a yellow oil H-46-a (1.8 g, 8.65 mmol, 80.48% yield). MS m / z (ESI): 208.1 [M+H] + .
[0471] Step 2: Dissolve compound H-46-a (1.2 g, 5.77 mmol) in acetonitrile (20 mL), add methyl prop-2-enoate (744.99 mg, 8.65 mmol), diacetoxypalladium (0.13 g, 0.577 mmol), tri(o-tolyl)phosphine (0.176 g, 0.577 mmol), and triethylamine (1.75 g, 17.31 mmol, 2.41 mL). Under nitrogen, stir at 90°C overnight. Filter and concentrate under reduced pressure to obtain a yellow solid. The solid was purified by column chromatography (0-40% EA / PE) to obtain compound H-46-b (1.15 g, 5.39 mmol, 93.51% yield) as a yellow solid. MS m / z (ESI): 228.1 [M+H] + .
[0472] Step 3: Compound H-46-b (1.15 g, 5.39 mmol) was dissolved in toluene (20 mL), and N-(2-methoxyethyl)hydroxylamine hydrochloride (737.23 mg, 8.09 mmol), paraformaldehyde (367.45 mg, 10.79 mmol), and triethylamine (1.64 g, 16.18 mmol, 2.26 mL) were added. The mixture was stirred at 70°C overnight. The mixture was concentrated under reduced pressure to obtain a yellow solid. The solid was purified by column chromatography (0-50% EA / PE) to obtain compound H-46-c (trans racemate, 1.3 g, 4.11 mmol, yield 76.19%) as a yellow solid. MS m / z (ESI): 331.1 [M+H] + .
[0473] Step 4: Dissolve compound H-46-c (1.3 g, 4.11 mmol) in H2O (2 mL), add lithium hydroxide (295.28 mg, 12.33 mmol) and tetrahydrofuran (20 mL), and stir at room temperature for 2 hours. Add 3N hydrochloric acid solution to adjust the pH to 4, extract with dichloromethane, dry the organic phase over anhydrous sodium sulfate, and concentrate under reduced pressure to obtain compound H-46-d (trans racemate, 0.9 g, 2.98 mmol, yield 72.44%) as a yellow solid. MS m / z (ESI): 303.1 [M+H] + .
[0474] Step 5: Dissolve compound H-46-d (0.9 g, 2.98 mmol) in tert-butanol (20 mL), add [azido(phenyl)phosphoryl]benzene (1.45 g, 5.95 mmol), triethylamine (602.57 mg, 5.95 mmol, 830.56 μL), and tert-butyl tert-butyloxycarbonyl carbonate (974.74 mg, 4.47 mmol). Stir overnight at 90°C under nitrogen. Concentrate under reduced pressure to obtain a yellow solid. The solid is purified by column chromatography (0-80% EA / PE) to obtain compound H-46-e (trans racemate, 0.19 g, 508.85 μmol, yield 17.09%) as a yellow oil. MS m / z (ESI): 374.1 [M+H] + .
[0475] Step 6: Dissolve compound H-46-e (0.19 g, 508.85 μmol) in dioxane (6 mL), add hydrogen chloride (55.66 mg, 1.53 mmol), and stir at room temperature for 2 hours. Concentrate under reduced pressure to obtain compound H-46-f (trans racemate, 0.13 g, 475.71 μmol, yield 93.49%) as a yellow oil. MS m / z (ESI): 274.1 [M+H] + .
[0476] Step 7: Compound H-46-f (0.12 g, 439.11 μmol) was dissolved in acetonitrile (10 mL), and intermediate 1 (180.68 mg, 439.11 μmol) and triethylamine (133.30 mg, 1.32 mmol, 187.74 μL) were added. The mixture was stirred at 80°C for 2 hours. The mixture was concentrated under reduced pressure to yield a yellow solid. The solid was purified by pre-HPLC (preparative column: 21.2 × 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30% to 60% acetonitrile) to yield compound H-46 (trans racemate, 34.04 mg, 57.19 μmol, yield 13.02%). MS m / z (ESI): 591.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ9.25(s,1H),8.59(s,1H),8.14(s,1H),7.89-7.87(m,1H),7.59-7.29(m,7H),4.72(s,1H), 4.35(s,1H),3.53-3.50(m,3H),3.25(s,3H),3.04-3.02(m,5H),2.58-2.55(m,2H),2.49(s,3H),1.97-1.95(m,3H).
[0477] Example 47: Preparation of Compound H-47
[0478] Step 1: Dissolve 4-bromo-2-(difluoromethyl)pyridine (1 g, 4.81 mmol), methyl acrylate (1.24 g, 14.42 mmol), tri(o-methylphenyl)phosphine (146.32 mg, 480.76 μmol), triethylamine (1.46 g, 14.42 mmol, 2.01 mL), and palladium acetate (107.94 mg, 480.76 μmol) in acetonitrile (15 mL). Stir the reaction mixture under nitrogen at 90°C for 16 hours. Concentrate under reduced pressure. The resulting residue is purified by silica gel column chromatography using a solvent system (petroleum ether / ethyl acetate: 1 / 0 to 4 / 1) to afford compound H-47-a (1 g, yellow solid) in a 97.57% yield. MS m / z (ESI): 214.1 [M+H]. + .
[0479] Step 2: Add N-(2-methoxyethyl)hydroxylamine hydrochloride (658.25 mg, 5.16 mmol) to toluene (30 mL), followed by triethylamine (1.42 g, 14.07 mmol, 1.96 mL), paraformaldehyde (422.60 mg, 14.07 mmol), and compound H-47-a (1 g, 4.69 mmol). Under argon, the reaction mixture was heated to 75°C and stirred for 16 hours. The mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using a solvent system (petroleum ether / ethyl acetate: 1 / 0 to 3 / 1) to afford compound H-47-b (trans racemate, 1.16 g, light yellow oil) in a yield of 78.18%. MS m / z (ESI): 317.1 [M+H] + .
[0480] Step 3: Dissolve compound H-47-b (1.16 g, 3.67 mmol) in water (10 mL) and THF (30 mL), and add lithium hydroxide monohydrate (230.85 mg, 5.50 mmol). Stir the reaction mixture at room temperature for 1 hour. Adjust the pH to 6 with 1N hydrochloric acid, remove the organic solvent under reduced pressure, and extract with dichloromethane (50 mL x 3). The organic phase is dried, filtered, and concentrated to obtain compound H-47-c (trans racemate, 1.02 g, yellow oil) in a yield of 92.01%. MS m / z (ESI): 303.1 [M+H] + .
[0481] Step 4: Compound H-47-c (1.02 g, 3.37 mmol) was added to tert-butyl alcohol (20 mL), followed by diphenylphosphoryl azide (1.23 g, 5.06 mmol) and triethylamine (853.65 mg, 8.44 mmol, 1.18 mL). Under argon, the mixture was heated to 95°C and stirred for 16 hours. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using an eluent system (petroleum ether / ethyl acetate: 1 / 0 to 2 / 1) to afford compound H-47-d (trans racemate, 183 mg, yellow solid) in a yield of 14.52%. MS m / z (ESI): 374.2 [M+H] + .
[0482] Step 5: Add compound H-47-d (65 mg, 174.08 μmol) to a 4N hydrochloric acid solution in 1,4-dioxane (10 mL). Stir the reaction mixture at room temperature for 1 hour. Concentrate under reduced pressure to obtain compound H-47-e (trans racemate, 53 mg, white solid) in a yield of 98.30%. MS m / z (ESI): 274.0 [M+H] + .
[0483] Step 6: Compound H-47-e (53 mg, 193.94 μmol) and intermediate 1 (77 mg, 187.14 μmol) were added to acetonitrile (20 mL), followed by N,N-diisopropylethylamine (72.56 mg, 561.42 μmol, 97.79 μL). The reaction mixture was stirred at 80°C for 2 hours. After concentration under reduced pressure, the residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain compound H-47 (trans racemate, 54.86 mg) in a yield of 49.63%. MS m / z (ESI): 591.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6)δ9.26(s,1H),8.59(d,J=4.6Hz,1H),8.17(s,1H),7.71-7.56(m,3H),7.49(dd,J=15.5,7.6Hz,3H),7.42-7.28(m,2H),6.91( t,J=56Hz,1H),4.71(s,1H),4.34(s,1H),3.54(s,2H),3.30(s,2H),3.2 6(s,3H),3.05(s,4H),2.68(t,J=6.3Hz,2H),2.58(s,3H),1.97(s,2H).
[0484] Example 48: Preparation of Compound H-48
[0485] Step 1: Dissolve tert-butyl 2-(triphenyl-5-phosphono)acetate (3.47 g, 9.96 mmol) and 2-chloroisonicotinaldehyde (1.41 g, 9.96 mmol) in dichloromethane (20 mL). Under argon, the reaction mixture was stirred at room temperature for 5 hours. The mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using a 3 / 1 system of petroleum ether / ethyl acetate to afford compound H-48-a (1.6 g, colorless oil) in a yield of 75.90%. MS m / z (ESI): 212.0 [M+H]. + .
[0486] Step 2: Add N-(2-methoxyethyl)hydroxylamine hydrochloride (1.08 g, 8.50 mmol) to toluene (20 mL), followed by triethylamine (2.15 g, 21.25 mmol, 2.96 mL), paraformaldehyde (638.23 mg, 21.25 mmol), and compound H-48-a (1.4 g, 7.08 mmol). Under argon, the reaction mixture was heated to 70°C and stirred for 16 hours. The mixture was concentrated under reduced pressure and the resulting residue was purified by silica gel column chromatography using a 3 / 1 solvent system (petroleum ether / ethyl acetate) to afford compound H-48-b (trans racemic form, 1.5 g, colorless oil) in a 40% yield. MS m / z (ESI): 315.0 [M+H] + .
[0487] Step 3: Dissolve compound H-48-b (1 g, 3.33 mmol) in tetrahydrofuran (8 mL) and water (2 mL), and add lithium hydroxide monohydrate (209.49 mg, 4.99 mmol). The reaction solution was stirred at room temperature for 1 hour. Adjust the pH to 3 with 1N hydrochloric acid and extract with dichloromethane (30 mL x 3). Dry over anhydrous sodium sulfate and dry under reduced pressure to obtain crude compound H-48-c (trans racemic form, 0.5 g, 1.74 mmol) with a yield of 52.45%. The crude product was used directly in the next step. MS m / z (ESI): 287.0 [M+H] + .
[0488] Step 4: Compound H-48-c (0.5 g, 1.74 mmol), diphenylphosphoryl azide (636.18 mg, 2.62 mmol), triethylamine (528.41 mg, 5.23 mmol), and di-tert-butyl dicarbonate (758.64 mg, 3.48 mmol) were added to tert-butyl alcohol (10 mL). Under argon, the mixture was heated to 95°C and stirred for 16 hours. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using a 1 / 1 system of petroleum ether / ethyl acetate to afford compound H-48-d (trans racemate, 0.1 g, light yellow oil) in a yield of 16.02%. MS m / z (ESI): 358.0 [M+H] + .
[0489] Step 5: Dissolve compound H-48-d (100 mg, 279.46 μmol) in dichloromethane (5 mL), then add 4N hydrochloric acid in 1,4-dioxane (1.4 mL). Stir the reaction mixture at room temperature for 1 hour. Concentrate under reduced pressure to obtain the hydrochloride salt of compound H-48-e (trans racemate, 70 mg, light yellow solid) in a yield of 97.19%. MS m / z (ESI): 258.0 [M+H] + .
[0490] Step 6: Compound H-48-e hydrochloride (70 mg, 271.62 μmol) and intermediate 1 (111.76 mg, 271.62 μmol) were added to acetonitrile (10 mL), followed by N,N-diisopropylethylamine (105.31 mg, 814.85 μmol, 141.93 μL). The reaction mixture was stirred at 80°C for 2 hours. After concentration under reduced pressure, the residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain product H-48 (trans racemic form, 22.25 mg) in a yield of 14.19%. MS m / z (ESI): 575.3 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ9.26 (s, 1H), 8.32 (d, J = 5.1Hz, 1H), 8.17 (s, 1H), 7.61 (d d,J=8.5,1.1Hz,2H),7.56-7.47(m,2H),7.44-7.36(m,2H),7.31(d,J=7.1Hz,2H) ,4.64(s,1H),4.32(s,1H),3.53(t,J=5.3Hz,2H),3.29(s,2H),3.26(s,3H),3.0 4(td,J=10.8,6.3Hz,4H),2.68(t,J=6.2Hz,2H),2.58(s,3H),2.02-1.94(m,2H).
[0491] Example 49: Preparation of Compound H-49
[0492] Step 1: Dissolve tert-butyl 2-(triphenyl-5-phosphono)acetate (3.76 g, 9.99 mmol) and 2-fluoro-4-formyl-benzonitrile (1.49 g, 9.99 mmol) in dichloromethane (20 mL). Under argon, the reaction mixture was stirred at room temperature for 5 hours. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using a 3 / 1 system of petroleum ether / ethyl acetate to afford compound H-49-a (1.5 g, colorless oil) in a yield of 68.48%. MS m / z (ESI): 248.1 [M+H]. + .
[0493] Step 2: Add N-(2-methoxyethyl)hydroxylamine hydrochloride (368.47 mg, 4.04 mmol) to toluene (20 mL), followed by triethylamine (368.47 mg, 4.04 mmol), paraformaldehyde (121.43 mg, 4.04 mmol), and compound H-49-a (1 g, 4.04 mmol). Under argon, the reaction mixture was heated to 70°C and stirred for 16 hours. The mixture was concentrated under reduced pressure and the resulting residue was purified by silica gel column chromatography using a 3 / 1 solvent system (petroleum ether / ethyl acetate) to afford compound H-49-b (trans racemic form, 0.6 g, colorless oil) in a yield of 42.34%. MS m / z (ESI): 351.1 [M+H] + .
[0494] Step 3: Dissolve compound H-49-b (0.6 g, 1.71 mmol) in dichloromethane (8 mL) and add hydrochloric acid (4 M, 8.56 mL). Stir the reaction mixture at room temperature for 1 hour. Dried to dryness under reduced pressure to obtain crude compound H-49-c (trans racemic form, 0.5 g, white solid) in a yield of 99.22%. The crude product was used directly in the next step. MS m / z (ESI): 295.0 [M+H] + .
[0495] Step 4: Compound H-49-c (0.5 g, 1.70 mmol), diphenylphosphoryl azide (619.82 mg, 2.55 mmol), di-tert-butyl dicarbonate (741.65 mg, 3.40 mmol), and triethylamine (528.41 mg, 5.23 mmol) were added to tert-butanol (10 mL). Under argon, the mixture was heated to 95°C and stirred for 16 hours. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using a 1 / 1 system of petroleum ether / ethyl acetate to afford compound H-49-d (trans racemate, 80 mg, light yellow oil) in a yield of 12.89%. MS m / z (ESI): 366.1 [M+H] + .
[0496] Step 5: Dissolve compound H-49-d (80 mg, 218.94 μmol) in dichloromethane (5 mL), then add 4N hydrochloric acid in 1,4-dioxane (1.1 mL). Stir the reaction mixture at room temperature for 1 hour. Concentrate under reduced pressure to obtain compound H-49-e hydrochloride (trans racemate, 58 mg, light yellow solid) in a yield of 99.86%. MS m / z (ESI): 266.1 [M+H] + .
[0497] Step 6: Compound H-49-e hydrochloride (50 mg, 188.48 μmol) and intermediate 1 (77.55 mg, 188.48 μmol) were added to acetonitrile (10 mL), followed by N,N-diisopropylethylamine (73.08 mg, 565.43 μmol, 98.49 μL). The reaction mixture was stirred at 90°C for 2 hours. After concentration under reduced pressure, the residue was purified by preparative liquid chromatography (preparative column: 21.2 x 250 mm C18 column; system: 10 mM NH4HCO3H2O; wavelength: 254 / 214 nm; gradient: 30%-60% acetonitrile) to obtain product H-49 (trans racemic form, 42.06 mg) in a yield of 36.48%. MS m / z (ESI): 583.3 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ9.26 (s, 1H), 8.17 (s, 1H), 7.86 (t, J = 7.3Hz, 1H), 7.60 (d,J=7.7Hz,2H),7.52(dd,J=15.4,7.7Hz,2H),7.39(t,J=7.4Hz,2H),7.31(d, J=7.0Hz,2H),4.68(s,1H),4.31(s,1H),3.52(s,2H),3.30(s,2H),3.25(s,3H) ,3.04(t,J=8.8Hz,4H),2.71-2.63(m,2H),2.58(s,3H),1.97(d,J=5.0Hz,2H).
[0498] Test Case
[0499] Positive control compound D1, CAS No. 1824664-89-2, was purchased from Chukai Pharmaceuticals and has the following structure:
[0500] Test Example 1: Cytological Experiment of U2OS-TrkA-SHC1-β-Gal Cells
[0501] 1. Reagents Required for the Experiment
[0502] 2. Instruments required for the experiment
[0503] 3. Experimental steps
[0504] (1) U2OS-TrkA-SHC1-β-Gal cells in the logarithmic phase were seeded into 384-well plates in 15 μL of DMEM containing 10% FBS at a cell density of 4000 cells / well;
[0505] (2) Place the 384-well plate seeded with cells in a cell culture incubator at 37°C with 5% CO2 and culture for approximately 16-20 hours;
[0506] (3) Prepare the test compound at a final concentration of approximately 200 times using 100% DMSO, and prepare 10 μg / mL nerve growth factor (NGF). Then, dilute the test compound and NGF 40-fold using DMEM and store for later use.
[0507] (4) Add 5 μL of the test compound prepared in step 3 to the 384-well plate, add 5 μL of 2.5% DMSO solution (the balance is DMEM) to the positive control well, add 5 μL of the positive control compound D1 with a final concentration of 0.3 μM to the negative control well, centrifuge at 100 rpm for 1 min, and then incubate at 37°C for 30 min;
[0508] (5) Add 5 μL of NGF solution prepared in step 3 to the 384-well plate, centrifuge at 100 rpm for 1 min, and then incubate at 37°C for 5 h;
[0509] (6) Take out the 384-well plate and let it stand for 10 minutes to return to room temperature;
[0510] (7) Prepare the required volume of detection solution according to the instructions of the PathHunter detection kit, add 25 μL of the prepared detection solution to each well of the 384-well plate, centrifuge at 1000 rpm for 1 min, and incubate at room temperature for 1 h;
[0511] (8) The fluorescence signal value was read using a PerkinElmer Victor X5 microplate reader.
[0512] 4. Data Calculation
[0513] The inhibition rate of the compound was calculated according to the following formula:
[0514] Where, Inhibition% is the percentage of inhibition of the compound on U2OS-TrkA-SHC1-β-Gal cells; Max well is the positive control well, i.e., the maximum value well; Min well is the negative control well, i.e., the minimum value well; Compound is the compound well; Signal is the fluorescence signal value of each well.
[0515] XLFIT 5.0 software (IDBS, UK) was used for fitting, with the logarithm of compound concentration as the X-axis and the inhibition rate as the Y-axis, and the half-maximal inhibitory concentration (IC) of the compound was calculated using a four-parameter model. 50 The test results are shown in Table 1.
[0516] Table 1 Inhibitory activity of test compounds on U2OS-TrkA-SHC1-β-Gal cells
[0517] As shown in Table 1, the compounds provided in the Examples of the present application have high inhibitory activity against cells expressing TrkA.
[0518] Test Example 2: Cytological Experiment of TrkB / TrkC Cells
[0519] Cell treatment: Pathhunter cell lines (provided and tested by Eurofins, containing TrkB / TrkC cells) were removed from liquid nitrogen according to standard protocols. 20 μL of cells were seeded into a white 384-well plate and incubated for the appropriate time prior to testing.
[0520] Agonist activity assay sample preparation: Dilute the sample stock solution in assay buffer to a 5X final concentration working solution. Add 5 μL of the 5X working solution to the cells and incubate at room temperature for 3 hours.
[0521] Antagonist Activity Assay Sample Preparation: For most assays, cells were incubated as follows: Dilute the sample stock solution in assay buffer to a 5X final concentration working solution. Add 5 μL of the 5X working solution to the cells and incubate at 37°C for 60 minutes. Add 5 μL of the 6X EC80 agonist to the cells and incubate at room temperature for 3 hours.
[0522] For specific targets, such as DDR1, cells were incubated as follows: cells were plated and incubated for 2 hours. The stock sample solution was diluted in assay buffer to a 5X final concentration of the working solution. 5 μL of the 5X working solution was added to the cells and incubated at 37°C for 60 minutes. 5 μL of the 6X EC80 agonist was added to the cells and incubated at 37°C overnight.
[0523] Signal acquisition: Add 12.5 or 15 μL of dedicated agonist or antagonist detection reagent and incubate at room temperature for 1 hour. Detect chemiluminescent signals in the microplate using a PerkinElmer Envision™ microplate reader.
[0524] Data Analysis: Compound activity was analyzed using CBIS data analysis software (ChemInnovation, CA). Agonist activity was calculated as follows:
[0525] % activity = 100% x (average RLU value of test sample - average RLU value of solvent control) / (average RLU value of maximum RLU control ligand - average RLU value of solvent control)
[0526] The formula for calculating the antagonist inhibitory activity is as follows:
[0527] % inhibition rate = 100% × (1-(average RLU value of test sample-average RLU value of solvent control) / (average RLU value of EC80 control-average RLU value of solvent control)). The test results are shown in Table 2:
[0528] Table 2 Inhibitory activity of test compounds on TrkB / TrkC cells
[0529] Test Example 3: TrkA Enzyme Experimental Method
[0530] 1. Experimental Reagents
[0531] 2. Experimental Instruments
[0532] 3. Experimental steps
[0533] (1) Prepare the test compound to 100 times the final concentration with DMSO, then dilute it to 2.5 times the final concentration with ddH2O (DMSO content is 2.5%) and store until ready for use;
[0534] (2) Prepare 1 x enzyme reaction buffer: 50 mM 3-(N-morpholino)propanesulfonic acid (MOPS), 5 mM MgCl2, 0.005% Triton X-100, 2 mM DTT and 0.01 mM Na3VO4;
[0535] (3) Add 4 μL of the test compound prepared in step 1 to the compound wells of the 384-well plate, centrifuge at 1000 rpm for 1 min, and add 4 μL of 2.5% DMSO prepared in ddH2O to the positive control wells and negative control wells respectively;
[0536] (4) Prepare a mixture of TrkA and TK substrate-biotin using 1 x buffer, where the final reaction concentration of TrkA is 5.84 nM and the final reaction concentration of TK substrate-biotin is 1 μM. Then add 4 μL of the mixture to all wells of the 384-well plate;
[0537] (5) Centrifuge the 384-well plate at 1000 rpm for 1 min and set aside;
[0538] (6) Prepare ATP solution with a final concentration of 30 μM using 1 x buffer. Add 2 μL of the prepared ATP solution to the positive control wells and test compound wells in a 384-well plate, and add 2 μL of 1 x buffer to the negative control wells.
[0539] (7) Centrifuge the 384-well plate at 1000 rpm for 1 min and allow to react at room temperature for 1 h.
[0540] (8) Add 5 μL of 1 x TK Antibody-cryptate detection solution (HTRF KinEASE-TK kit) to all wells of the 384-well plate and centrifuge at 1000 rpm for 1 min;
[0541] (9) Add 5 μl of Streptavidin-XL665 detection solution (HTRF KinEASE-TK kit) with a final concentration of 125 nM to all wells of the 384-well plate;
[0542] (10) Centrifuge at 1000 rpm for 1 min, place in the dark at room temperature for 1 h, and read the homogeneous time-resolved fluorescence (HTRF) signal using a PerkinElmer Victor X5 microplate reader. x 340_E m 665 / 615.
[0543] 4. Data Calculation
[0544] The ratio of the value measured at a signal of 665 nm to the value measured at a signal of 615 nm for each well was calculated according to the following formula.
[0545] The inhibition rate of the test compound on TrkA was calculated according to the following formula.
[0546] Among them, the Max well is the positive control well, i.e., the maximum value well. The Min well is the negative control well, i.e., the minimum value well. Compound: Compound well. XLFIT 5.0 software (IDBS, UK) was used for fitting, with the logarithm of compound concentration as the X-axis and the inhibition rate as the Y-axis, and the half-maximal inhibitory concentration (IC) of the compound was calculated using a four-parameter model. 50 The test results are shown in Table 3.
[0547] Table 3 Inhibitory activity of test compounds on TrkA enzyme
[0548] As shown in Table 3, the compounds provided in the examples of the present application have significant inhibitory activity against TrkA enzyme.
[0549] Test Example 4: Inhibitory effect of test compounds on hERG
[0550] 1. Materials and Reagents
[0551] The positive control compound is cisapride. Source: Sigma, Catalog No.: C4740-10mg, Molecular Weight: 483.96, Storage Conditions: DMSO stock solution, sealed and stored at -40°C away from light.
[0552] The solvent is DMSO. Source: Sigma, Catalog No.: 276855-100mL, Molecular Weight: 78.13, Storage Conditions: Store sealed at room temperature and away from light.
[0553] The cells used were the CHO-hERG cell line (Chinese hamster ovary cells stably expressing the hERG channel). Source: Constructed by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Culture conditions: 5% CO2 (volume fraction, balance air), 37°C incubator. Cryopreservation conditions: Liquid nitrogen.
[0554] Solutions and reagents: Extracellular solution: 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1.25 mM MgCl2, 10 mM 4-hydroxyethylpiperazineethanesulfonic acid (HEPES), and 10 mM glucose, adjusted to pH 7.4 with NaOH; intracellular solution: 140 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 10 mM ethylene glycol bis(2-aminoethyl ether)tetraacetic acid (EGTA), and 10 mM HEPES, adjusted to pH 7.2 with KOH.
[0555] Experimental instruments: Patch clamp amplifier (Axon, USA); digital-to-analog converter (Axon, USA); data acquisition and analysis software (Axon, USA); inverted microscope (Olympus, Japan); rapid drug delivery system (Bio-Logic, France); micromanipulator (Syskiyou, USA); electrode puller (Sutter, USA); glass electrode (Sutter, USA); anti-vibration table and shielding net (TMC, USA); CO2 incubator (Thermo, USA); biological safety cabinet (Thermo, USA); water purification device (Millipore, USA).
[0556] 2. Test methods
[0557] 2.1 Cell Culture and Treatment: CHO cells stably expressing hERG were cultured in 35 mm diameter cell culture dishes in a 37°C, 5% CO2 incubator, and passaged every 48 hours at a 1:5 ratio. The cell culture medium consisted of 90% F12 medium (Invitrogen), 10% fetal bovine serum (Gibco), 100 μg / mL G418 antibiotic (Invitrogen), and 100 μg / mL Hygromycin B antibiotic (Invitrogen). On the day of the experiment, the cell culture medium was aspirated, the cells were rinsed once with extracellular medium, and then digested with 0.25% trypsin-EDTA (Invitrogen) at room temperature for 3-5 minutes. The digestion medium was then aspirated, the cells were resuspended in extracellular medium, and transferred to a dish for electrophysiological recording.
[0558] 2.2 Preparation of test compounds: On the day of the test, the test compound was prepared with DMSO to a 10 mM stock solution, and then serially diluted 3-fold with DMSO (i.e., 10 μL of the solution to be diluted was added to 20 μL of DMSO), and serially diluted to 8 concentrations. Then, 10 μL of the DMSO solution containing the test compound at each diluted concentration was added to 4990 μL of extracellular fluid, i.e., the final concentration of the test compound was obtained by 500-fold dilution.
[0559] Preparation of the positive control compound cisapride: 10 μL of a 150 μM cisapride stock solution in DMSO was added to 4990 μL of extracellular fluid and diluted 500-fold to obtain a final concentration of the positive control compound cisapride for testing (i.e., 300 nM); the DMSO content in the final test solution did not exceed 0.2%. At this concentration, DMSO in the test solution had no effect on the hERG potassium channel.
[0560] 2.3 Electrophysiological recording process: For CHO cells stably expressing hERG potassium channels, the hERG potassium channel current was recorded using the whole-cell patch clamp technique at room temperature. The glass microelectrode was pulled from a glass electrode blank (BF150-86-10, Sutter) using a puller. After perfusing the electrode with internal fluid, the tip resistance was approximately 2-5 MΩ. The glass microelectrode was inserted into the probe hole of the patch clamp amplifier. The glass microelectrode was adsorbed on the cell surface and connected to the patch clamp amplifier to accurately record changes in ion channel-mediated current. The clamping voltage and data recording were controlled and recorded by a computer using pClamp software. The sampling frequency was 10 kHz and the filtering frequency was 2 kHz. The values were read using the whole-cell mode. After obtaining whole-cell recordings, the cells were clamped at -80mV, and the step voltage for inducing hERG potassium current (I hERG) was given a 2s depolarizing voltage from -80mV to +20mV, then repolarized to -50mV, and returned to -80mV after 1s. This voltage stimulus was given every 10s, and the administration process was started after determining that the hERG potassium current was stable (1 minute). Each test concentration of the compound was given for at least 1 minute to the steady state of action or for a maximum of 3 minutes. For each test concentration, the test was performed on at least 2 cells (n≥2).
[0561] 3. Test results
[0562] Data were analyzed and processed using pClamp 10, GraphPad Prism 8, and Excel software.
[0563] The degree of inhibition of hERG potassium current (peak value of hERG tail current induced at -50 mV) by different compound concentrations was calculated using the following formula: Inhibition% = [1-(I / Io)] × 100%, where Inhibition% represents the percentage of inhibition of hERG potassium current by the compound, and I and Io represent the amplitude of hERG potassium current after and before drug addition, respectively.
[0564] The IC of the compound was calculated using GraphPad Prism 8 software by fitting the following equation: 50 Value: Y=Bottom+(Top-Bottom) / (1+10^((LogIC 50 -X)×HillSlope)),
[0565] Wherein, X is the Log value of the compound concentration, Y is the inhibition percentage at the corresponding concentration, Bottom and Top are the minimum inhibition percentage and maximum inhibition percentage measured at each compound concentration during the test, and HillSlope is the slope factor.
[0566] The test results are shown in Table 4.
[0567] Table 4 IC of the test compounds against hERG potassium channel current inhibition 50 value
[0568] As can be seen from Table 4, the compounds provided in the examples of the present application have a weak inhibitory effect on hERG potassium channel current, indicating that the compounds of the present application have little effect on potassium ion channel current in vitro and are highly safe for the heart.
[0569] Test Example 5: In vivo pharmacokinetic study in rats after single administration
[0570] Experimental animals: SD rats were purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd.
[0571] Experimental Procedure: The pharmacokinetic characteristics of the test compound were evaluated in rodents following intravenous and oral administration using standard protocols. The test compound was prepared as a clear solution or homogeneous suspension in a solvent, depending on the dose and concentration, and administered to Sprague Dawley rats via single intravenous and oral administration. Sprague Dawley rats (male, 200-300 g, 7-9 weeks old) were randomly assigned to each group, three per group. The intravenous group had free access to food and water before dosing; the oral group received free access to water before dosing and fasted overnight. Food was resumed four hours after dosing (unless otherwise indicated).
[0572] The intravenous and oral administration groups were treated with a buffered solution of dimethyl sulfoxide (DMSO), 200 μmol / L polyethylene glycol-15-hydroxystearate, and 176 μmol / L sulfobutylcyclodextrin (5:10:85, by volume). Vortexing and sonication were performed to dissolve the compound to prepare solutions at 5 mg / mL or 1 mg / mL. Solutions were required to be clear for the intravenous administration group and homogenous suspension or clear for the oral administration group. Whole blood samples were collected from rats at 0.083, 0.25, 0.5, 1, 2, 4, 7, and 24 hours after intravenous administration of 1 mg / kg or at 0.083, 0.25, 0.5, 1, 2, 4, 7, and 24 hours after oral administration of 5 mg / kg. Whole blood samples were centrifuged at 3700 rpm for 15 minutes, and the supernatant was separated to obtain plasma samples. Plasma samples were added with a certain volume of acetonitrile solution containing internal standard to precipitate proteins. The supernatant was centrifuged and added with a certain volume of diluent (such as pure water, methanol / water solution, etc., which can be adjusted according to the situation). After mixing, the blood drug concentration was quantitatively analyzed by LC-MS / MS analysis method, and the pharmacokinetic parameters such as peak concentration C were calculated using Data Analysie System software (Shanghai Bojia Pharmaceutical Technology Co., Ltd., version 3.0). max , peak time T max , clearance rate CL, half-life T 1 / 2, area under the drug-time curve AUC, bioavailability F and other parameters. The experimental results are shown in Tables 5 and 6.
[0573] Table 5 Pharmacokinetic properties of compounds in rats
[0574] Table 6 Pharmacokinetic properties of compounds in rats
[0575] It can be seen from the results in Table 5 and Table 6 that the example compounds of the present application have excellent pharmacokinetic properties when administered at low doses.
[0576] The technical features of the above-mentioned embodiments can be combined arbitrarily. In order to make the description concise, not all possible combinations of the technical features in the above-mentioned embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0577] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present application shall be included in the scope of protection of the present application.
Claims
1. A compound having a structure represented by formula (I), or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof: in, Ring A is a benzene ring or a 5- or 6-membered heteroaryl ring; Ring B is a 5- or 6-membered heteroaryl ring or a 5- to 8-membered heterocycloalkenyl ring; Ring C is a benzene ring or a 5- or 6-membered heteroaryl ring; (R1) n It means that the hydrogen on ring A is replaced by n R1, n is 0, 1, 2, 3, 4 or 5; each R1 is the same or different and is independently cyano, hydroxyl, carboxyl, halogen, -NR a0 R b0 , C 3-6 Cycloalkyl, C 1-8 Alkyl, C 1-8 Alkoxy, -C(O)C 1-8 Alkyl, -C(O)OC 1-8 Alkyl, -OC(O)C 1-8 Alkyl or -C(O)NR a0 R b0 ; or any two R1s connected to the same ring atom or different ring atoms are connected to form a 3- to 7-membered saturated or partially unsaturated monocyclic ring or a 3- to 7-membered saturated or partially unsaturated monocyclic ring; wherein the C 1-8 Alkyl, C 1-8 The alkoxy, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring and 3- to 7-membered saturated or partially unsaturated monocyclic ring are unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from the group consisting of deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -NR a1 R b1 、-SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl; wherein the phenyl and 5- to 6-membered heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from Substituent Group S; (R2) m Indicates that the hydrogen on ring B is replaced by m R2, m is 0, 1, 2 or 3; each R2 is the same or different and is independently cyano, hydroxyl, carboxyl, halogen, -NR a0 R b0 , C 3-6 Cycloalkyl, C 1-8 Alkyl, C 1-8 Alkoxy, -C(O)C 1-8 Alkyl, -C(O)OC 1-8 Alkyl, -SO2C 1-8 Alkyl, -SO2C 3-6 Cycloalkyl, -SO2NR a0 R b0 or -C(O)NR a0 R b0 ; or any two R2 connected to the same ring atom or different ring atoms are connected to form a 3-7 membered saturated or partially unsaturated monocyclic heterocycle or a 3-7 membered saturated or partially unsaturated monocyclic ring; wherein the C 1-8 Alkyl, C 1-8 The alkoxy, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring and 3- to 7-membered saturated or partially unsaturated monocyclic ring are unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from the group consisting of deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -NR a1 R b1 、-SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl; wherein the phenyl and 5- to 6-membered heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from Substituent Group S; (R3) t The hydrogen on the ring C is replaced by t R3, t is 0, 1, 2 or 3; each R3 is the same or different and is independently hydrogen, cyano, hydroxyl, carboxyl, halogen, C 3-6 Cycloalkyl, C 1-8 Alkyl, C 1-8 Alkoxy, -NR a0 R b0 、-C(O)C 1-8 Alkyl, -C(O)OC 1-8 Alkyl, -OC(O)C 1-8 Alkyl or -C(O)NR a0 R b0 ; or connected to the same ring atom or different rings Any two R3 on the C atom are connected to form a 3- to 7-membered saturated or partially unsaturated monocyclic ring or a 3- to 7-membered saturated or partially unsaturated monocyclic ring; wherein the C 1-8 Alkyl, C 1-8 The alkoxy, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring and 3- to 7-membered saturated or partially unsaturated monocyclic ring are unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from the group consisting of deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -NR a1 R b1 、-SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl; wherein the phenyl and 5- to 6-membered heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from Substituent Group S; R0 is C 1-8 alkyl or 3 to 6 membered heterocycloalkyl, the C 1-8 The alkyl group is substituted by 1, 2 or 3 substituents each independently selected from the group consisting of hydroxy, halogen, C 1-8 Alkoxy and C 3-6 Cycloalkyloxy; the 3 to 6 membered heterocycloalkyl is unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from the following group: C 1-8 Alkyl and C 3-6 Cycloalkyl; R a , R b are the same or different and are each independently hydrogen or C 1-8 alkyl; p is 1, 2, or 3; The substituent group S is selected from the following groups: halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -NR a1 R b1 、-SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl; R a0 , R b0 are independently hydrogen, C 1-3 Alkyl or acetyl; or R a0 , R b0 Together with the connected nitrogen atom, it forms a 4- to 6-membered saturated monocyclic heterocyclic ring; the 4- to 6-membered saturated monocyclic heterocyclic ring is unsubstituted or substituted by 1, 2 or 3 substituents independently selected from the following groups: deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NH2, -C(O)NH(C 1-3 alkyl), -C(O)N(C 1-3 Alkyl)2, -C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy and 3- to 6-membered heterocycloalkyl; R a1 , R b1 are independently hydrogen, C 1-3 Alkyl or acetyl; or R a1 , R b1 Together with the connected nitrogen atom, it forms a 4- to 6-membered saturated monocyclic heterocyclic ring; the 4- to 6-membered saturated monocyclic heterocyclic ring is unsubstituted or substituted by 1, 2 or 3 substituents independently selected from the following groups: deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NH2, -C(O)NH(C 1-3 alkyl), -C(O)N(C 1-3 Alkyl)2, -C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy and 3- to 6-membered heterocycloalkyl.
2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: R a , R b All are hydrogen.
3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: R a0 , R b0 All are hydrogen.
4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: R0 is C 1-8 A straight chain alkyl group or a 3- to 6-membered heterocyclic alkyl group, wherein the C 1-8 The linear alkyl group is substituted by 1, 2 or 3 substituents each independently selected from the group consisting of hydroxy, halogen, C 1-8 Alkoxy and C 3-6 Cycloalkyloxy.
5. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: R0 is -(CR 01 R 02 ) q OH, -(CR 03 R 04 ) q OC 1-8 Alkyl, -(CR 05 R 06 ) q OC 3-6 Cycloalkyl, halogenated C 1-8 Alkyl or 3- to 6-membered heterocycloalkyl; q is 1, 2, 3 or 4; and R 01 , R 02 , R 03 , R 04 , R 05 , R 06 are the same or different and are each independently hydrogen or C 1-8 alkyl.
6. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: R0 is monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl or difluoroethyl, or is selected from one of the following structures:
7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: The compound represented by the formula (I) is a single isomer represented by the formula (I-1) or a single isomer structure represented by the formula (I-2):
8. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: The compound represented by formula (I) is a structure represented by formula (IIA) or formula (IIB): in, Z1 is N or CR Z1 ; Z2 is CR Z2 or N; and Z3 is -N=, -N(R Z31 )-or-C(R Z32 )=; L1 is -N=C(R L1a )-, -N(R L1b )-C(O)-, -C(R L1c )=C(R L1d )-, -O-C(O)-, -C(O)-O-, -O- or -N(R L1e )-; L2 is -C(R L2a )=N-C(R L2b )=, -N(R L2c )-C(O)-C(R L2d )=, -N(R L2e )-C(O)-N= or -N=C(R L2f )-C(R L2g )=; is a single bond or a double bond; R Z1 , R Z2 , R Z31 , R Z32 are independently hydrogen, halogen, cyano, hydroxyl, carboxyl, C 1-8 Alkyl, C 1-8 Alkoxy, -C(O)C 1-8 Alkyl, -C(O)OC 1-8 Alkyl, -C(O)NR a0 R b0 or -NR a0 R b0 ; R L1a , R L1c , R L1d , R L2a , R L2b , R L2d , R L2f , R L2g are independently hydrogen, halogen, C 1-8 Alkyl, C 1-8 Alkoxy or -NR a0 R b0 ; said C 1-8 The alkyl group is unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from the group consisting of deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -NR a1 R b1 、-SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl; wherein the phenyl and 5- to 6-membered heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from Substituent Group S; R L1b , R L1e , R L2c , R L2e are independently hydrogen, C 1-8 Alkyl, -SO2C 1-3 Alkyl, -SO2C 3-6 Cycloalkyl or -SO2NR a0 R b0 ; said C 1-8 The alkyl group is unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from the group consisting of deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -NR a1 R b1 、-SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)NR a1 R b1 、-C(O)OC 1-3 Alkyl, -OC(O)C 1-3 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl; wherein the phenyl, 5- to 6-membered heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from Substituent Group S.
9. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: The compound represented by the formula (I) is a single isomer represented by the formula (IIA-1), a single isomer represented by the formula (IIA-2), a single isomer represented by the formula (IIB-1) or a single isomer represented by the formula (IIB-2):
10. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: structure Select one of the following structures:
11. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: R L1a , R L1c , R L1d are each independently hydrogen, methyl, ethyl, n-propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl, difluoroethyl, trifluoroethyl, -NH2, -NHC 1-3 Alkyl or -N(C 1-3 Alkyl)2.
12. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: R L1b , R L1e are each independently hydrogen, methyl, ethyl, n-propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl, difluoroethyl, trifluoroethyl, -SO2C 1-3 Alkyl or -SO2C 3-6 Cycloalkyl.
13. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: structure Select one of the following structures:
14. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: structure Select one of the following structures:
15. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: R L2a , R L2b , R L2d , R L2f , R L2g are each independently hydrogen, methyl, ethyl, n-propyl, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl, difluoroethyl, trifluoroethyl, -NH2, -NHC 1-3 Alkyl or -N(C 1-3 Alkyl)2.
16. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: structure Select one of the following structures:
17. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: Ring A is a benzene ring, a thiophene ring, a furan ring, a thiazole ring, an isothiazole ring, an imidazole ring, an oxazole ring, a pyrrole ring, a pyrazole ring, a triazole ring (including a 1,2,3-triazole ring, a 1,2,4-triazole ring, a 1,2,5-triazole ring, and a 1,3,4-triazole ring), a tetrazole ring, an isoxazole ring, an oxadiazole ring (including a 1,2,3-oxadiazole ring, a 1,2,4-oxadiazole ring, a 1,2,5-oxadiazole ring, and a 1,3,4-oxadiazole ring), a thiadiazole ring, a pyridine ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, a triazine ring, or a tetrazine ring.
18. The compound according to claim 17, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: Ring A is a benzene ring.
19. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: Ring C is a benzene ring or a pyridine ring.
20. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: (R1) n It means that the hydrogen on ring A is replaced by n R1, n is 0, 1, 2, 3, 4 or 5; each R1 is the same or different and is independently halogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl or n-pentyl.
21. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: (R2) m represents that the hydrogen on ring B is replaced by m R2, m is 0, 1, 2 or 3; each R2 is the same or different and is independently cyano, hydroxyl, carboxyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, methoxy, ethoxy, n-propoxy, isopropoxy, butoxy, -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, -SO2C 1-3 Alkyl, -SO2C 3-6 cycloalkyl, monochloromethyl, dichloromethyl, trichloromethyl, monochloroethyl, 1,2-dichloroethyl, trichloroethyl, monobromoethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl, difluoroethyl or trifluoroethyl.
22. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: (R3) t wherein the hydrogen on the ring C is replaced by t R3, t is 0, 1, 2 or 3; each R3 is the same or different and is independently cyano, hydroxyl, carboxyl, halogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-methylcyclopropyl, 1-methylcyclobutyl, 1-methylcyclopentyl, 1-methylcyclohexyl, monochloromethyl, dichloromethyl, trichloromethyl, monochloroethyl, 1,2-dichloroethyl, trichloroethyl, monobromoethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoroethyl, difluoroethyl, trifluoroethyl, monodeuteromethyl, monodeuteroethyl, dideuteromethyl, dideuteroethyl, trideuteromethyl, trideuteroethyl, methoxy, ethoxy, n-propoxy, isopropoxy, butoxy, -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 alkyl)2 or -C(O)NH2.
23. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: The 3- to 7-membered saturated or partially unsaturated monocyclic heterocycle formed by any two substituents connected to the same ring atom or different ring atoms is selected from the group consisting of an azetidine ring, an oxetane ring, a tetrahydrofuran ring, a tetrahydrothiophene ring, a tetrahydropyrrole ring, a piperidine ring, a pyrroline ring, an oxazolidine ring, a piperazine ring, a dioxolane ring, a dioxane ring, a morpholine ring, a thiomorpholine ring, a thiomorpholine-1,1-dioxide, a tetrahydropyran ring, an azetidine-2-one ring, an oxetane-2-one ring, a pyrrolidine-2-one ring, a pyrrolidine-2,5-dione ring, a piperidine-2-one ring, a dihydrofuran-2(3H)-one ring, a dihydrofuran-2,5-dione ring, a tetrahydro-2H-pyran-2-one ring, a piperazine-2-one ring, a morpholine-3-one ring , 1,2-dihydroazetidine ring, 1,2-dihydrooxetadiene ring, 2,5-dihydro-1H-pyrrole ring, 2,5-dihydrofuran ring, 2,3-dihydrofuran ring, 2,3-dihydro-1H-pyrrole ring, 3,4-dihydro-2H-pyran ring, 1,2,3,4-tetrahydropyridine ring, 3,6-dihydro-2H-pyran ring, 1,2 ,3,6-tetrahydropyridine ring, 4,5-dihydro-1H-imidazole ring, 1,4,5,6-tetrahydropyrimidine ring, 3,4,7,8-tetrahydro-2H-1,4,6-oxadiazolidine ring, 1,6-dihydropyrimidine ring, 4,5,6,7-tetrahydro-1H-1,3-diazepine ring or 2,5,6,7-tetrahydro-1,3,5-oxadiazepine ring.
24. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: The 3- to 7-membered saturated or partially unsaturated monocyclic heterocycle formed by any two substituents connected to the same ring atom or different ring atoms is a 4- to 6-membered saturated monocyclic heterocycle, and the 4- to 6-membered saturated monocyclic heterocycle is selected from: an azetidine ring, an oxetane ring, a tetrahydrofuran ring, a tetrahydrothiophene ring, a tetrahydropyrrole ring, a piperidine ring, a piperazine ring, a morpholine ring, a thiomorpholine ring, thiomorpholine-1,1-dioxide or a tetrahydropyran ring.
25. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: The 3- to 7-membered saturated or partially unsaturated monocyclic ring formed by any two substituents connected to the same ring atom or different ring atoms is selected from: a cyclopropyl ring, a cyclobutyl ring, a cyclopentyl ring, a cyclopentenyl ring, a cyclohexyl ring, a cyclohexenyl ring, a cyclohexadienyl ring, a cycloheptyl ring, a cycloheptatrienyl ring, a cyclopentanone ring or a cyclopentane-1,3-dione ring.
26. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: The 3- to 7-membered saturated or partially unsaturated monocyclic ring formed by any two substituents connected to the same ring atom or different ring atoms is a 3- to 6-membered saturated monocyclic ring, and the 3- to 6-membered saturated monocyclic ring is selected from: a cyclopropyl ring, a cyclobutyl ring, a cyclopentyl ring or a cyclohexyl ring.
27. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: When Ring A, Ring B or Ring C is a 5- or 6-membered heteroaryl ring, the 5- or 6-membered heteroaryl ring is each independently selected from: thienyl, furanyl, thiazolyl, isothiazolyl, imidazolyl, oxazolyl, pyrrolyl, pyrazolyl, triazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl or tetrazinyl.
28. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: The 5- or 6-membered heteroaryl rings are each independently selected from one of the following structures:
29. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: In the formula (I), the 3- to 6-membered heterocycloalkyl group in each group is a 4- to 6-membered heterocycloalkyl group, each independently selected from: azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyrrolyl, oxazolidinyl, dioxolanyl, piperidinyl, piperazinyl, morpholinyl, dioxane, thiomorpholinyl, thiomorpholine-1,1-dioxide, tetrahydropyranyl, pyrrolidin-2-one, dihydrofuran-2(3H)-one, morpholine-3-one, piperazine-2-one or piperidine-2-one.
30. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: R a0 , R b0 The 4- to 6-membered saturated monocyclic heterocyclic ring formed together with the nitrogen atom to which it is attached is selected from: azetidinyl, tetrahydropyrrolyl, piperidinyl, piperazinyl or morpholinyl.
31. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: R a1 , R b1 The 4- to 6-membered saturated monocyclic heterocyclic ring formed together with the nitrogen atom to which it is attached is selected from: azetidinyl, tetrahydropyrrolyl, piperidinyl, piperazinyl or morpholinyl.
32. The compound of claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: The compound of formula (I) is any of the following compounds, or a pharmaceutically acceptable salt or a stereoisomer thereof:
33. A pharmaceutical composition, characterized in that The invention comprises a compound according to any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof; and a pharmaceutically acceptable carrier.
34. Use of the compound according to any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or the pharmaceutical composition according to claim 33 in the preparation of a medicament for inhibiting TrkA.
35. Use of the compound according to any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or the pharmaceutical composition according to claim 33 in the preparation of a medicament for treating or preventing pain, cancer, inflammation or neurodegenerative diseases.
36. A compound according to any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, for use as a medicament.
37. A compound according to any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a pharmaceutical composition according to claim 33 for use in treating or preventing pain, cancer, inflammation or neurodegenerative diseases.
38. A compound represented by formula (III-A): in, Ring A, Ring B, (R1) n ,m,R a , R b , p as defined in claim 1; LG is a leaving group, R2' is as defined in R2 of claim 1, and when R2' is a hydroxyl group or an amino group, the hydroxyl group or the amino group is optionally protected by a corresponding hydroxyl protecting group or an amino protecting group.
39. The compound according to claim 38, characterized in that LG is -O-phenyl, said phenyl being unsubstituted or substituted by 1, 2 or 3 substituents each independently selected from the group consisting of deuterium, halogen, nitro, cyano, hydroxyl, carboxyl, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, halo C 1-3 Alkyl, halogenated C 1-3 Alkoxy, -SO2C 1-3 Alkyl, -S(O)C 1-3 Alkyl, -C(O)OC 1-3 Alkyl and -OC(O)C 1-3 alkyl.
40. A method for preparing a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, comprising the following steps: i) reacting a compound of formula (III-A) with a compound of formula (III-B) to obtain a compound of formula (I) or a compound of formula (I) protected by a hydroxyl protecting group or an amino protecting group, Among them, ring A, ring B, ring C, (R1) n ,m,(R3) t , R0, R a , R b , p as defined in claim 1; LG is a leaving group, R2' is as defined in R2 of claim 1, and when R2' is a hydroxyl group or an amino group, the hydroxyl group or the amino group is optionally protected by a corresponding hydroxyl protecting group or an amino protecting group; When R2' is a hydroxyl group protected by a hydroxyl protecting group or an amino group protected by an amino protecting group, the compound of formula (I) protected by the hydroxyl protecting group or the amino protecting group is deprotected to obtain the compound of formula (I).
Citation Information
Patent Citations
Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
CN103649076A
N-pyrrolidinyl, n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TRKA kinase inhibitors
CN104781255A
Heterocycle derivatives having trka inhibitory activity
US20180201607A1
TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015039333A1
